Original Article
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
N Engl J Med 2003; 349:427-434July 31, 2003
- Abstract
Background
Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma.
Methods
A randomized, double-blind, phase 2 trial was conducted comparing placebo with bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two weeks; the time to progression of disease and the response rate were primary end points. Crossover from placebo to antibody treatment was allowed, and survival was a secondary end point.
Results
Minimal toxic effects were seen, with hypertension and asymptomatic proteinuria predominating. The trial was stopped after the interim analysis met the criteria for early stopping. With 116 patients randomly assigned to treatment groups (40 to placebo, 37 to low-dose antibody, and 39 to high-dose antibody), there was a significant prolongation of the time to progression of disease in the high-dose–antibody group as compared with the placebo group (hazard ratio, 2.55; P<0.001). There was a small difference, of borderline significance, between the time to progression of disease in the low-dose–antibody group and that in the placebo group (hazard ratio, 1.26; P=0.053). The probability of being progression-free for patients given high-dose antibody, low-dose–antibody, and placebo was 64 percent, 39 percent, and 20 percent, respectively, at four months and 30 percent, 14 percent, and 5 percent at eight months. At the last analysis, there were no significant differences in overall survival between groups (P>0.20 for all comparisons).
Conclusions
Bevacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer.
Media in This Article
Figure 1
Kaplan–Meier Analysis of Survival Free of Tumor Progression for Patients Receiving High-Dose Bevacizumab (Panel A) or Low-Dose Bevacizumab (Panel B), as Compared with Placebo.Figure 2
Serial Radiographs of a Patient Treated with High-Dose Bevacizumab.Article Activity
- Article
Studies of the hereditary form of clear-cell renal carcinoma, which occurs in the von Hippel–Lindau syndrome, led to the identification of the von Hippel–Lindau tumor suppressor gene (VHL). The gene is mutated both in hereditary renal-cell carcinoma (where one mutation is a germ-line mutation) and in most cases of sporadic clear-cell renal carcinoma (where both alleles have acquired mutations or deletions).1,2 One consequence of these mutations is the overproduction of vascular endothelial growth factor through a mechanism involving hypoxia-inducible factor α.3-7 In addition, both VHL-deficient mice and vascular endothelial growth factor–knockout mice die in utero from defective vasculogenesis.8,9 Thus, by its regulation of vascular endothelial growth factor, the von Hippel–Lindau protein is tightly linked to angiogenesis. Vascular endothelial growth factor stimulates the growth of endothelial cells and appears to be a central factor in angiogenesis, particularly during embryogenesis, ovulation, wound healing, and tumor growth.10
Studies of human tumor xenografts in immunodeficient mice showed that neutralization of vascular endothelial growth factor inhibited the growth of a variety of model tumors.11,12 Presta and colleagues “humanized” the murine antibody used in these studies, A.4.6.1, by placing its complementarity-determining (antigen-binding) regions into a human IgG1 constant-region framework and modifying further amino acid residues to optimize antigen binding.13 In the resulting product, bevacizumab (or rhMAb-VEGF), 7 percent of the amino acids are from the murine antibody. In phase 1 testing, bevacizumab had a low toxicity profile in most patients, had a terminal elimination half-life of approximately 21 days, and did not induce antibodies to bevacizumab.14 The severe toxic effects that occurred in the phase 1 trial were infrequent intratumoral bleeding (including fatal hemoptysis), pulmonary emboli, and peripheral venous thrombosis. We conducted a randomized, placebo-controlled phase 2 trial of bevacizumab in patients with advanced renal-cell carcinoma.
Methods
Patients
Patients with histologically confirmed renal cancer of the clear-cell type, measurable metastatic disease, and documented progression of disease were eligible for this study. Other requirements included an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower and previous therapy with interleukin-2 (or contraindications to standard interleukin-2 therapy). The exclusion criteria were a history of central nervous system involvement, any other therapy or major surgery within the previous four weeks, a history of intratumoral bleeding, a serum creatinine level of more than 2 mg per deciliter (17 μmol per liter), a serum bilirubin level of more than 2 mg per deciliter (34 μmol per liter), and ischemic vascular disease.
All patients gave written informed consent. This protocol was approved by the institutional review board of the National Cancer Institute (NCI). The study was sponsored by the Cancer Therapy Evaluation program of the NCI, and bevacizumab was supplied by Genentech under a cooperative research and development agreement with the NCI. Trial design, data accrual (with the exception of assays for vascular endothelial growth factor and bevacizumab performed by Genentech on coded patient specimens), data analysis, and manuscript preparation were performed entirely by the authors.
The patients were evaluated by physical examination, magnetic resonance imaging of the brain, and complete computed tomographic scanning no more than one month before randomization, five weeks after the beginning of therapy, and then every two months for the first year of therapy and every three months for the second year of therapy.
A complete response was defined as the absence of all evidence of disease for at least a month. A partial response was defined as a decrease of at least 50 percent in the sum of the products of the maximal perpendicular diameters of measured lesions, lasting for a minimum of one month, with no progression of any lesion or appearance of new lesions. Minor and mixed responses were not included as responses.
Annual interim evaluations were performed by an independent data safety and monitoring board, and the method of O'Brien and Fleming was used to determine the threshold for statistical significance at each interim evaluation that would constitute grounds to recommend termination of the trial.15 For the first year of the trial, this threshold was a P value of 0.0006 or less; for the second year, it was a P value of 0.015 or less; and for the third year, it was a P value of 0.047 or less. The estimated and actual accrual rates were similar enough that these proposed intervals did not require revision.
Randomization and Treatment
In this phase 2 study, the patients were stratified according to whether or not they had received interleukin-2 therapy and were then randomly assigned to receive either a vehicle-only placebo, 3 mg of bevacizumab per kilogram of body weight, or 10 mg of bevacizumab per kilogram. During all treatment and evaluations, neither the patients nor any participating health care personnel were aware of the treatment assignment. Based on pharmacokinetic modeling, treatment with bevacizumab began with one loading dose, in which 150 percent of the assigned dose was administered by intravenous infusion over a 2-hour period, and then, beginning one week later, the standard assigned dose was administered (by progressively shorter infusions that reached a minimum of 30 minutes) every two weeks. Plasma levels of vascular endothelial growth factor and serum levels of bevacizumab were measured. The plasma vascular endothelial growth factor assay used the 3.5.F.8 murine antibody for both capture and detection. This assay detects both free and bevacizumab-bound vascular endothelial growth factor equally, with a lower limit of detection of 40 pg per milliliter.
Evaluation
For the purposes of end-point evaluation, the criteria for declaring tumor progression were the unequivocal appearance of new lesions; an increase of more than 25 percent in the product of the maximal perpendicular diameters of any measured lesion, as compared with base-line evaluation (or the smallest size subsequent to base line); or a tumor-related deterioration in ECOG performance status to 3 or more. For a declaration of progressive disease to be made, the lesions had to attain a minimal diameter of 1.5 cm (to ensure accurate measurement).
The indications for removing patients from the study and unblinding their treatment assignments were as follows. To permit adequate time for the initial assessment of the therapy while protecting patients with rapid disease progression who were assigned to placebo, the evaluation conducted five weeks after enrollment differed from subsequent evaluations. At five weeks, patients with increases of more than 2 cm in any lesion, a clinically significant deterioration in performance status, or new, severe symptoms (e.g., bone pain or nerve compression) were removed from the study. At all other evaluations, the indication for removal from the study was progressive disease. These different indications for removal from the study did not affect the end-point analyses, which were always based on tumor progression, as defined above.
Statistical Analysis
Using NCI Surgery Branch historical data from patients with no response to interleukin-2 therapy, we used the following criteria to estimate the sample size necessary to detect a doubling of the time to progression in patients receiving either dose of bevacizumab as compared with those receiving placebo: a 24-month accrual period, a 12-month evaluation period after the completion of accrual, a power of 80 percent, and an overall alpha of 0.05 to detect a doubling of the hazard ratio for each of the two primary comparisons (high-dose antibody vs. placebo and low-dose antibody vs. placebo). The calculation indicated that 40 patients per group would be required (50 were permitted, to allow for some patients who could not be evaluated).
The primary evaluation was based on the time from enrollment to disease progression; a secondary analysis examined the time to disease progression from the five-week assessment, in order to determine whether the effect of treatment was delayed and to ensure that small variations in the interval from the pretreatment evaluation to the time of randomization did not affect the uniform determination of the time to progression. Each P value was adjusted for the performance of two primary comparisons on the basis of treatment groups.
The time to progression and the overall response rate were the primary end points, and the analyses were performed on an intention-to-treat basis. Survival was declared a secondary end point, because patients whose disease progressed while they were receiving placebo were offered crossover either to 3 mg of bevacizumab per kilogram alone or to a combination of 3 mg of bevacizumab per kilogram and thalidomide. The time to progression of disease and survival were assessed with use of Kaplan–Meier curves and tested for significance by the log-rank test. Hazard ratios were determined with the Cox proportional-hazards model. All P values are two-tailed.
Results
Between October 1998 and September 2001, 116 patients were enrolled, of whom 108 had progressive disease during the course of the study. The median follow-up time from study entry was 27 months. Forty patients were randomly assigned to placebo, 37 to low-dose bevacizumab, and 39 to high-dose bevacizumab. All planned doses of the study drug were given unless grade 3 toxic effects occurred, in which case doses were withheld as specified by the study protocol. Only one patient (who was assigned to low-dose bevacizumab) was lost to follow-up after therapy. The three groups had similar demographic and clinical characteristics and laboratory results (Table 1Table 1
Characteristics of Patients before Treatment.). All patients received at least one dose of the assigned drug, and 114 of the 116 patients underwent at least one planned follow-up evaluation (evidence concerning disease progression was available for the remaining 2 patients).There were no life-threatening toxic effects (grade 4, major organ) or deaths possibly related to bevacizumab (Table 2Table 2
Toxic Effects of Treatment.). Hypertension and asymptomatic proteinuria were associated with bevacizumab therapy (Table 2). Of 13 patients with grade 2 or 3 hypertension, 7 (54 percent) had grade 2 or 3 proteinuria; of 63 patients with grade 0 or 1 hypertension, 10 (16 percent) had grade 2 or 3 proteinuria (P=0.007 by Fisher's exact test). None of these patients, or any other patient, had renal insufficiency. Hypertension and proteinuria uniformly decreased after the cessation of therapy, but death from renal cancer, the slow rate of correction of hypertension and proteinuria, and the commencement of other therapies prevented the documentation of complete resolution of these toxic effects in all but one patient.There were no episodes of grade 4 hypertension during randomized therapy, but in one patient who was initially assigned to placebo, hypertension with coma developed after the patient crossed over to low-dose bevacizumab plus thalidomide. These complications resolved completely after therapy was stopped. Typically, hypertension during the study was treated by the patients' private physicians with standard regimens for essential hypertension. Among all bevacizumab-treated patients who required therapy for newly diagnosed hypertension (for whom the dates of onset could be most accurately determined), the median interval from the first dose of bevacizumab to the onset of hypertension was 131 days (range, 7 to 316). Grade 1 or 2 hemoptysis developed in four patients (one receiving high-dose bevacizumab, one receiving low-dose bevacizumab, and two receiving placebo), and one patient receiving placebo had a pulmonary embolus.
At the second interim evaluation (which analyzed the data on 110 patients), the NCI data safety and monitoring board recommended closure of accrual on the basis of the difference between the placebo and high-dose bevacizumab groups in the time to progression of disease. According to intention-to-treat analysis, progression-free survival in the group receiving 10 mg of bevacizumab per kilogram (with a median time to progression of 4.8 months) was significantly longer than that in the placebo group (with a median time to progression of 2.5 months, P<0.001 by the log-rank test) (Figure 1AFigure 1
Kaplan–Meier Analysis of Survival Free of Tumor Progression for Patients Receiving High-Dose Bevacizumab (Panel A) or Low-Dose Bevacizumab (Panel B), as Compared with Placebo.). The difference between the time to progression of disease in the group receiving 3 mg of bevacizumab per kilogram (median time, 3.0 months) and that in the placebo group was of borderline significance (P=0.041 by the log-rank test) (Figure 1B).The planned analysis of progression from the five-week assessment yielded the same results. The percentages of patients assigned to high-dose bevacizumab, low-dose bevacizumab, and placebo who had no tumor progression were 64 percent, 39 percent, and 20 percent, respectively, four months after randomization and 30 percent, 14 percent, and 5 percent eight months after randomization. A Cox proportional-hazards model yielded hazard ratios for the time to progression of disease of 2.55 among patients given high-dose bevacizumab (P<0.001) and 1.26 among those given low-dose bevacizumab (P=0.053), as compared with those given placebo.
Only four patients had objective responses (all of which were partial responses), and all of these had received high-dose bevacizumab; thus, the response rate for high-dose bevacizumab was 10 percent (95 percent confidence interval, 2.9 to 24.2 percent). One patient had a partial response for the maximal treatment period of two years. This patient then stopped therapy, had a relapse six months later, and is currently having a second partial response after retreatment under a compassionate exemption (Figure 2Figure 2
Serial Radiographs of a Patient Treated with High-Dose Bevacizumab.). Another patient treated for two years had a sustained minor response, had a relapse after stopping therapy, and had another minor response after being retreated.Measurements of plasma vascular endothelial growth factor were available for 113 patients. Of these, 76 had a base-line level below the lower limit of detection (40 pg per milliliter). There were no significant associations between a detectable pretreatment level of vascular endothelial growth factor and the clinical response or the time to progression in either bevacizumab group (all P values were greater than 0.20). However, the limited sensitivity of the assay does not permit the definitive conclusion that there is no correlation between the base-line plasma level of vascular endothelial growth factor and the clinical response or the time to progression. After antibody therapy was started, the plasma levels of vascular endothelial growth factor rose steadily (the assay measures both free and antibody-bound vascular endothelial growth factor). After 5 weeks and 13 weeks of therapy, all bevacizumab-treated patients had detectable plasma levels of vascular endothelial growth factor. The median levels were 196 and 246 pg per milliliter, respectively, for patients receiving high-dose bevacizumab and 155 and 170 pg per milliliter for patients receiving low-dose bevacizumab. The percentages of patients assigned to placebo who had undetectable plasma levels of vascular endothelial growth factor at base line, 5 weeks, and 13 weeks were 66 percent, 67 percent, and 75 percent, respectively. Patients receiving low-dose bevacizumab had mean (±SE) peak and trough serum levels of bevacizumab of 101±9 and 39±3 μg per milliliter, respectively; patients receiving high-dose bevacizumab had mean peak and trough levels of 392±24 and 157±13 μg per milliliter, respectively. In both groups, the trough levels were above that needed to abolish detectable free vascular endothelial growth factor in the plasma of patients in previous phase 1 studies.14
At the most recent analysis, in February 2003, 19 of 116 patients (16 percent) were alive, and there were no significant differences in survival between the treatment groups (all P values were greater than 0.20) (Figure 3Figure 3
Overall Survival of Patients Receiving Placebo, Low-Dose Bevacizumab, or High-Dose Bevacizumab.). The complete radiographic records of 113 patients (3 were no longer complete at the time of audit) were blindly audited by a team of extramural radiologists under the supervision of the Cancer Therapy and Evaluation Program of the NCI. The prolongation of time to progression of disease was confirmed radiologically.Discussion
We selected vascular endothelial growth factor as a target for treatment of clear-cell kidney cancer because mutations in the von Hippel–Lindau tumor-suppressor gene, which probably cause most sporadic clear-cell kidney cancers, result in overproduction of this growth factor by the tumors. In our study, the aim was to neutralize vascular endothelial growth factor with a humanized monoclonal antibody (bevacizumab) in patients with metastatic clear-cell renal cancer. Using a randomized, double-blind, placebo-controlled design, we found that the time to tumor progression was prolonged by a factor of 2.55 in patients given 10 mg of bevacizumab per kilogram every two weeks, as compared with patients in the placebo group. Survival was not a primary end point in this trial, which allowed patients to cross over from placebo to bevacizumab therapy at the time of disease progression. Indeed, the survival of bevacizumab-treated patients was not significantly different from that of the patients receiving placebo.
During bevacizumab therapy, the plasma level of vascular endothelial growth factor rose. It is important to note that the assay we used measured both free and antibody-bound vascular endothelial growth factor. The explanation for this increase and its clinical significance are unknown, but it might have been due to diminished clearance of bevacizumab-bound, inactive vascular endothelial growth factor or to an antibody-mediated blockade of the binding of vascular endothelial growth factor to its receptors.
Hypotheses about the mechanism responsible for the delay we observed in tumor progression are based on in vitro data, the results of treatment of human tumor xenografts in immunodeficient mice, and studies of human renal cancer. These data suggest that the antitumor effects of the antibody against vascular endothelial growth factor are due to inhibition of angiogenesis. Both in vitro and in tumor xenografts, vascular endothelial growth factor has potent angiogenic activity, which is inhibited by neutralizing antibodies to vascular endothelial growth factor; the result is a decrease in tumor blood flow and microvessel densities.11 Human clear-cell renal cancers have significantly higher microvessel counts than non–clear-cell renal cancers, and these counts are correlated with the expression of vascular endothelial growth factor.16 Endothelial cells and hematopoietic cells (but not renal cancer cells) are the predominant cells that express receptors for vascular endothelial growth factor, but the inhibition of the growth of human tumor xenografts in immunodeficient mice argues against contributions from an immunologic mechanism. For all these reasons, the inhibitory effect of bevacizumab on the growth of clear-cell renal cancer is likely to be due to its antiangiogenic action.
Antiangiogenic strategies for the treatment of cancer have generated widespread enthusiasm based on promising in vitro and preclinical studies. The concepts that growing tumors require the manufacture of new blood vessels and that very little of the rest of the normal adult body has such a requirement have led to the belief that there is valuable therapeutic potential in this area. Early clinical studies of antiangiogenic compounds such as endostatin, TNP-470, and thalidomide were not designed to assess their clinical efficacy.17,18 In retrospect, only a randomized assessment of a time-to-progression end point could have demonstrated the activity of bevacizumab in renal cancer. Reliance on major response rates would have resulted in the conclusion that this drug was ineffective. Nevertheless, without a demonstration of improved overall survival, this single-agent trial serves primarily as a proof of principle and the basis for further investigation.
The magnitude of the clinical benefit of bevacizumab in this trial was small. The differences in the time to the progression of disease between the high-dose bevacizumab group and the placebo group was only a few months. Nevertheless, the likelihood is high that this difference was due to true biologic activity. The lack of an overall survival benefit in this trial and the small size of the increase in the time to progression may reflect the crossover design and the rigorous indications for declaring progression and removing a patient from the study (an increase in diameter of any single lesion by as little as 12 percent could constitute tumor progression). Some patients left the study with only small new lesions or mixed responses, but often with minimal or no increase in the size of preexisting tumors. In fact, 23 patients treated with high-dose bevacizumab showed no net increase in the size of index lesions from base line to the time of tumor progression. Tumor progression in these patients was typically based on the appearance of small new lesions or an increase in the size of some lesions that was offset by regression in other lesions. It would be worthwhile to determine survival in patients allowed to continue to receive bevacizumab despite tumor progression.
Future treatments for renal cancer that target angiogenic mechanisms should consider pathways other than that mediated by vascular endothelial growth factor. There are other proteins in the local microenvironment of some tumors that can promote angiogenesis. For example, fibroblast growth factor 5, which has angiogenic activity, is secreted by most renal cancers,19 suggesting that combinations of bevacizumab and inhibitors of members of the fibroblast growth factor family may have promise for treatment of this disease. It is likely that the future of antiangiogenic therapy will require a rational combination of inhibitors, directed by a better understanding of the biology of each individual type of cancer.
We are indebted to the Surgery Branch research nurses and immunotherapy fellows, the day hospital nursing staff, Don White, Maria Merino, W. Marston Linehan, Richard Klausner, Gwen Fyfe, and William Novotny for their invaluable assistance in the conduct of this study.
Source Information
From the Surgery Branch (J.C.Y., L.H., R.M.S., P.H., D.J.S., S.L.T., S.A.R.), the Biostatistics and Data Management Section (S.M.S.), and the Cancer Therapy Evaluation Program (H.X.C.), National Cancer Institute, Bethesda, Md.
Address reprint requests to Dr. Yang at Rm. 2B-37, Bldg. 10, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, or at james_yang@nih.gov.
- References
References
1
Gnarra JR ,Duan DR ,Weng Y , et al. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta 1996;1242:201-210
Web of Science | Medline2
Gnarra JR ,Tory K ,Weng Y , et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90
CrossRef | Web of Science | Medline3
Gnarra JR ,Zhou S ,Merrill MJ , et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 1996;93:10589-10594
CrossRef | Web of Science | Medline4
Iliopoulos O ,Levy AP ,Jiang C ,Kaelin WG Jr ,Goldberg MA . Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996;93:10595-10599
CrossRef | Web of Science | Medline5
Mukhopadhyay D ,Knebelmann B ,Cohen HT ,Ananth S ,Sukhatme VP . The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-5639
Web of Science | Medline6
Maxwell PH ,Wiesener MS ,Chang GW , et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275
CrossRef | Web of Science | Medline7
Ivan M ,Haberberger T ,Gervasi DC , et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 2002;99:13459-13464
CrossRef | Web of Science | Medline8
Gnarra JR ,Ward JM ,Porter FD , et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A 1997;94:9102-9107
CrossRef | Web of Science | Medline9
Haigh JJ ,Gerber HP ,Ferrara N ,Wagner EF . Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 2000;127:1445-1453
Web of Science | Medline10
Ferrara N . Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-543
CrossRef | Web of Science | Medline11
Kim KJ ,Li B ,Winer J , et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844
CrossRef | Web of Science | Medline12
Borgstrom P ,Bourdon MA ,Hillan KJ ,Sriramarao P ,Ferrara N . Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998;35:1-10
CrossRef | Web of Science | Medline13
Presta LG ,Chen H ,O'Connor SJ , et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599
Web of Science | Medline14
Gordon MS ,Margolin K ,Talpaz M , et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850
Web of Science | Medline15
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline16
Turner KJ ,Moore JW ,Jones A , et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-2961
Web of Science | Medline17
Mundhenke C ,Thomas JP ,Wilding G , et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 2001;7:3366-3374
Web of Science | Medline18
Stadler WM ,Kuzel T ,Shapiro C ,Sosman J ,Clark J ,Vogelzang NJ . Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999;17:2541-2545
Web of Science | Medline19
Hanada K ,Perry-Lalley DM ,Ohnmacht GA ,Bettinotti MP ,Yang JC . Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res 2001;61:5511-5516
Web of Science | Medline
- Citing Articles (933)
Citing Articles
1
Laura Horsley, Kalena Marti, GC Jayson. (2012) Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opinion on Drug Metabolism & Toxicology1-11
CrossRef2
Niyaz A. Naik, Imtiyaz A. Bhat, Dil Afroze, Roohi Rasool, Hyder Mir, Syed Irtiza Andrabi, Sonaullah Shah, Mushtaq A. Siddiqi, Zafar A. Shah. (2012) Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India). Tumor Biology
CrossRef3
Stefan Verlohren, Holger Stepan, Ralf Dechend. (2012) Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clinical Science 122:2, 43-52
CrossRef4
Caroline Hilmi, Mélanie Guyot, Gilles Pagès. (2012) VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy. Journal of Nucleic Acids 2012, 1-7
CrossRef5
Abbott L. Willard, Ira M. Herman. (2012) Vascular Complications and Diabetes: Current Therapies and Future Challenges. Journal of Ophthalmology 2012, 1-14
CrossRef6
Astrid A.M. Van der Veldt, Mark Lubberink, Idris Bahce, Maudy Walraven, Michiel P. de Boer, Henri N.J.M. Greuter, N. Harry Hendrikse, Jonas Eriksson, Albert D. Windhorst, Pieter E. Postmus, Henk M. Verheul, Erik H. Serné, Adriaan A. Lammertsma, Egbert F. Smit. (2012) Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs. Cancer Cell 21:1, 82-91
CrossRef7
Conrad M. Tobert, Robert G. Uzzo, Christopher G. Wood, Brian R. Lane. (2012) Adjuvant and neoadjuvant therapy for renal cell carcinoma: A survey of the Society of Urologic Oncology. Urologic Oncology: Seminars and Original Investigations
CrossRef8
Marie-Laure Couec, Nicolas André, Estelle Thebaud, Odile Minckes, Xavier Rialland, Nadège Corradini, Isabelle Aerts, Perrine Marec Bérard, Franck Bourdeaut, Pierre Leblond, . (2012) Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends. Pediatric Blood & Cancern/a-n/a
CrossRef9
Eric M. George, Ana C. Palei, Joey P. Granger. (2012) Endothelin as a final common pathway in the pathophysiology of preeclampsia. Current Opinion in Nephrology and Hypertension1
CrossRef10
Rosalie Fisher, James Larkin, Charles Swanton. (2011) Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. The EPMA Journal
CrossRef11
H. Mishima, K. Oba, J. Sakamoto, K. Muro, T. Yoshino, I. Hyodo, Y. Maehara. (2011) FOLFIRI plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study). Japanese Journal of Clinical Oncology
CrossRef12
Jill E. Larsen, John D. Minna. (2011) Molecular Biology of Lung Cancer: Clinical Implications. Clinics in Chest Medicine 32:4, 703-740
CrossRef13
Jin-Sun Kong, Seung-Ah Yoo, Jong-Hoon Kang, Wooree Ko, Sangmin Jeon, Chi-Bom Chae, Chul-Soo Cho, Wan-Uk Kim. (2011) Suppression of neovascularization and experimental arthritis by D-form of anti-flt-1 peptide conjugated with mini-PEG™. Angiogenesis 14:4, 431-442
CrossRef14
Yun-ze Xu, Yu Zhu, Zhou-jun Shen, Jia-yan Sheng, Hong-chao He, Gui Ma, Yi-cheng Qi, Ju-ping Zhao, Yu-xuan Wu, Wen-bin Rui, Qing Wei, Wen-long Zhou, Xin Xie, Guang Ning. (2011) Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine 40:3, 445-451
CrossRef15
Patricia E. Kook, Mathias Maier, Tibor Schuster, Nikolaus Feucht, Chris P. Lohmann. (2011) Nine-month results of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular oedema: a retrospective analysis. Acta Ophthalmologica 89:8, 769-773
CrossRef16
Ketao Jin, Kuifeng He, Fei Teng, Guangliang Li, Haohao Wang, Na Han, Zhenzhen Xu, Jiang Cao, Jianming Wu, Decao Yu, Lisong Teng. (2011) FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo. Clinical and Translational Oncology 13:12, 878-884
CrossRef17
Fei Liu, Xianguo Chen, Ejun Peng, Wei Guan, Youyuan Li, Zhiquan Hu, Zhangqun Ye, Qianyuan Zhuang. (2011) VEGF pathway-targeted therapy for advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology [Medical Sciences] 31:6, 799-806
CrossRef18
Lucy Mathot, Johan Stenninger. (2011) The behavior of seeds and soil in the mechanism of metastasis; a deeper understanding. Cancer Scienceno-no
CrossRef19
Nancy Y Lee, Qiang Zhang, David G Pfister, John Kim, Adam S Garden, James Mechalakos, Kenneth Hu, Quynh T Le, A Dimitrios Colevas, Bonnie S Glisson, Anthony TC Chan, K Kian Ang. (2011) Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. The Lancet Oncology
CrossRef20
T. Schmidt, P. Carmeliet. (2011) Angiogenesis: A Target in Solid Tumors, Also in Leukemia?. Hematology 2011:1, 1-8
CrossRef21
Gaetan des Guetz, Bernard Uzzan, Kader Chouahnia, Jean-François Morère. (2011) Cardiovascular toxicity of anti-angiogenic drugs. Targeted Oncology
CrossRef22
L. García-Fernández, M. R. Aguilar, L. Ochoa-Callejero, C. Abradelo, A. Martínez, J. San Román. (2011) bFGF interaction and in vivo angiogenesis inhibition by self-assembling sulfonic acid-based copolymers. Journal of Materials Science: Materials in Medicine
CrossRef23
Kimberly R. Pechman, Deborah L. Donohoe, Devyani P. Bedekar, Shekar N. Kurpad, Raymond G. Hoffmann, Kathleen M. Schmainda. (2011) Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume. Journal of Neuro-Oncology 105:2, 233-239
CrossRef24
M. H. G. Langenberg, P. O. Witteveen, J. Roodhart, M. P. Lolkema, H. M. W. Verheul, M. Mergui-Roelvink, E. Brendel, J. Kratzschmar, B. Loembe, A. Nol-Boekel, O. Christensen, J. H. M. Schellens, E. E. Voest. (2011) Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Annals of Oncology 22:11, 2508-2515
CrossRef25
Alfonso De Stefano, Chiara Carlomagno, Stefano Pepe, Roberto Bianco, Sabino De Placido. (2011) Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemotherapy and Pharmacology 68:5, 1207-1213
CrossRef26
Masaki Mandai, Noriomi Matsumura, Tsukasa Baba, Ken Yamaguchi, Junzo Hamanishi, Ikuo Konishi. (2011) Ovarian clear cell carcinoma as a stress-responsive cancer: Influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Letters 310:2, 129-133
CrossRef27
Chris Coppin, Christian Kollmannsberger, Lyly Le, Franz Porzsolt, Timothy J. Wilt. (2011) Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU International 108:10, 1556-1563
CrossRef28
Pierpaolo Peruzzi, E. Antonio Chiocca. (2011) Bringing the Endovascular Neurosurgeon into the Neuro-oncology Treatment Team. World Neurosurgery
CrossRef29
Jérôme Barrière, Benjamin Hoch, Jean-Marc Ferrero. (2011) New perspectives in the treatment of metastatic renal cell carcinoma. Critical Reviews in Oncology/Hematology
CrossRef30
Vladimir V Iakovlev, Manal Gabril, William Dubinski, Andreas Scorilas, Youssef M Youssef, Hala Faragalla, Kalman Kovacs, Fabio Rotondo, Shereen Metias, Androu Arsanious, Anna Plotkin, Andrew H F Girgis, Catherine J Streutker, George M Yousef. (2011) Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Laboratory Investigation
CrossRef31
David A. Reardon, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, Anuradha Bulusu, Stevie Threatt, Allan H. Friedman, James J. Vredenburgh, Henry S. Friedman. (2011) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. Journal of Neuro-Oncology
CrossRef32
Hasan Korkaya, Suling Liu, Max S. Wicha. (2011) Breast cancer stem cells, cytokine networks, and the tumor microenvironment. Journal of Clinical Investigation 121:10, 3804-3809
CrossRef33
Pia P. Vihinen, Susan Ramadan, Meri-Sisko Vuoristo, Micaela Hernberg, Kristiina Tyynelä-Korhonen, Tanja Skyttä, Ilkka Koskivuo, Pirkko-Liisa Kellokumpu-Lehtinen, Kari Syrjänen, Seppo Pyrhönen. (2011) Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. Melanoma Research 21:5, 431-437
CrossRef34
Güllü Görgün, Kenneth C Anderson. (2011) Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer. Immunotherapy 3:10, 1253-1264
CrossRef35
Shiri Zayit-Soudry, Esther Zemel, Adiel Barak, Ido Perlman, Anat Loewenstein. (2011) SAFETY OF INTRAVITREAL BEVACIZUMAB IN THE DEVELOPING RABBIT RETINA. Retina 31:9, 1885-1895
CrossRef36
Georgios V. Koukourakis, Anastasia Sotiropoulou-Lontou. (2011) Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clinical and Translational Oncology 13:10, 710-714
CrossRef37
Guru Sonpavde, Toni K. Choueiri, Bernard Escudier, Vincenzo Ficarra, Thomas E. Hutson, Peter F. Mulders, Jean-Jacques Patard, Brian I. Rini, Michael Staehler, Cora N. Sternberg, Christian G. Stief. (2011) Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. European Urology
CrossRef38
R Grepin, M Guyot, M Jacquin, J Durivault, E Chamorey, A Sudaka, C Serdjebi, B Lacarelle, J-Y Scoazec, S Negrier, H Simonnet, G Pages. (2011) Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines. Oncogene
CrossRef39
Praveen Kandula, Rajiv Agarwal. (2011) Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney International
CrossRef40
Cynthia E. Weber, Paul C. Kuo. (2011) The tumor microenvironment. Surgical Oncology
CrossRef41
Roger Henriksson, Thomas Asklund, Hans Skovgaard Poulsen. (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. Journal of Neuro-Oncology 104:3, 639-646
CrossRef42
Danielle M. Patterson, Dongbing Gao, Denae N. Trahan, Brett A. Johnson, Andrew Ludwig, Eveline Barbieri, Zaowen Chen, Jose Diaz-Miron, Lyubomir Vassilev, Jason M. Shohet, Eugene S. Kim. (2011) Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis 14:3, 255-266
CrossRef43
P. Vader, B.J. Crielaard, S.M. van Dommelen, R. van der Meel, G. Storm, R.M. Schiffelers. (2011) Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles. Journal of Controlled Release
CrossRef44
Fabrizio Marcucci, Angelo Corti. (2011) How to improve exposure of tumor cells to drugs — Promoter drugs increase tumor uptake and penetration of effector drugs. Advanced Drug Delivery Reviews
CrossRef45
S. Kruijff, E. Bastiaannet, A. H. Brouwers, W. B. Nagengast, M. J. Speijers, A. J. H. Suurmeijer, G. A. Hospers, H. J. Hoekstra. (2011) Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma. Annals of Surgical Oncology
CrossRef46
Martin H. Voss, Ana M. Molina, Robert J. Motzer. (2011) mTOR Inhibitors in Advanced Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, 835-852
CrossRef47
David J. Gallagher, Hikmat Al-Ahmadie, Irina Ostrovnaya, Scott R. Gerst, Ashley Regazzi, Ilana Garcia-Grossman, Jamie Riches, Sivaraman K. Gounder, Anne-Marie Flaherty, Alisa Trout, Matthew I. Milowsky, Dean F. Bajorin. (2011) Sunitinib in Urothelial Cancer: Clinical, Pharmacokinetic, and Immunohistochemical Study of Predictors of Response. European Urology 60:2, 344-349
CrossRef48
Jacalyn Rosenblatt, David F. McDermott. (2011) Immunotherapy for Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, 793-812
CrossRef49
Zaher K. Otrock, Hassan A. Hatoum, Khaled M. Musallam, Ahmad H. Awada, Ali I. Shamseddine. (2011) Is VEGF a predictive biomarker to anti-angiogenic therapy?. Critical Reviews in Oncology/Hematology 79:2, 103-111
CrossRef50
Katherine M. Krajewski, Angela A. Giardino, Katherine Zukotynski, Annick D. Van den Abbeele, Ivan Pedrosa. (2011) Imaging in Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, 687-715
CrossRef51
Laurence Albiges, Mohamed Salem, Brian Rini, Bernard Escudier. (2011) Vascular Endothelial Growth Factor–Targeted Therapies in Advanced Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, 813-833
CrossRef52
Wenting Wu, Qian Shi, Daniel J. Sargent. (2011) Statistical Considerations for the Next Generation of Clinical Trials. Seminars in Oncology 38:4, 598-604
CrossRef53
Chintan Parekh, Rima Jubran, Anat Erdreich-Epstein, Ashok Panigrahy, Stefan Bluml, Jonathan Finlay, Girish Dhall. (2011) Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. Journal of Neuro-Oncology 103:3, 673-680
CrossRef54
Anthony T. Ruys, Pieter J. Tanis, Nagtegaal D. Iris, Peter Duijvendijk, Cornelis Verhoef, Robert J. Porte, Thomas M. Gulik. (2011) Surgical Treatment of Renal Cell Cancer Liver Metastases: A Population-Based Study. Annals of Surgical Oncology 18:7, 1932-1938
CrossRef55
A Leary, JM Larkin, Lisa M Pickering. (2011) Cytokine therapy for renal cell cancer: the evolving role of immunomodulation. Therapy 8:4, 347-358
CrossRef56
Kostas N. Syrigos, Eleni Karapanagiotou, Paraskevi Boura, Christian Manegold, Kevin Harrington. (2011) Bevacizumab-Induced Hypertension. BioDrugs 25:3, 159-169
CrossRef57
Lance C Pagliaro, Nizar Tannir, Kanishka Sircar, Eric Jonasch. (2011) Systemic therapy for sarcomatoid renal cell carcinoma. Expert Review of Anticancer Therapy 11:6, 913-920
CrossRef58
A Heine, S A E Held, A Bringmann, T A W Holderried, P Brossart. (2011) Immunomodulatory effects of anti-angiogenic drugs. Leukemia 25:6, 899-905
CrossRef59
Jerome P Schartman, Joseph M Coney, Joan H Hornik, David G Miller. (2011) Pegaptanib octasodium for the treatment of diabetic macular edema. Expert Opinion on Pharmacotherapy 12:8, 1317-1323
CrossRef60
Bernard Escudier, Laurence Albiges. (2011) Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma. Drugs 71:9, 1179-1191
CrossRef61
, Laurence Legros, Bohrane Slama, Jean-Michel Karsenti, Norbert Vey, Shanti Natarajan-Amé, Eric Watel, Bruno Richard, Krimo Bouabdallah, Lionel Mannone, Maxime Benchetrit, Irit Touitou, Sébastien Huault, Jérome Durivault, Damien Ambroseti, Anne-Odile Hueber, Pierre Fenaux, Francois Dreyfus. (2011) Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. Annals of Hematology
CrossRef62
Kevin V.S. Tan, Benjamin Namdarian, Anthony J. Costello, Christopher M. Hovens. (2011) Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 29:3, 237-243
CrossRef63
Michael J. Zelefsky, Carlo Greco, Robert Motzer, Juan Martin Magsanoc, Xin Pei, Michael Lovelock, Jim Mechalakos, Joan Zatcky, Zvi Fuks, Yoshiya Yamada. (2011) Tumor Control Outcomes After Hypofractionated and Single-Dose Stereotactic Image-Guided Intensity-Modulated Radiotherapy for Extracranial Metastases From Renal Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics
CrossRef64
Brian Rini, Mhd Yaser Al-Marrawi. (2011) Pazopanib for the treatment of renal cancer. Expert Opinion on Pharmacotherapy 12:7, 1171-1189
CrossRef65
Katherine M. Krajewski, Mengye Guo, Annick D. Van den Abbeele, Jeffrey Yap, Nikhil Ramaiya, Jyothi Jagannathan, Daniel Y.C. Heng, Michael B. Atkins, David F. McDermott, Fabio A.B. Schutz, Ivan Pedrosa, Toni K. Choueiri. (2011) Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. European Urology 59:5, 856-862
CrossRef66
G. K. Siddiqui, A. B. Maclean, K. Elmasry, A. Wong te Fong, R. W. Morris, M. Rashid, R. H. J. Begent, G. M. Boxer. (2011) Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis 14:2, 155-161
CrossRef67
Rajni Sinha, Nutan DeJoubner, Christopher Flowers. (2011) Novel agents for diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs 20:5, 669-680
CrossRef68
A. J. Zurita, E. Jonasch, X. Wang, M. Khajavi, S. Yan, D. Z. Du, L. Xu, M. H. Herynk, K. S. McKee, H. T. Tran, C. J. Logothetis, N. M. Tannir, J. V. Heymach. (2011) A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Annals of Oncology
CrossRef69
Anikó Maráz. (2011) Új lehetőségek a vesedaganatok onkológiai kezelésében. Orvosi Hetilap 152:17, 655-662
CrossRef70
Sònia Tugues, Sina Koch, Laura Gualandi, Xiujuan Li, Lena Claesson-Welsh. (2011) Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer. Molecular Aspects of Medicine 32:2, 88-111
CrossRef71
Christopher L. Hallemeier, Richard Choo, Brian J. Davis, Thomas M. Pisansky, Leonard L. Gunderson, Bradley C. Leibovich, Michael G. Haddock. (2011) Long-Term Outcomes After Maximal Surgical Resection and Intraoperative Electron Radiotherapy for Locoregionally Recurrent or Locoregionally Advanced Primary Renal Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics
CrossRef72
Elena Galfrascoli, Sheila Piva, Michela Cinquini, Antonio Rossi, Nicla La Verde, Annalisa Bramati, Anna Moretti, Andrea Manazza, Giovanna Damia, Valter Torri, Gaetana Muserra, Gabriella Farina, Marina Chiara Garassino. (2011) Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis. Digestive and Liver Disease 43:4, 286-294
CrossRef73
Jan Poleszczuk, Marek Bodnar, Urszula Foryś. (2011) New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model. Mathematical Biosciences and Engineering 8:2, 591-603
CrossRef74
O. L. Chinot, T. Motte Rouge, N. Moore, A. Zeaiter, A. Das, H. Phillips, Z. Modrusan, T. Cloughesy. (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Advances in Therapy 28:4, 334-340
CrossRef75
James Larkin, Charles Swanton, Lisa Pickering. (2011) Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Review of Anticancer Therapy 11:4, 639-649
CrossRef76
Alberto Zambelli, Matteo Giovanni Della Porta, Ermanno Eleuteri, Luciana De Giuli, Oronzo Catalano, Carlo Tondini, Alberto Riccardi. (2011) Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. The Breast 20:2, 176-183
CrossRef77
Timothy Poterucha, Brian Burnette, Aminah Jatoi. (2011) A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Medical Oncology
CrossRef78
Shree Gopal Sharma, Nidhi Aggarwal, Siddhartha Datta Gupta, Manoj Kumar Singh, Ruchika Gupta, Amit Kumar Dinda. (2011) Angiogenesis in renal cell carcinoma: correlation of microvessel density and microvessel area with other prognostic factors. International Urology and Nephrology 43:1, 125-129
CrossRef79
Eric Tartour, H. Pere, B. Maillere, M. Terme, N. Merillon, J. Taieb, F. Sandoval, F. Quintin-Colonna, K. Lacerda, A. Karadimou, C. Badoual, A. Tedgui, W. H. Fridman, S. Oudard. (2011) Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer and Metastasis Reviews 30:1, 83-95
CrossRef80
I. Arratibel-Echarren, K. Albright, J. Dalmau, M.R. Rosenfeld. (2011) Utilización de bevacizumab en las complicaciones neurológicas durante el tratamiento inicial de los gliomas malignos. Neurología 26:2, 74-80
CrossRef81
Katrin Singer, Eva Gottfried, Marina Kreutz, Andreas Mackensen. (2011) Suppression of T-cell responses by tumor metabolites. Cancer Immunology, Immunotherapy 60:3, 425-431
CrossRef82
H. R. Mellor, A. R. Bell, J.-P. Valentin, R. R. A. Roberts. (2011) Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer. Toxicological Sciences 120:1, 14-32
CrossRef83
Flávia Gomes de Góes Rocha, Fernanda B. Calvo, Karen C. Chaves, Jean P. S. Peron, Rodolfo F. Marques, Tânia R. de Borba, Marina S. Braga, Cleide B. Pereira, Elisabete J. Vicente, Roger Chammas, Nestor Schor, Maria H. Bellini. (2011) Endostatin- and interleukin-2-expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinoma. The Journal of Gene Medicine 13:3, 148-157
CrossRef84
Alessandro Sciarra, Susanna Cattarino, Stefano Salciccia, Andrea Alfarone, Alessandro Gentilucci, Ulderico Parente, Gianna Mariotti, Michele Innocenzi, Vincenzo Gentile. (2011) The emerging role of targeted therapy in renal cell carcinoma (RCC): Is it time for a neoadjuvant or an adjuvant approach?. Critical Reviews in Oncology/Hematology
CrossRef85
Jorge A. Garcia, Tarek Mekhail, Paul Elson, Pierre Triozzi, Cheryl Nemec, Robert Dreicer, Ronald M. Bukowski, Brian I Rini. (2011) Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU International 107:4, 562-570
CrossRef86
Aviad Hoffman, Alexander J. Lazar, Raphael E. Pollock, Dina Lev. (2011) New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resistance Updates 14:1, 52-66
CrossRef87
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy & Radiopharmaceuticals 26:1, 1-64
CrossRef88
Kristan D. Guenterberg, Valerie P. Grignol, Kiran V. Relekar, Kimberly A. Varker, Helen X. Chen, Kari L. Kendra, Thomas E. Olencki, William E. Carson. (2011) A Pilot Study of Bevacizumab and Interferon-α2b in Ocular Melanoma. American Journal of Clinical Oncology 34:1, 87-91
CrossRef89
M. Siebels, K. Rohrmann, R. Oberneder, M. Stahler, N. Haseke, J. Beck, R. Hofmann, M. Kindler, P. Kloepfer, C. Stief. (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World Journal of Urology 29:1, 121-126
CrossRef90
Omid Farokhzad, Robert S. Langer. (2011) Nanoparticle Delivery of Cancer Drugs. Annual Review of Medicine 63:1, 110301100719093
CrossRef91
Paula A. Videira, A. Rita Piteira, M. Guadalupe Cabral, Catarina Martins, Manuela Correia, Paulo Severino, Helena Gouveia, Mylène Carrascal, Joana F. Almeida, Hélder Trindade, Lúcio Lara Santos. (2011) Effects of Bevacizumab on Autocrine VEGF Stimulation in Bladder Cancer Cell Lines. Urologia Internationalis 86:1, 95-101
CrossRef92
Daniel Spira, Michael Fenchel, Ulrich M. Lauer, Claus D. Claussen, Michael Gregor, Michael Bitzer, Marius Horger. (2011) Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib. Academic Radiology 18:1, 89-96
CrossRef93
Janina Müller-Deile, Mario Schiffer. (2011) Renal Involvement in Preeclampsia: Similarities to VEGF Ablation Therapy. Journal of Pregnancy 2011, 1-6
CrossRef94
Hilary Glen, Susan Mason, Hitesh Patel, Kenneth Macleod, Valerie G Brunton. (2011) E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 11:1, 309
CrossRef95
Erika P. Hamilton, Kimberly L. Blackwell. (2011) Safety of Bevacizumab in Patients with Metastatic Breast Cancer. Oncology 80:5-6, 314-325
CrossRef96
George J. Netto, Jonathan I. Epstein. 2011. Immunohistology of the Prostate, Bladder, Kidney, and Testis. , 593-661.
CrossRef97
Ignacio Durán. (2011) Renal cell cancer. Anti-Cancer Drugs 22, S1-S3
CrossRef98
Hemant K. Bid, Peter J. Houghton. (2011) Targeting Angiogenesis in Childhood Sarcomas. Sarcoma 2011, 1-10
CrossRef99
Gian Paolo Giuliari, Ama Sadaka, David M. Hinkle, E. Rand Simpson. (2011) Current treatments for radiation retinopathy. Acta Oncologica 50:1, 6-13
CrossRef100
I. Arratibel-Echarren, K. Albright, J. Dalmau, M.R. Rosenfeld. (2011) Use of Bevacizumab for neurological complications during initial treatment of malignant gliomas. Neurología (English Edition) 26:2, 74-80
CrossRef101
Yves Allory, Stéphane Culine, Alexandre de la Taille. (2011) Kidney Cancer Pathology in the New Context of Targeted Therapy. Pathobiology 78:2, 90-98
CrossRef102
Claudia A. Bertuccio. (2011) Relevance of VEGF and Nephrin Expression in Glomerular Diseases. Journal of Signal Transduction 2011, 1-9
CrossRef103
Carmen P. Escalante, Ali Zalpour. (2011) Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers. Cardiology Research and Practice 2011, 1-8
CrossRef104
Shaad E. Abdullah, Roman Perez-Soler. (2011) Mechanisms of resistance to vascular endothelial growth factor blockade. Cancern/a-n/a
CrossRef105
Aymen A Elfiky, Saadia A Aziz, Patricia J Conrad, Summar Siddiqui, Wolfgang Hackl, Michel Maira, Camp L Robert, Harriet M Kluger. (2011) Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. Journal of Translational Medicine 9:1, 133
CrossRef106
David A. Reardon, Annick Desjardins, Katherine B. Peters, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, April Coan, Stevie Threatt, Allan H. Friedman, Henry S. Friedman. (2011) Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancern/a-n/a
CrossRef107
Napoleon Santos, Justin B. Wenger, Pamela Havre, Yanxia Liu, Roi Dagan, Iman Imanirad, Alison M. Ivey, Robert A. Zlotecki, Chester B. Algood, Scott M. Gilbert, Carmen J. Allegra, Paul Okunieff, Johannes Vieweg, Nam H. Dang, Hendrik Luesch, Long H. Dang. (2011) Combination Therapy for Renal Cell Cancer: What Are Possible Options?. Oncology 81:3-4, 220-229
CrossRef108
Stacey D Finley, Marianne O Engel-Stefanini, P I Imoukhuede, Aleksander S Popel. (2011) Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Systems Biology 5:1, 193
CrossRef109
Simon P. Kim, Paul L. Crispen, R. Houston Thompson, Christopher J. Weight, Stephen A. Boorjian, Brian A. Costello, Christine M. Lohse, Bradley C. Leibovich. (2011) Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma. Cancern/a-n/a
CrossRef110
Daniel P. Lindholm, Barbro Eriksson, Dan Granberg. (2010) Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma. Medical Oncology
CrossRef111
Ilse Roodink, William P.J. Leenders. (2010) Targeted therapies of cancer: Angiogenesis inhibition seems not enough. Cancer Letters 299:1, 1-10
CrossRef112
M. Ronzoni, M. Manzoni, S. Mariucci, F. Loupakis, S. Brugnatelli, K. Bencardino, B. Rovati, C. Tinelli, A. Falcone, E. Villa, M. Danova. (2010) Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Annals of Oncology 21:12, 2382-2389
CrossRef113
Nicola Maurea, Carmela Coppola, Gianluca Ragone, Giuseppe Frasci, Annamaria Bonelli, Carmela Romano, Rosario Vincenzo Iaffaioli. (2010) Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. Journal of Cardiovascular Medicine 11:12, 861-868
CrossRef114
Bing Wang, Pravin T.P. Kaumaya, David E. Cohn. (2010) Immunization with synthetic VEGF peptides in ovarian cancer. Gynecologic Oncology 119:3, 564-570
CrossRef115
Tait Shanafelt, Clive Zent, John Byrd, Charles Erlichman, Betsy Laplant, Asish Ghosh, Timothy Call, Miguel Villalona-Calero, Diane Jelinek, Deborah Bowen, Kristina Laumann, Wenting Wu, Curtis Hanson, Neil Kay. (2010) Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 51:12, 2222-2229
CrossRef116
Saritha Sandra D'Souza, Anupama E. Gururaj, Harsha M. Raj, Jochen Rössler, Bharathi P. Salimath. (2010) Inhibition of ascites tumor growth in vivo by sTie-2 is potentiated by a combinatorial therapy with sFLT-1. The Journal of Gene Medicine 12:12, 968-980
CrossRef117
Jin Ma, TiePei Zhu, Xiajin Tang, Panpan Ye, Zhen Zhang. (2010) Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. Clinical & Experimental Ophthalmology 38:9, 875-884
CrossRef118
Hitomi Nagayama, Kazufumi Matsumoto, Naoyuki Isoo, Hideki Ohno, Naoyuki Takahashi, Takashi Nakaoka, Masaru Shinozaki, Makoto Watanabe, Yusuke Inoue, Fumitaka Nagamura, Naoki Oyaizu, Naohide Yamashita. (2010) Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clinical Journal of Gastroenterology 3:6, 307-317
CrossRef119
Adrian M Jubb, Adrian L Harris. (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. The Lancet Oncology 11:12, 1172-1183
CrossRef120
Attila Molvarec, Mika Ito, Tomoko Shima, Satoshi Yoneda, Gergely Toldi, Balázs Stenczer, Barna Vásárhelyi, János Rigó, Shigeru Saito. (2010) Decreased proportion of peripheral blood vascular endothelial growth factor–expressing T and natural killer cells in preeclampsia. American Journal of Obstetrics and Gynecology 203:6, 567.e1-567.e8
CrossRef121
H. F. Langer, K.-J. Chung, V. V. Orlova, E. Y. Choi, S. Kaul, M. J. Kruhlak, M. Alatsatianos, R. A. DeAngelis, P. A. Roche, P. Magotti, X. Li, M. Economopoulou, S. Rafail, J. D. Lambris, T. Chavakis. (2010) Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 116:22, 4395-4403
CrossRef122
Cécile Ortholan, Jérôme Durivault, Jean-Michel Hannoun-Levi, Mélanie Guyot, Christine Bourcier, Damien Ambrosetti, Stephen Safe, Gilles Pagès. (2010) Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment. European Journal of Cancer 46:16, 3022-3036
CrossRef123
Mark A. Perazella, Gilbert W. Moeckel. (2010) Nephrotoxicity From Chemotherapeutic Agents: Clinical Manifestations, Pathobiology, and Prevention/Therapy. Seminars in Nephrology 30:6, 570-581
CrossRef124
Shivanni Kummar, Helen X. Chen, John Wright, Susan Holbeck, Myrtle Davis Millin, Joseph Tomaszewski, James Zweibel, Jerry Collins, James H. Doroshow. (2010) Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nature Reviews Drug Discovery 9:11, 843-856
CrossRef125
Vera Eremina, Susan E. Quaggin. (2010) Biology of Anti-Angiogenic Therapy–Induced Thrombotic Microangiopathy. Seminars in Nephrology 30:6, 582-590
CrossRef126
Huan N. Vu, Walter J. Miller, Sarah A. O'Connor, Mei He, Peter H. Schafer, Faribourz Payvandi, George W. Muller, David I. Stirling, Steven K. Libutti. (2010) CC-5079: A Small Molecule with MKP1, Antiangiogenic, and Antitumor Activity. Journal of Surgical Research 164:1, 116-125
CrossRef127
Kyungik Lee, Ki-Woong Jeong, Yeonjoo Lee, Ji Yeon Song, Maeng Sup Kim, Gwan Sun Lee, Yangmee Kim. (2010) Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. European Journal of Medicinal Chemistry 45:11, 5420-5427
CrossRef128
M L Subramanian, G Abedi, S Ness, E Ahmed, M Fenberg, M K Daly, A Houranieh, E B Feinberg. (2010) Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye 24:11, 1708-1715
CrossRef129
Emily S. Robinson, Eliyahu V. Khankin, S. Ananth Karumanchi, Benjamin D. Humphreys. (2010) Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker. Seminars in Nephrology 30:6, 591-601
CrossRef130
R. Goodwin, K. Ding, L. Seymour, A. LeMaitre, A. Arnold, F. A. Shepherd, M. Dediu, T. Ciuleanu, D. Fenton, M. Zukin, D. Walde, F. Laberge, M. Vincent, P. M. Ellis, S. A. Laurie, . (2010) Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Annals of Oncology 21:11, 2220-2226
CrossRef131
Olivier Adotevi, Helene Pere, Patrice Ravel, Nacilla Haicheur, Cecile Badoual, Nathalie Merillon, Jacques Medioni, Severine Peyrard, Stephane Roncelin, Virginie Verkarre, Arnaud Mejean, Wolf H. Fridman, Stephane Oudard, Eric Tartour. (2010) A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients. Journal of Immunotherapy 33:9, 991-998
CrossRef132
K.A. Slimani, W. Allam, Y. Sbitti, M. Ichou, H. Errihani. (2010) Actualités thérapeutiques dans le cancer du rein métastatique. Journal Africain du Cancer / African Journal of Cancer 2:4, 231-234
CrossRef133
Juan Barbastefano, Jorge A. Garcia, Paul Elson, Laura S. Wood, Brian R. Lane, Robert Dreicer, Steven C. Campbell, Brian I. Rini. (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU International 106:9, 1266-1269
CrossRef134
Ming-Mo Hou, Jia-Juan Hsieh, Nai-Jen Chang, Hsuan-Ying Huang, Hung-Ming Wang, Cheng-Keng Chuang, Todd Hsu, John Wen-Cheng Chang. (2010) Response to Sorafenib in a Patient with Metastatic Xp11 Translocation Renal Cell Carcinoma. Clinical Drug Investigation 30:11, 799-804
CrossRef135
James J. Vredenburgh, Annick Desjardins, John P. Kirkpatrick, David A. Reardon, Katherine B. Peters, James E. Herndon II, Jennifer Marcello, Leighann Bailey, Stevie Threatt, John Sampson. (2010) Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated with Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation OncologyBiologyPhysics
CrossRef136
Hirotsugu Kenmotsu, Masahiro Yasunaga, Koichi Goto, Tatsuya Nagano, Jun-ichiro Kuroda, Yoshikatsu Koga, Amane Takahashi, Yutaka Nishiwaki, Yasuhiro Matsumura. (2010) The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer 116:19, 4597-4604
CrossRef137
Przemyslaw Twardowski, Walter M. Stadler, Paul Frankel, Primo N. Lara, Christopher Ruel, Gurkamal Chatta, Elisabeth Heath, David I. Quinn, David R. Gandara. (2010) Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial. Urology 76:4, 923-926
CrossRef138
Robert Goldstein, Lisa Pickering, James Larkin. (2010) Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. Expert Review of Anticancer Therapy 10:10, 1545-1557
CrossRef139
Ushma S. Neill. (2010) Napoleone Ferrara receives the 2010 Lasker~DeBakey Clinical Award for breakthroughs in angiogenesis research. Journal of Clinical Investigation 120:10, 3409-3412
CrossRef140
Yasuhito Fujisaka, Yasuhide Yamada, Noboru Yamamoto, Toshio Shimizu, Yutaka Fujiwara, Kazuhiko Yamada, Tomohide Tamura, Hiroyuki Watanabe, Yu-Nien Sun, Michael B. Bass, Mitsuo Seki. (2010) Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 66:5, 935-943
CrossRef141
David Ternant, Nicolas Cézé, Thierry Lecomte, Danielle Degenne, Anne-Claire Duveau, Hervé Watier, Etienne Dorval, Gilles Paintaud. (2010) An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics. Therapeutic Drug Monitoring 32:5, 647-652
CrossRef142
Nicolas Girard. (2010) Thymic Tumors. Journal of Thoracic Oncology 5, S291-S295
CrossRef143
Richard M. Zuniga, Roy Torcuator, Rajan Jain, John Anderson, Thomas Doyle, Lonni Schultz, Tom Mikkelsen. (2010) Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. Journal of Neuro-Oncology 99:2, 237-242
CrossRef144
Francisco Robert, Alan Sandler, Joan H. Schiller, Glenn Liu, Karen Harper, Lev Verkh, Xin Huang, Jennifer Ilagan, Lesley Tye, Richard Chao, Anne M. Traynor. (2010) Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemotherapy and Pharmacology 66:4, 669-680
CrossRef145
Flávia Gomes Góes Rocha, Karen Cristina Barbosa Chaves, Roger Chammas, Jean Pierre Schatzmann Peron, Luiz Vicente Rizzo, Nestor Schor, Maria Helena Bellini. (2010) Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice. Cancer Immunology, Immunotherapy 59:9, 1357-1365
CrossRef146
Sebastiano Buti, Silvia Lazzarelli, Matteo Dalla Chiesa, Cecilia Simonelli, Giovanni Lo Re, Arvin Lheshi, Spazzapan Simon, Rodolfo Mattioli, Caterina Caminiti, Giancarlo Mazza, Maddalena Donini, Rodolfo Passalacqua. (2010) Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study. Journal of Immunotherapy 33:7, 735-741
CrossRef147
Giuseppe Curigliano, Erica L. Mayer, Harold J. Burstein, Eric P. Winer, Aron Goldhirsch. (2010) Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress in Cardiovascular Diseases 53:2, 94-104
CrossRef148
Raymond C. Wadlow, David P. Ryan. (2010) The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer 116:15, 3537-3548
CrossRef149
D. Tsavachidou-Fenner, N. Tannir, P. Tamboli, W. Liu, D. Petillo, B. Teh, G. B. Mills, E. Jonasch. (2010) Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Annals of Oncology 21:8, 1599-1606
CrossRef150
Manuela Schmidinger, Joaquim Bellmunt. (2010) Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treatment Reviews 36:5, 416-424
CrossRef151
M.P. Smerdel, K.D. Steffensen, M. Waldstrøm, I. Brandslund, A. Jakobsen. (2010) The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecologic Oncology 118:2, 167-171
CrossRef152
Carolina Muriel, Emilio Esteban, Norberto Corral, Paula J. Fonseca, María Luque, José Pablo Berros, Yolanda Fernández, Pilar Blay, Joaquín Fra, Noemí Villanueva, Miguel Sanmamed, Pablo Pardo, Marta Izquierdo, José María Vieitez, Enrique Estrada, Ángel J. Lacave. (2010) Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. Clinical and Translational Oncology 12:8, 562-567
CrossRef153
Pia P. Vihinen, Micaela Hernberg, Meri-Sisko Vuoristo, Kristiina Tyynelä, Marjut Laukka, Johan Lundin, Johanna Ivaska, Seppo Pyrhönen. (2010) A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma. Melanoma Research 20:4, 318-325
CrossRef154
Giannis Mountzios, Meletios-Athanassios Dimopoulos, Jean-Charles Soria, Despina Sanoudou, Christos A. Papadimitriou. (2010) Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. Critical Reviews in Oncology/Hematology 75:2, 94-109
CrossRef155
Shanchun Guo, Laronna S. Colbert, Miles Fuller, Yuanyuan Zhang, Ruben R. Gonzalez-Perez. (2010) Vascular endothelial growth factor receptor-2 in breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1806:1, 108-121
CrossRef156
M Watanabe, J L Boyer, R G Crystal. (2010) AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Therapy 17:8, 1042-1051
CrossRef157
Christina Derleth, Ingrid A. Mayer. (2010) Antiangiogenic Therapies in Early-Stage Breast Cancer. Clinical Breast Cancer 10:0, E23-E31
CrossRef158
Benjamin P. Nicholson, Andrew P. Schachat. (2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 248:7, 915-930
CrossRef159
Joleen Hubbard, Axel Grothey. (2010) Antiangiogenesis agents in colorectal cancer. Current Opinion in Oncology 22:4, 374-380
CrossRef160
Przemyslaw W. Twardowski, Robert A. Figlin. 2010. Treatment of Metastatic Kidney Cancer. , 343-350.
CrossRef161
Maxine Sun, Giovanni Lughezzani, Paul Perrotte, Pierre I. Karakiewicz. (2010) Treatment of metastatic renal cell carcinoma. Nature Reviews Urology 7:6, 327-338
CrossRef162
Qiang Chen, Rong-Bo Lin, Yun-Bin Ye, Nan-Feng Fan, Zeng-Qing Guo, Zhi-Feng Zhou, Xiao-Jie Wang, Min-Shui Chen, Shu-Pin Chen, Jie-Yu Li. (2010) The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report. Medical Oncology 27:2, 554-558
CrossRef163
Alejandro Forner, Carlos Rodríguez De Lope, María Reig, Jordi Bruix. (2010) Tratamiento del carcinoma hepatocelular avanzado. Gastroenterología y Hepatología 33:6, 461-468
CrossRef164
Olivier Rixe, Brian Rini. (2010) Renal cell carcinoma: ten years of significant advances. Targeted Oncology 5:2, 73-74
CrossRef165
Qiong Zhou, Haiyi Liu, Fuyuan Qiao, Yuanyuan Wu, Jingjing Xu. (2010) VEGF deficit is involved in endothelium dysfunction in preeclampsia. Journal of Huazhong University of Science and Technology [Medical Sciences] 30:3, 370-374
CrossRef166
George J. Netto, Jonathan I. Epstein. (2010) Theranostic and prognostic biomarkers. Pathology 42:4, 384-394
CrossRef167
Marta Barontini, Patricia L.M. Dahia. (2010) VHL Disease. Best Practice & Research Clinical Endocrinology & Metabolism 24:3, 401-413
CrossRef168
Bristi Basu, Tim Eisen. (2010) Perspectives in drug development for metastatic renal cell cancer. Targeted Oncology 5:2, 139-156
CrossRef169
E. Herrmann, S. Bierer, C. Wülfing. (2010) Update on systemic therapies of metastatic renal cell carcinoma. World Journal of Urology 28:3, 303-309
CrossRef170
Gennady Bratslavsky, Ziya Kirkali. (2010) The Changing Face of Renal-Cell Carcinoma. Journal of Endourology 24:5, 753-757
CrossRef171
David F. McDermott, Daniel J. George. (2010) Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data. Cancer Treatment Reviews 36:3, 216-223
CrossRef172
Chau Tran, Thomas McNally, Michael J Birrer. (2010) Personalizing therapy for ovarian cancer. Therapy 7:3, 229-239
CrossRef173
Toni K. Choueiri, Mei Sheng Duh, Jessica Clement, Ashley J. Brick, Miranda J. Rogers, Christabel Kwabi, Karishma Shah, Andrew G. Percy, Lucia Antràs, Sujata S. Jayawant, Kristina Chen, Si-Tien Wang, Andi Luka, Maureen P. Neary, David McDermott, William K. Oh. (2010) Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU International 105:9, 1247-1254
CrossRef174
Vishal Ranpura, Bhargava Pulipati, David Chu, Xiaolei Zhu, Shenhong Wu. (2010) Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis. American Journal of Hypertension 23:5, 460-468
CrossRef175
Nathan Lawrentschuk, Ian D. Davis, Damien M. Bolton, Andrew M. Scott. (2010) Functional imaging of renal cell carcinoma. Nature Reviews Urology 7:5, 258-266
CrossRef176
Hartmut Kirchner, Dirk Strumberg, Amit Bahl, Friedrich Overkamp. (2010) Patient-based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 10:4, 585-596
CrossRef177
Vishal Ranpura, Sanjaykumar Hapani, Jeff Chuang, Shenhong Wu. (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncologica 49:3, 287-297
CrossRef178
SHIRI ZAYIT-SOUDRY, ESTHER ZEMEL, ANAT LOEWENSTEIN, IDO PERLMAN. (2010) SAFETY EVALUATION OF REPEATED INTRAVITREAL INJECTIONS OF BEVACIZUMAB AND RANIBIZUMAB IN RABBIT EYES. Retina 30:4, 671-681
CrossRef179
Gerald W. Prager, Eva-Maria Lackner, Maria-Theresa Krauth, Matthias Unseld, Marina Poettler, Sylvia Laffer, Sabine Cerny-Reiterer, Wolfgang Lamm, Gabriela V. Kornek, Bernd R. Binder, Christoph C. Zielinski, Peter Valent. (2010) Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. Molecular Oncology 4:2, 150-160
CrossRef180
Li Ma, Ferenc Reinhardt, Elizabeth Pan, Jürgen Soutschek, Balkrishen Bhat, Eric G Marcusson, Julie Teruya-Feldstein, George W Bell, Robert A Weinberg. (2010) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nature Biotechnology 28:4, 341-347
CrossRef181
Denise A. Yardley. (2010) Integrating Bevacizumab Into the Treatment of Patients With Early-Stage Breast Cancer: Focus on Cardiac Safety. Clinical Breast Cancer 10:2, 119-129
CrossRef182
Giuseppe Lombardi, Fable Zustovich, Martin Donach, Maurizia Dalla Palma, Ornella Nicoletto, Davide Pastorelli. (2010) An update on targeted therapy in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations
CrossRef183
F. Elice, F. Rodeghiero. (2010) Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thrombosis Research 125, S55-S57
CrossRef184
Thean Hsiang TAN, Ganesalingam PRANAVAN, Hodo Z HAXHIMOLLA, Desmond YIP. (2010) New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Asia-Pacific Journal of Clinical Oncology 6:1, 5-18
CrossRef185
Hester van Cruijsen, Emile E. Voest, Cornelis J.A. Punt, Klaas Hoekman, Petronella O. Witteveen, Martijn R. Meijerink, Thomas A. Puchalski, Jane Robertson, Owain Saunders, Juliane M. Jürgensmeier, Carla M.L. van Herpen, Giuseppe Giaccone. (2010) Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. European Journal of Cancer 46:5, 901-911
CrossRef186
Michele Basso, Alessandra Cassano, Carlo Barone. (2010) A survey of therapy for advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 28:2, 121-133
CrossRef187
C.A. Cuenod, L. Fournier, D. Balvay, R. Thiam, S. Oudard. (2010) Biomarqueurs en imagerie pour l’évaluation des nouvelles thérapies anticancéreuses. Oncologie 12:3, 178-186
CrossRef188
Susan A. J. Vaziri, Jenny Kim, Mahrukh K. Ganapathi, Ram Ganapathi. (2010) Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors. Current Oncology Reports 12:2, 102-108
CrossRef189
KENJI YAMASHIRO, AKITAKA TSUJIKAWA, KAZUAKI MIYAMOTO, HIDEASU OH, ATSUSHI OTANI, HIROSHI TAMUARA, SOTARO OOTO, MANABU SASAHARA, DAISUKE IWAMA, NAGAHISA YOSHIMURA. (2010) STERILE ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB OBTAINED FROM A SINGLE BATCH. Retina 30:3, 485-490
CrossRef190
Robyn J. Macfarlane, Kim N. Chi. (2010) Novel Targeted Therapies for Prostate Cancer. Urologic Clinics of North America 37:1, 105-119
CrossRef191
Davide Pastorelli, Fable Zustovich, Giovanni Faggioni, Stefania Zovato, Martin Donach, Ornella Nicoletto, Miriam Farina, Lara Furini, Renato Ceravolo, Paolo Carli, Giuseppe Lombardi. (2010) Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma. Anti-Cancer Drugs 21:2, 210-213
CrossRef192
Zachary A. Knight, Henry Lin, Kevan M. Shokat. (2010) Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10:2, 130-137
CrossRef193
W. Marston Linehan, Gennady Bratslavsky, Peter A. Pinto, Laura S. Schmidt, Len Neckers, Donald P. Bottaro, Ramaprasad Srinivasan. (2010) Molecular Diagnosis and Therapy of Kidney Cancer*. Annual Review of Medicine 61:1, 329-343
CrossRef194
Wei Luo, Wang-Jun Liao, Li Ma, Yong-Ta Huang, Min Shi, Qian Wen, Xiao-Ning Wang. (2010) Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin. Cancer Immunology, Immunotherapy 59:2, 247-256
CrossRef195
M. Schenck, L.-O. Muegge. (2010) „Targeted therapy“ bei metastasiertem Nierenzellkarzinom. Der Onkologe 16:2, 157-167
CrossRef196
Asako Itoh, Katsumi Iwase, Shin Jimbo, Haruo Yamamoto, Naoki Yamamoto, Masahiro Kokubo, Takao Senda, Akira Nakai, Akio Nagagasaka, Takaaki Nagasaka, Yatsuka Hibi, Teppei Seko. (2010) Expression of Vascular Endothelial Growth Factor and Presence of Angiovascular Cells in Tissues from Different Thyroid Disorders. World Journal of Surgery 34:2, 242-248
CrossRef197
N Murukesh, C Dive, G C Jayson. (2010) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. British Journal of Cancer 102:1, 8-18
CrossRef198
G Mickisch, M Gore, B Escudier, G Procopio, S Walzer, M Nuijten. (2010) Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. British Journal of Cancer 102:1, 80-86
CrossRef199
Nicole M. Agostino, Rebecca Gingrich, Joseph J. Drabick. (2010) Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature. Advances in Urology 2010, 1-4
CrossRef200
Jin-Sun Kong, Seung-Ah Yoo, Jung-Wook Kim, Seung-Pil Yang, Chi-Bom Chae, Valeria Tarallo, Sandro De Falco, Sung-Ho Ryu, Chul-Soo Cho, Wan-Uk Kim. (2010) Antiâneuropilin-1 peptide inhibition of synoviocyte survival, angiogenesis, and experimental arthritis. Arthritis & Rheumatism 62:1, 179-190
CrossRef201
Wei Zhang, Yi Lin, Baoshi Chen, Sonya Wei Song, Tao Jiang. (2010) Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features. Child's Nervous System 26:1, 137-143
CrossRef202
Eugene Hwang, Hyo Jin Lee, Chong Koo Sul, Jae Sung Lim. (2010) Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience. Korean Journal of Urology 51:7, 450
CrossRef203
Alfredo Carrato Mena, Enrique Grande Pulido, Carmen Guillén-Ponce. (2010) Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anti-Cancer Drugs 21:Supplement 1, S3-S11
CrossRef204
John McLaughlin, Vadim Markovtsov, Hui Li, Steve Wong, Marina Gelman, Yanhong Zhu, Christian Franci, D. Wayne Lang, Erlina Pali, Joe Lasaga, Caroline Low, Feifei Zhao, Betty Chang, Tarikere L. Gururaja, Weiduan Xu, Muhammad Baluom, David Sweeny, David Carroll, Arvinder Sran, Sambaiah Thota, Manjeet Parmer, Angela Romane, George Clemens, Elliott Grossbard, Kunbin Qu, Yonchu Jenkins, Taisei Kinoshita, Vanessa Taylor, Sacha J. Holland, Ankush Argade, Rajinder Singh, Polly Pine, Donald G. Payan, Yasumichi Hitoshi. (2010) Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. Journal of Cancer Research and Clinical Oncology 136:1, 99-113
CrossRef205
P. Starlinger, K. Gebhardt, T. Grünberger, C. Brostjan. (2010) Systemic effects of anti-VEGF therapy – Mini-review. European Surgery 42:1, 12-16
CrossRef206
Ingrid A. Boere, Paul Hamberg, Stefan Sleijfer. (2010) It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factorâvascular endothelial growth factor receptor pathway in patients with solid malignancies. Cancer Science 101:1, 7-15
CrossRef207
Norihiko Tsuchiya, Tomonori Habuchi. (2010) Current status and future issue of molecular targeted agents in solid tumors: lessons learned from renal cell carcinoma. Drug Delivery System 25:2, 134-142
CrossRef208
Charles W. Kanaly, Dale Ding, Amy B. Heimberger, John H. Sampson. (2010) Clinical Applications of a Peptide-Based Vaccine for Glioblastoma. Neurosurgery Clinics of North America 21:1, 95-109
CrossRef209
Bettina Reismüller, Amedeo A. Azizi, Andreas Peyrl, Monika Heinrich, Mariella Gruber-Olipitz, Doris Luckner, Klara Vergesslich Rothschild, Irene Slavc. (2010) Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatric Blood & Cancern/a-n/a
CrossRef210
Hassane Izzedine, Christophe Massard, Jean Philippe Spano, François Goldwasser, David Khayat, Jean Charles Soria. (2010) VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. European Journal of Cancer 46:2, 439-448
CrossRef211
D. Sánchez Zalabardo, J.A. Millán Serrano, Á. De Pablo Cárdenas, J.Á. Cuesta Alcalá. (2010) Treatment of locally advanced renal tumors. Actas Urológicas Españolas (English Edition) 34:2, 134-141
CrossRef212
Manju L. Subramanian, Steven Ness, Gelareh Abedi, Ednan Ahmed, Mary Daly, Edward Feinberg, Sumit Bhatia, Payal Patel, Maileah Nguyen, Antoun Houranieh. (2009) Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial. American Journal of Ophthalmology 148:6, 875-882.e1
CrossRef213
Susana M. Campos, Benjamin D. Humphreys. (2009) Safety of Bevacizumab in Advanced Ovarian and Müllerian Cancers: A Review. Clinical Cancer Reviews 3:1, E7-E13
CrossRef214
Ronan J. Kelly, Olivier Rixe. (2009) Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Targeted Oncology 4:4, 297-305
CrossRef215
Giuseppe Di Lorenzo, Riccardo Autorino, Cora N. Sternberg. (2009) Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era. European Urology 56:6, 959-971
CrossRef216
Ila Tamaskar, Roberto Pili. (2009) Update on novel agents in renal cell carcinoma. Expert Review of Anticancer Therapy 9:12, 1817-1827
CrossRef217
Mariëtte HW Kappers, Joep HM van Esch, Stefan Sleijfer, AH Jan Danser, Anton H van den Meiracker. (2009) Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. Journal of Hypertension 27:12, 2297-2309
CrossRef218
R Humar, L Zimmerli, E Battegay. (2009) Angiogenesis and hypertension: an update. Journal of Human Hypertension 23:12, 773-782
CrossRef219
Fiona J Gilbert, Trevor S Ahearn. (2009) Dynamic contrast-enhanced MRI in cancer. Imaging in Medicine 1:2, 173-186
CrossRef220
Nikhil G Thaker, Ian F Pollack. (2009) Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Review of Neurotherapeutics 9:12, 1815-1836
CrossRef221
J.M. Foidart, J.P. Schaaps, F. Chantraine, C. Munaut, S. Lorquet. (2009) Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia—a step forward but not the definitive answer. Journal of Reproductive Immunology 82:2, 106-111
CrossRef222
Alain Ravaud, Hervé Wallerand. (2009) Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin Inhibitors. European Urology Supplements 8:10, 793-798
CrossRef223
Peter E Clark. (2009) The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney International 76:9, 939-945
CrossRef224
Sergio Bracarda. (2009) Metastatic Renal Cell Carcinoma: Pathogenesis and the Current Medical Landscape. European Urology Supplements 8:10, 787-792
CrossRef225
Gaetano Facchini, Francesco Perri, Michele Caraglia, Carmela Pisano, Stefano Striano, Luigi Marra, Francesco Fiore, Pasquale Aprea, Sandro Pignata, Rosario Vincenzo Iaffaioli. (2009) New treatment approaches in renal cell carcinoma. Anti-Cancer Drugs 20:10, 893-900
CrossRef226
Bristi Basu, Swethajit Biswas, Jessica Wrigley, Bhawna Sirohi, Pippa Corrie. (2009) Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Review of Anticancer Therapy 9:11, 1583-1598
CrossRef227
Yann Neuzillet, Stéphane Culine, Jean-Jacques Patard. (2009) Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine. International Journal of Urology 16:11, 855-861
CrossRef228
M. Ringhoffer, L. Rinnab, R. Küfer, J. Greiner. (2009) Systemtherapie des metastasierten Nierenzellkarzinoms. Der Urologe 48:11, 1308-1317
CrossRef229
Kim N. Chi, Anders Bjartell, David Dearnaley, Fred Saad, Fritz H. Schröder, Cora Sternberg, Bertrand Tombal, Tapio Visakorpi. (2009) Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. European Urology 56:4, 594-605
CrossRef230
Jerry Y. Hsu, Heather A. Wakelee. (2009) Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor. BioDrugs 23:5, 289-304
CrossRef231
TIMOTHY Y. Y. LAI, DAVID T. L. LIU, KWOK-PING CHAN, FIONA O. J. LUK, CHI-PUI PANG, DENNIS S. C. LAM. (2009) VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina 29:9, 1218-1226
CrossRef232
Hans Petter Eikesdal, Raghu Kalluri. (2009) Drug resistance associated with antiangiogenesis therapy. Seminars in Cancer Biology 19:5, 310-317
CrossRef233
Vanessa Baeriswyl, Gerhard Christofori. (2009) The angiogenic switch in carcinogenesis. Seminars in Cancer Biology 19:5, 329-337
CrossRef234
(2009) Binding Models of Flavonols to Human Vascular Endothelial Growth Factor Receptor 2. Bulletin of the Korean Chemical Society 30:9, 2083-2086
CrossRef235
Gregory P. Sfakianos, T. Michael Numnum, Caitlin B. Halverson, Deepa Panjeti, James E. Kendrick, J. Michael Straughn. (2009) The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study. Gynecologic Oncology 114:3, 424-426
CrossRef236
J. -M. Halimi, M. Azizi, G. Bobrie, O. Bouché, G. Deray, G. Guetz, T. Lecomte, B. Levy, J. -J. Mourad, D. Nochy, S. Oudard, P. Rieu, D. Sahali. (2009) Effets vasculaires et rénaux des médicaments anti-angiogéniques: recommandations françaises pour la pratique. Oncologie 11:9-10, 476-489
CrossRef237
Lai-Chun Ong, In-Chin Song, Yi Jin, Irene H. C. Kee, Eeyan Siew, Sidney Yu, Choon-Hua Thng, Hung Huynh, Pierce K. H. Chow. (2009) Effective Inhibition of Xenografts of Hepatocellular Carcinoma (HepG2) by Rapamycin and Bevacizumab in an Intrahepatic Model. Molecular Imaging and Biology 11:5, 334-342
CrossRef238
Anthony W. Tolcher. (2009) Stable Disease Is a Valid End Point in Clinical Trials. The Cancer Journal 15:5, 374-378
CrossRef239
Anil A. Thomas, Brian I. Rini, Andrew J. Stephenson, Jorge A. Garcia, Amr Fergany, Venkatesh Krishnamurthi, Andrew C. Novick, Inderbir S. Gill, Eric A. Klein, Ming Zhou, Steven C. Campbell. (2009) Surgical Resection of Renal Cell Carcinoma After Targeted Therapy. The Journal of Urology 182:3, 881-886
CrossRef240
Wilfred D. Stein, Hui Huang, Michael Menefee, Maureen Edgerly, Herb Kotz, Andrew Dwyer, James Yang, Susan E. Bates. (2009) Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell Carcinoma. The Cancer Journal 15:5, 441-447
CrossRef241
Sarah Blagden, Hani Gabra. (2009) Promising molecular targets in ovarian cancer. Current Opinion in Oncology 21:5, 412-419
CrossRef242
Kevin G Kwan, Anil Kapoor. (2009) Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. Current Opinion in Supportive and Palliative Care 3:3, 157-165
CrossRef243
Nathalie Theou-Anton, Sandrine Faivre, Chantal Dreyer, Eric Raymond. (2009) Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer. Drug Safety 32:9, 717-734
CrossRef244
Iñaki Marina Clopés, David Filella Agulló, Joaquin López-Contreras, Alexandre Roca. (2009) Hipertensión arterial en pacientes en tratamiento con bevacizumab. Medicina Clínica 133:9, 360-361
CrossRef245
Axel Grothey, Evanthia Galanis. (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nature Reviews Clinical Oncology 6:9, 507-518
CrossRef246
Iris J. A. M. Jonkers, Marjolijn Buren. (2009) Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clinical and Experimental Nephrology 13:4, 397-401
CrossRef247
N. Mellas, S. Mellas, O. Masbah, H. Errihani. (2009) Mise au point sur le traitement médical du cancer du rein métastatique. Journal africain du cancer / African Journal of Cancer 1:3, 154-158
CrossRef248
Ziya Kirkali, Emre Tüzel. (2009) Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?. Future Oncology 5:6, 871-888
CrossRef249
K Guse, I Diaconu, M Rajecki, M Sloniecka, T Hakkarainen, A Ristimäki, A Kanerva, S Pesonen, A Hemminki. (2009) Ad5/3-9HIF-Δ24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Therapy 16:8, 1009-1020
CrossRef250
Edmund Chiong, Christopher G Wood, Vitaly Margulis. (2009) Role of cytoreductive nephrectomy in renal cell carcinoma. Future Oncology 5:6, 859-869
CrossRef251
Helen X. Chen, Jessica N. Cleck. (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nature Reviews Clinical Oncology 6:8, 465-477
CrossRef252
Jacques Medioni, Eugeniu Banu, Dominique Helley, Florian Scotte, Laure Fournier, Arnaud Mejean, Antoine Chedid, Michel Azizi, Jean-Marie Andrieu, Stéphane Oudard. (2009) Salvage Therapy with Bevacizumab–Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series. European Urology 56:1, 207-211
CrossRef253
Christian Wülfing, Jean-Pascal H. Machiels, Dirk J. Richel, Marc-Oliver Grimm, Uwe Treiber, Marco R. De Groot, Philippe Beuzeboc, Roma Parikh, Frank Pétavy, Iman A. El-Hariry. (2009) A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115:13, 2881-2890
CrossRef254
Joaquim Bellmunt, Per Flodgren, Jan Roigas, Stéphane Oudard. (2009) Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU International 104:1, 10-18
CrossRef255
Elena Soto-Vega, Carlos Arroyo, Yvonne Richaud-Patin, Mario García-Carrasco, Luis G. Vázquez-Lavista, Luis Llorente. (2009) P-glycoprotein activity in renal clear cell carcinoma. Urologic Oncology: Seminars and Original Investigations 27:4, 363-366
CrossRef256
Carla M.L. van Herpen, Winette T.A. van der Graaf, Wim J.G. Oyen. (2009) Time to target evaluation criteria of targeted therapies. Nuclear Medicine Communications 30:7, 487-489
CrossRef257
Edward T.H. Yeh, Courtney L. Bickford. (2009) Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology 53:24, 2231-2247
CrossRef258
I.M.E. Desar, C.M.L. van Herpen, H.W.M. van Laarhoven, J.O. Barentsz, W.J.G. Oyen, W.T.A. van der Graaf. (2009) Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treatment Reviews 35:4, 309-321
CrossRef259
Kelly L. Snider, Michael L. Maitland. (2009) Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Targeted Oncology 4:2, 67-76
CrossRef260
Shigeo Ninomiya, Masafumi Inomata, Masaaki Tajima, Anwar Tawik Ali, Yoshitake Ueda, Norio Shiraishi, Seigo Kitano. (2009) Effect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in Mice. Journal of Surgical Research 154:2, 196-202
CrossRef261
Marco Bonini-Filho, Rogério A. Costa, Daniela Calucci, Rodrigo Jorge, Luiz A.S. Melo, Ingrid U. Scott. (2009) Intravitreal Bevacizumab for Diabetic Macular Edema Associated With Severe Capillary Loss: One-Year Results of a Pilot Study. American Journal of Ophthalmology 147:6, 1022-1030.e5
CrossRef262
Masaki Watanabe, Julie L. Boyer, Ronald G. Crystal. (2009) Genetic Delivery of Bevacizumab to Suppress Vascular Endothelial Growth Factor-Induced High-Permeability Pulmonary Edema. Human Gene Therapy 20:6, 598-610
CrossRef263
Ronan J. Kelly, Bertrand Billemont, Olivier Rixe. (2009) Renal toxicity of targeted therapies. Targeted Oncology 4:2, 121-133
CrossRef264
Aaron M. Lipskar, Richard D. Glick, Jianzhong Huang, Jason C. Fisher, James DeVoti, Ray Pica, Morris Edelman, Bettie M. Steinberg, Samuel Z. Soffer. (2009) Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma. Journal of Pediatric Surgery 44:6, 1139-1147
CrossRef265
David J. Reeves, Chin Y. Liu. (2009) Treatment of metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology 64:1, 11-25
CrossRef266
Leslie A. Fecher, Ravi K. Amaravadi, Lynn M. Schuchter, Keith T. Flaherty. (2009) Drug Targeting of Oncogenic Pathways in Melanoma. Hematology/Oncology Clinics of North America 23:3, 599-618
CrossRef267
Dale R Shepard, Jorge A Garcia. (2009) Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy 9:6, 795-805
CrossRef268
Hernán Cortés-Funes. (2009) The role of antiangiogenesis therapy: Bevacizumab and beyond. Clinical and Translational Oncology 11:6, 349-355
CrossRef269
Bernard Escudier, Marine Gross Goupil, Christophe Massard, Karim Fizazi. (2009) Sequential therapy in renal cell carcinoma. Cancer 115:S10, 2321-2326
CrossRef270
David F. McDermott. (2009) Immunotherapy of metastatic renal cell carcinoma. Cancer 115:S10, 2298-2305
CrossRef271
Chao-Nan Qian, Dan Huang, Bill Wondergem, Bin Tean Teh. (2009) Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer 115:S10, 2282-2289
CrossRef272
Michael B. Atkins, Ronald M. Bukowski, Bernard J. Escudier, Robert A. Figlin, Gary H. Hudes, William G. Kaelin, W. Marston Linehan, David F. McDermott, James W. Mier, Ivan Pedrosa, Brian I. Rini, Sabina Signoretti, Jeffrey A. Sosman, Bin Tean Teh, Christopher G. Wood, Amado J. Zurita, Laura King. (2009) Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference. Cancer 115:S10, 2247-2251
CrossRef273
Ivan Pedrosa, David C. Alsop, Neil M. Rofsky. (2009) Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer 115:S10, 2334-2345
CrossRef274
Amado J. Zurita, Eric Jonasch, Hua-Kang Wu, Hai T. Tran, John V. Heymach. (2009) Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 115:S10, 2346-2354
CrossRef275
Brian I. Rini. (2009) Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 115:S10, 2306-2312
CrossRef276
Marc C. Smaldone, Jodi K. Maranchie. (2009) Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 27:3, 238-245
CrossRef277
W. Lieb, R. Safa, E. J. Benjamin, V. Xanthakis, X. Yin, L. M. Sullivan, M. G. Larson, H. M. Smith, J. A. Vita, G. F. Mitchell, D. B. Sawyer, R. S. Vasan. (2009) Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. European Heart Journal 30:9, 1121-1127
CrossRef278
Yusuke Oshima, Chiharu Shima, Taku Wakabayashi, Shunji Kusaka, Fumio Shiraga, Masahito Ohji, Yasuo Tano. (2009) Microincision Vitrectomy Surgery and Intravitreal Bevacizumab as a Surgical Adjunct to Treat Diabetic Traction Retinal Detachment. Ophthalmology 116:5, 927-938
CrossRef279
Zaher K. Otrock, Hassan A. Hatoum, Ahmad H. Awada, Rim S. Ishak, Ali I. Shamseddine. (2009) Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives. Critical Reviews in Oncology/Hematology 70:2, 93-102
CrossRef280
Yoichi Mizutani. (2009) Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. International Journal of Urology 16:5, 444-448
CrossRef281
Laurence Bastien, Stéphane Culine, Bernard Paule, Souhil Ledbai, Jean Jacques Patard, Alexandre de la Taille. (2009) Targeted therapies in metastatic renal cancer in 2009. BJU International 103:10, 1334-1342
CrossRef282
Camillo Porta, Cezary Szczylik. (2009) Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treatment Reviews 35:3, 297-307
CrossRef283
Ronald M. Bukowski. (2009) Targeted Therapies: Bevacizumab and interferon-α in metastatic renal-cell carcinoma. Nature Reviews Clinical Oncology 6:5, 253-254
CrossRef284
Jens Soltau, Joachim Drevs. (2009) Mode of action and clinical impact of VEGF signaling inhibitors. Expert Review of Anticancer Therapy 9:5, 649-662
CrossRef285
D. Pouessel, J. -J. Patard, S. Culine. (2009) Stratégie de la prise en charge médicale dans les stades métastatiques. Oncologie 11:5, 278-284
CrossRef286
José Tuñón, José María Ruiz-Moreno, José Luis Martín-Ventura, Luis M. Blanco-Colio, Oscar Lorenzo, Jesús Egido. (2009) Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration. Survey of Ophthalmology 54:3, 339-348
CrossRef287
Manuela Schmidinger, Christoph C. Zielinski. (2009) Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. Cancer Treatment Reviews 35:3, 289-296
CrossRef288
C. Dreyer, E. Raymond, S. Faivre. (2009) Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de Médecine Interne 30:5, 416-424
CrossRef289
Elizabeth R. Plimack, Nizar Tannir, E Lin, B. Nebiyou Bekele, Eric Jonasch. (2009) Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon. Cancer 115:9, 1859-1866
CrossRef290
Jenny J Kim, Brian I Rini. (2009) Recent advances in molecularly targeted therapy in advanced renal cell carcinoma. Therapy 6:3, 309-320
CrossRef291
Martin E. Gutierrez, Shivaani Kummar, Giuseppe Giaccone. (2009) Next generation oncology drug development: opportunities and challenges. Nature Reviews Clinical Oncology 6:5, 259-265
CrossRef292
Vitaly Margulis, Michelle McDonald, Pheroze Tamboli, David A. Swanson, Christopher G. Wood. (2009) Predictors of Oncological Outcome After Resection of Locally Recurrent Renal Cell Carcinoma. The Journal of Urology 181:5, 2044-2051
CrossRef293
H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, J. P. Spano. (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Annals of Oncology 20:5, 807-815
CrossRef294
C Alfaro, N Suarez, A Gonzalez, S Solano, L Erro, J Dubrot, A Palazon, S Hervas-Stubbs, A Gurpide, J M Lopez-Picazo, E Grande-Pulido, I Melero, J L Perez-Gracia. (2009) Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. British Journal of Cancer 100:7, 1111-1119
CrossRef295
Krishnansu S. Tewari, Bradley J. Monk. (2009) Recent Achievements and Future Developments in Advanced and Recurrent Cervical Cancer: Trials of the Gynecologic Oncology Group. Seminars in Oncology 36:2, 170-180
CrossRef296
Tomoaki Fujioka, Wataru Obara, . (2009) Evidence-based clinical practice guidelines for renal cell carcinoma (Summary - JUA 2007 Edition). International Journal of Urology 16:4, 339-353
CrossRef297
H J Mauceri, M A Beckett, H Liang, H G Sutton, S Pitroda, E Galka, E Efimova, T Darga, N N Khodarev, C R King, M C Posner, S Hellman, D W Kufe, R R Weichselbaum. (2009) Translational strategies exploiting TNF-α that sensitize tumors to radiation therapy. Cancer Gene Therapy 16:4, 373-381
CrossRef298
Alexander M. Holston, Cong Qian, Kai F. Yu, Franklin H. Epstein, S. Ananth Karumanchi, Richard J. Levine. (2009) Circulating angiogenic factors in gestational proteinuria without hypertension. American Journal of Obstetrics and Gynecology 200:4, 392.e1-392.e10
CrossRef299
Faina Gurevich, Mark A. Perazella. (2009) Renal Effects of Anti-angiogenesis Therapy: Update for the Internist. The American Journal of Medicine 122:4, 322-328
CrossRef300
Justine Bacchetta, Laurent Juillard, Pierre Cochat, Jean-Pierre Droz. (2009) Paraneoplastic glomerular diseases and malignancies. Critical Reviews in Oncology/Hematology 70:1, 39-58
CrossRef301
Varun Agrawal, Victor Marinescu, Mohit Agarwal, Peter A. McCullough. (2009) Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nature Reviews Cardiology 6:4, 301-311
CrossRef302
Stephen G Schwartz, Harry W Flynn, Ingrid U Scott. (2009) Emerging therapies for diabetic macular edema. Expert Review of Ophthalmology 4:2, 163-171
CrossRef303
X B Trinh, W A A Tjalma, P B Vermeulen, G Van den Eynden, I Van der Auwera, S J Van Laere, J Helleman, E M J J Berns, L Y Dirix, P A van Dam. (2009) The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. British Journal of Cancer 100:6, 971-978
CrossRef304
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Singhal, Aneesh B., Kimberly, W. Taylor, Schaefer, Pamela W., Hedley-Whyte, E. Tessa, . (2009) Case 8-2009. New England Journal of Medicine 360:11, 1126-1137
Full Text305
Joaquim Bellmunt, Emiliano Calvo, Daniel Castellano, Miguel Ángel Climent, Emilio Esteban, Xavier García del Muro, José Luis González-Larriba, Pablo Maroto, José Manuel Trigo. (2009) Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemotherapy and Pharmacology 63:S1, 1-13
CrossRef306
Theo M. de Reijke, Joaquim Bellmunt, Hein van Poppel, Sandrine Marreaud, Matti Aapro. (2009) EORTC-GU group expert opinion on metastatic renal cell cancer. European Journal of Cancer 45:5, 765-773
CrossRef307
A.C. Backen, J. Cummings, C. Mitchell, G. Jayson, T.H. Ward, C. Dive. (2009) ‘Fit-for-purpose’ validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. Journal of Immunological Methods 342:1-2, 106-114
CrossRef308
Mari Saito, Yuji Gunji, Yoshifumi Kashii, Jun Odaka, Tadahiko Yamauchi, Nobuyuki Kanai, Mariko Y. Momoi. (2009) Refractory Kaposiform Hemangioendothelioma That Expressed Vascular Endothelial Growth Factor Receptor (VEGFR)-2 and VEGFR-3. Journal of Pediatric Hematology/Oncology 31:3, 194-197
CrossRef309
S. Joseph Sirintrapun, Anil V. Parwani. (2009) Molecular Pathology of the Genitourinary Tract: Molecular Pathology of Kidney and Testes. Surgical Pathology Clinics 2:1, 199-223
CrossRef310
DENNIS S. C. LAM, TIMOTHY Y. Y. LAI, VINCENT Y. W. LEE, CARMEN K. M. CHAN, DAVID T. L. LIU, SHAHEEDA MOHAMED, CHI-LAI LI. (2009) EFFICACY OF 1.25 MG VERSUS 2.5 MG INTRAVITREAL BEVACIZUMAB FOR DIABETIC MACULAR EDEMA. Retina 29:3, 292-299
CrossRef311
Inger Rosner, Gennady Bratslavsky, Peter A. Pinto, W. Marston Linehan. (2009) The clinical implications of the genetics of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 27:2, 131-136
CrossRef312
Efstathios Kastritis, Andreas Charidimou, Andreas Varkaris, Meletios A. Dimopoulos. (2009) Targeted therapies in multiple myeloma. Targeted Oncology 4:1, 23-36
CrossRef313
Francesca Elice, Francesco Rodeghiero, Anna Falanga, Frederick R. Rickles. (2009) Thrombosis associated with angiogenesis inhibitors. Best Practice & Research Clinical Haematology 22:1, 115-128
CrossRef314
Dietmar W. Siemann, W.D. Brazelle, Juliane M. Jürgensmeier. (2009) The Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor Cediranib (Recentin; AZD2171) Inhibits Endothelial Cell Function and Growth of Human Renal Tumor Xenografts. International Journal of Radiation Oncology*Biology*Physics 73:3, 897-903
CrossRef315
Brian I Rini, Steven C Campbell, Bernard Escudier. (2009) Renal cell carcinoma. The Lancet 373:9669, 1119-1132
CrossRef316
Fiona Collinson, Gordon Jayson. (2009) New therapeutic agents in ovarian cancer. Current Opinion in Obstetrics and Gynecology 21:1, 44-53
CrossRef317
Piotr Rutkowski, Włodzimierz Ruka. (2009) Emergency surgery in the era of molecular treatment of solid tumours. The Lancet Oncology 10:2, 157-163
CrossRef318
Balazs Dome, Jozsef Timar, Andrea Ladanyi, Sandor Paku, Ferenc Renyi-Vamos, Walter Klepetko, Gyorgy Lang, Peter Dome, Krisztina Bogos, Jozsef Tovari. (2009) Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. Critical Reviews in Oncology/Hematology 69:2, 108-124
CrossRef319
Haziq Raees Chowdhury, Nishal Patel, Sobha Sivaprasad. (2009) Ocular neovascularization: potential for the angiopoietin/Tie-2 pathway. Expert Review of Ophthalmology 4:1, 65-78
CrossRef320
Vitaly Margulis, Surena F. Matin, Nizar Tannir, Pheroze Tamboli, Yu Shen, Marisa Lozano, David A. Swanson, Eric Jonasch, Christopher G. Wood. (2009) Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. Urology 73:2, 337-341
CrossRef321
Daniel C. Cho, Igor Puzanov, Meredith M. Regan, Talya Schwarzberg, Virginia Seery, Mee-Young Lee, Vivian Liu, Rupal Bhatt, Henry Koon, James W. Mier, Jeffrey A. Sosman, Michael B. Atkins, David F. McDermott. (2009) Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy 32:2, 181-185
CrossRef322
Makoto Kawaishi, Yutaka Fujiwara, Tomoya Fukui, Terufumi Kato, Kazuhiko Yamada, Yuichiro Ohe, Hideo Kunitoh, Ikuo Sekine, Noboru Yamamoto, Hiroshi Nokihara, Takeshi Watabe, Yuji Shimoda, Tokuzo Arao, Kazuto Nishio, Tomohide Tamura, Fumiaki Koizumi. (2009) Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel. Journal of Thoracic Oncology 4:2, 208-213
CrossRef323
Kojun OKAMOTO, Isamu KOYAMA, Mitsuo MIYAZAWA, Masayasu AIKAWA, Katsuya OKADA, Yasuko TOSHIMITSU, Satoshi TABUCHI, Toshimasa ISHII, Utaroh MOTOSUGI. (2009) Hepatic Metastasis 12 Years after Nephrectomy for Renal Cell Carcinoma. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 34:4, 642-645
CrossRef324
Min Ho Lee, Jin Hwan An, Ji Eun Lee, Boo Sub Oum. (2009) Short-term Efficacy of Intravitreal Bavacizumab for Polypoidal Choroidal Vasculopathy. Journal of the Korean Ophthalmological Society 50:1, 51
CrossRef325
Yong Woon Shin, Yoon Jung Lee, Byung Rho Lee, Hee Yoon Cho. (2009) Effects of an Intravitreal Bevacizumab Injection Combined With Panretinal Photocoagulation on High-Risk Proliferative Diabetic Retinopathy. Korean Journal of Ophthalmology 23:4, 266
CrossRef326
Young Sang Kim. (2009) Tumor Therapy Applying Membrane-bound Form of Cytokines. Immune Network 9:5, 158
CrossRef327
Renaud Grépin, Gilles Pagès. (2009) Le Vascular Endothelial Growth Factor (VEGF) : un modèle de régulation d'expression génique et un marqueur d'agressivité tumorale. Une cible thérapeutique évidente ?. Journal de la Société de Biologie 203:2, 181-192
CrossRef328
Alison T. Stopeck, Joseph M. Unger, Lisa M. Rimsza, William T. Bellamy, Maria Iannone, Daniel O. Persky, Michael Leblanc, Richard I. Fisher, Thomas P. Miller. (2009) A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leukemia & Lymphoma 50:5, 728-735
CrossRef329
Quynh-Thu Le, David Raben. (2009) Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas. Seminars in Radiation Oncology 19:1, 53-62
CrossRef330
James M. G. Larkin, Rosemary E. J. Clarke, Lisa M. Pickering. (2009) Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: biology and pathways. Medical Oncology 26:S1, 40-45
CrossRef331
Richa Tripathi, Gayatri Rath, Ranju Ralhan, Sunita Saxena, Sudha Salhan. (2009) Soluble and Membranous Vascular Endothelial Growth Factor Receptor-2 in Pregnancies Complicated by Pre-Eclampsia. Yonsei Medical Journal 50:5, 656
CrossRef332
Vitaly Margulis, Christopher G. Wood. (2009) Pre-surgical targeted molecular therapy in renal cell carcinoma. BJU International 103:2, 150-153
CrossRef333
Annkristin Heine, Tobias AW Holderried, Peter Brossart. (2009) Immunotherapy in renal cell carcinoma. Immunotherapy 1:1, 97-107
CrossRef334
Vincent Launay-Vacher, Gilbert Deray. (2009) Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anti-Cancer Drugs 20:1, 81-82
CrossRef335
Michael Thew. (2009) Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin). Clinical and Experimental Optometry 92:1, 34-37
CrossRef336
Aza Mohammed, Iqbal Shergill, Brian Little. (2009) Management of metastatic renal cell carcinoma: current trends. Expert Review of Molecular Diagnostics 9:1, 75-83
CrossRef337
Mototsugu Oya. (2009) Renal Cell Carcinoma: Biological Features and Rationale for Molecular-targeted Therapy. The Keio Journal of Medicine 58:1, 1-11
CrossRef338
Arlene Chan. (2009) Antiangiogenic Therapy for Metastatic Breast Cancer. Drugs 69:2, 167-181
CrossRef339
Hans Prenen, Thierry Gil, Ahmad Awada. (2009) New therapeutic developments in renal cell cancer. Critical Reviews in Oncology/Hematology 69:1, 56-63
CrossRef340
K Podar, D Chauhan, K C Anderson. (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23:1, 10-24
CrossRef341
Sam S. Chang, Adam S. Kibel. (2009) The role of systemic cytotoxic therapy for prostate cancer. BJU International 103:1, 8-17
CrossRef342
Reiko Takemura, Yoko Hamamoto. (2009) Side Effects of Molecularly Targeted Drugs and Their Molecular Mechanisms. JOURNAL OF HEALTH SCIENCE 55:3, 338-346
CrossRef343
Michelle Lockley, Tim Eisen. (2009) Sorafenib: a multitargeted oral agent for the treatment of advanced renal cell cancer. Therapy 6:1, 111-124
CrossRef344
KAMRAN BADIZADEGAN, JACQUELINE L. WOLF. 2009. Liver Pathology in Pregnancy. , 1231-1243.
CrossRef345
Jan S. A. G. Schouten, Ellen C. Heij, Carroll A. B. Webers, Igor J. Lundqvist, Fred Hendrikse. (2009) A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 247:1, 1-11
CrossRef346
Stephen F. Thung, Errol R. Norwitz. 2009. Endocrine Diseases of Pregnancy. , 615-658.
CrossRef347
Chun Lam, S. Ananth Karumanchi. 2009. Pregnancy and the Kidney. , 483-513.
CrossRef348
Michael S. Gordon, David Mendelson, Robert Carr, Raymond A. Knight, Rod A. Humerickhouse, Maria Iannone, Alison T. Stopeck. (2008) A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 113:12, 3420-3429
CrossRef349
Arvind P. Pathak, Warren E. Hochfeld, Simon L. Goodman, Michael S. Pepper. (2008) Circulating and imaging markers for angiogenesis. Angiogenesis 11:4, 321-335
CrossRef350
Christoph Eimer, Holger Gerullis, Thomas Otto. (2008) „Targeted therapy“ des metastasierten Nierenzellkarzinoms (mRCC). Onkopipeline 1:3, 82-90
CrossRef351
Erica P. Gunderson, Vicky Chiang, Cora E. Lewis, Janet Catov, Charles P. Quesenberry, Stephen Sidney, Gina S. Wei, Roberta Ness. (2008) Long-Term Blood Pressure Changes Measured From Before to After Pregnancy Relative to Nonparous Women. Obstetrics & Gynecology 112:6, 1294-1302
CrossRef352
M Barry Stokes, Maria C Erazo, Vivette D D'Agati. (2008) Glomerular disease related to anti-VEGF therapy. Kidney International 74:11, 1487-1491
CrossRef353
Marianna Aita, Gianpiero Fasola, Carlotta Defferrari, Annalisa Brianti, Maria Giovanna Dal Bello, Alessandro Follador, Graziella Sinaccio, Paolo Pronzato, Francesco Grossi. (2008) Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology 68:3, 183-196
CrossRef354
Naoyuki Satoh, Yoshihiro Yamada, Yumi Kinugasa, Nobuyuki Takakura. (2008) Angiopoietin-1 alters tumor growth by stabilizing blood vessels or by promoting angiogenesis. Cancer Science 99:12, 2373-2379
CrossRef355
Fernando Cotait Maluf, Gustavo dos Santos Fernandes, Ariel Galapo Kann, José Luis Aguilar-Ponce, Jaime de la Garza, Antonio Carlos Buzaid. (2008) Exploring the role of novel agents in the treatment of renal cell carcinoma. Cancer Treatment Reviews 34:8, 750-760
CrossRef356
Philip Leonard, Pierre D. Scotney, Talat Jabeen, Shalini Iyer, Louis J. Fabri, Andrew D. Nash, K. Ravi Acharya. (2008) Crystal Structure of Vascular Endothelial Growth Factor-B in Complex with a Neutralising Antibody Fab Fragment. Journal of Molecular Biology 384:5, 1203-1217
CrossRef357
T J Price, L Lipton, J McGreivy, S McCoy, Y-N Sun, M A Rosenthal. (2008) Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. British Journal of Cancer 99:9, 1387-1394
CrossRef358
Lie S. Chan, Jurstine Daruwalla, Christopher Christophi. (2008) SELECTIVE TARGETING OF THE TUMOUR VASCULATURE*. ANZ Journal of Surgery 78:11, 955-967
CrossRef359
Margaret E. Macy, Kelly K. Sawczyn, Timothy P. Garrington, Douglas K. Graham, Lia Gore. (2008) Pediatric developmental therapies: Interesting new drugs now in early-stage clinical trials. Current Oncology Reports 10:6, 477-490
CrossRef360
C Magnon, P Opolon, E Connault, L M Mir, M Perricaudet, D Martel-Renoir. (2008) Canstatin gene electrotransfer combined with radiotherapy: preclinical trials for cancer treatment. Gene Therapy 15:21, 1436-1445
CrossRef361
Antonio Lopez–Beltran, Ziya Kirkali, Liang Cheng, Lars Egevad, Juan C. Regueiro, Ana Blanca, Rodolfo Montironi. (2008) Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. Seminars in Diagnostic Pathology 25:4, 232-244
CrossRef362
H. Moch. (2008) Molekulare Basis der zielgerichteten Therapien bei metastasierenden Nierenzellkarzinomen. Der Pathologe 29:S2, 184-186
CrossRef363
Anne Schlesinger-Raab, Uwe Treiber, Dirk Zaak, Dieter Hölzel, Jutta Engel. (2008) Metastatic renal cell carcinoma: Results of a population-based study with 25 years follow-up. European Journal of Cancer 44:16, 2485-2495
CrossRef364
Glenn S. Kroog, Robert J. Motzer. (2008) Systemic Therapy for Metastatic Renal Cell Carcinoma. Urologic Clinics of North America 35:4, 687-701
CrossRef365
Tobias Klatte, Allan J. Pantuck. (2008) Molecular Biology of Renal Cortical Tumors. Urologic Clinics of North America 35:4, 573-580
CrossRef366
Francesca Elice, Jack Jacoub, Frederick R. Rickles, Anna Falanga, Francesco Rodeghiero. (2008) Hemostatic complications of angiogenesis inhibitors in cancer patients. American Journal of Hematology 83:11, 862-870
CrossRef367
A. Ravaud, J. -C. Bernhard, J. -M. Ferrière. (2008) Bévacizumab et temsirolimus: quel apport dans la stratégie de prise en charge du cancer du rein métastatique ?. Oncologie 10:11, 653-656
CrossRef368
Jaafar Bennouna, Emmanuelle Bompas, Eve Marie Neidhardt, Frédéric Rolland, Irène Philip, Céline Galéa, Samuel Salot, Soraya Saiagh, Marie Audrain, Marie Rimbert, Sylvie Lafaye-de Micheaux, Jérôme Tiollier, Sylvie Négrier. (2008) Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy 57:11, 1599-1609
CrossRef369
Ferry ALM Eskens, Stefan Sleijfer. (2008) The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?. European Journal of Cancer 44:16, 2350-2356
CrossRef370
R. Kath. (2008) Molekulare Therapie beim Nierenzellkarzinom. Der Onkologe 14:10, 1055-1064
CrossRef371
Antonio Farina, Akihiko Sekizawa, Paola De Sanctis, Yuditiya Purwosunu, Takashi Okai, Dong Hyun Cha, Jin Hee Kang, Claudia Vicenzi, Annalisa Tempesta, Noroyono Wibowo, Luisella Valvassori, Nicola Rizzo. (2008) Gene expression in chorionic villous samples at 11 weeks' gestation from women destined to develop preeclampsia. Prenatal Diagnosis 28:10, 956-961
CrossRef372
Vijayshankar Ganesh Sivanandam, Sam Laurel Stephen, Ruben Hernandez-Alcoceba, Pilar Alzuguren, Maider Zabala, Nico van Rooijen, Cheng Qian, Irina Berger, Marie-Luise Gross, Jesus Prieto, Stefan Kochanek. (2008) Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1. The Journal of Gene Medicine 10:10, 1083-1091
CrossRef373
Bhanu K Vakkalanka, Ronald M Bukowski. (2008) Novel drugs for renal cell carcinoma. Expert Opinion on Investigational Drugs 17:10, 1501-1516
CrossRef374
A.S. Merseburger, M.A. Kuczyk. (2008) Der Stellenwert der Targeted-Therapie beim Nierenzellkarzinom. Der Urologe 47:10, 1303-1310
CrossRef375
Shanthi Marur, James Eliason, Lance K. Heilbrun, Brenda Dickow, Daryn W. Smith, Karen Baranowski, Samir Alhasan, Ulka Vaishampayan. (2008) Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma. Urology 72:4, 898-902
CrossRef376
Peter E. Clark, Michael S. Cookson. (2008) The von Hippel-Lindau gene. Cancer 113:S7, 1768-1778
CrossRef377
Bernard Escudier, Jan Cosaert, Pavel Pisa. (2008) Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Review of Anticancer Therapy 8:10, 1545-1557
CrossRef378
Xiaoli Hui, Yu Han, Shuhui Liang, Zhiguo Liu, Jingtao Liu, Liu Hong, Lina Zhao, Li He, Shanshan Cao, Bei Chen, Kun Yan, Bin Jin, Na Chai, Jing Wang, Kaichun Wu, Daiming Fan. (2008) Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. Journal of Controlled Release 131:2, 86-93
CrossRef379
Simon Chowdhury, James M.G. Larkin, Martin E. Gore. (2008) Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. European Journal of Cancer 44:15, 2152-2161
CrossRef380
Jose L. Mauriz, Javier González-Gallego. (2008) Antiangiogenic drugs: Current knowledge and new approaches to cancer therapy. Journal of Pharmaceutical Sciences 97:10, 4129-4154
CrossRef381
H. P. Eikesdal, H. Sugimoto, G. Birrane, Y. Maeshima, V. G. Cooke, M. Kieran, R. Kalluri. (2008) Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proceedings of the National Academy of Sciences 105:39, 15040-15045
CrossRef382
Bernard Escudier. (2008) Signaling Inhibitors in Metastatic Renal Cell Carcinoma. The Cancer Journal 14:5, 325-329
CrossRef383
Bhanu K Vakkalanka, Brian I Rini. (2008) Targeted therapy in renal cell carcinoma. Current Opinion in Urology 18:5, 481-487
CrossRef384
Brian I. Rini, Keith Flaherty. (2008) Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 26:5, 543-549
CrossRef385
Aaron P. Brown, Deborah E. Citrin, Kevin A. Camphausen. (2008) Clinical biomarkers of angiogenesis inhibition. Cancer and Metastasis Reviews 27:3, 415-434
CrossRef386
Vitaly Margulis, Surena F Matin, Christopher G Wood. (2008) Cytoreductive nephrectomy in metastatic renal cell carcinoma. Current Opinion in Urology 18:5, 474-480
CrossRef387
R. Simó, C. Hernández. (2008) Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51:9, 1574-1580
CrossRef388
M Slevin, P Kumar, Quiyu Wang, S Kumar, J Gaffney, M Grau-Olivares, J Krupinski. (2008) New VEGF antagonists as possible therapeutic agents in vascular disease. Expert Opinion on Investigational Drugs 17:9, 1301-1314
CrossRef389
Balázs Döme, Melinda Magyar. (2008) A daganatos érhálózat mint terápiás célpont nem kissejtes tüdőrákban. Magyar Onkológia 52:3, 247-259
CrossRef390
A. Graser, C.R. Becker, M.F. Reiser, C. Stief, M. Staehler. (2008) Volumetrie von Metastasen beim Nierenzellkarzinom. Der Radiologe 48:9, 850-856
CrossRef391
Nizar M. Tannir, Peter F. Thall, Chaan S. Ng, Xuemei Wang, Leiko Wooten, Arlene Siefker-Radtke, Paul Mathew, Lance Pagliaro, Christopher Wood, Eric Jonasch. (2008) A Phase II Trial of Gemcitabine Plus Capecitabine for Metastatic Renal Cell Cancer Previously Treated With Immunotherapy and Targeted Agents. The Journal of Urology 180:3, 867-872
CrossRef392
Toni K. Choueiri, Susan A.J. Vaziri, Erich Jaeger, Paul Elson, Laura Wood, Ish Prasad Bhalla, Eric J. Small, Vivian Weinberg, Nancy Sein, Jeff Simko, Ali-Reza Golshayan, Linda Sercia, Ming Zhou, Frederic M. Waldman, Brian I. Rini, Ronald M. Bukowski, Ram Ganapathi. (2008) von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma. The Journal of Urology 180:3, 860-866
CrossRef393
DANIEL KOOK, ATMIN WOLF, THOMAS KREUTZER, ALJOSCHA NEUBAUER, RUPERT STRAUSS, MICHAEL ULBIG, ANSLEM KAMPIK, CHRISTOS HARITOGLOU. (2008) LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMA. Retina 28:8, 1053-1060
CrossRef394
Collin M. Burkart, Jedidiah J. Grisel, David B. Hom. (2008) Spontaneous Nasal Septal Perforation With Antiangiogenic Bevacizumab Therapy. The Laryngoscope 118:9, 1539-1541
CrossRef395
Vitaly Margulis, Christopher G. Wood. (2008) Cytoreductive Nephrectomy in the Era of Targeted Molecular Agents: Is It Time to Consider Presurgical Systemic Therapy?. European Urology 54:3, 489-492
CrossRef396
A. P. Berger, A. Hobisch. (2008) Treatment options in localised and metastatic renal cell carcinoma. memo - Magazine of European Medical Oncology 1:3, 167-170
CrossRef397
S. Negrier. (2008) Temsirolimus in metastatic renal cell carcinoma. Annals of Oncology 19:8, 1369-1370
CrossRef398
B. Melichar, P. Koralewski, A. Ravaud, A. Pluzanska, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, R. Delva, E. Sevin, S. Negrier, J. McKendrick, A. Santoro, P. Pisa, B. Escudier. (2008) First-line bevacizumab combined with reduced dose interferon- 2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology 19:8, 1470-1476
CrossRef399
Cora N Sternberg. (2008) Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. Nature Clinical Practice Urology 5:8, 422-423
CrossRef400
Andrew Z Wang, Frank Gu, Liangfang Zhang, Juliana M Chan, Aleksander Radovic-Moreno, Mariam R Shaikh, Omid C Farokhzad. (2008) Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opinion on Biological Therapy 8:8, 1063-1070
CrossRef401
Shaoqi Wang, Shaoxiang Wang, Juan Wang. (2008) Current status of studies on targeted therapy for renal cell carcinoma. Chinese Journal of Clinical Oncology 5:4, 294-298
CrossRef402
Alain Ravaud, Hervé Wallerand, Stéphane Culine, Jean-Christophe Bernhard, Patricia Fergelot, Karim Bensalah, Jean-Jacques Patard. (2008) Update on the Medical Treatment of Metastatic Renal Cell Carcinoma. European Urology 54:2, 315-325
CrossRef403
Michael T. Stumpp, H. Kaspar Binz, Patrick Amstutz. (2008) DARPins: A new generation of protein therapeutics. Drug Discovery Today 13:15-16, 695-701
CrossRef404
J A Jefferson, S J Shankland, R H Pichler. (2008) Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney International 74:1, 22-36
CrossRef405
Ruud P.M. Dings, Emily S. Van Laar, Jeremy Webber, Yan Zhang, Robert J. Griffin, Stephen J. Waters, John R. MacDonald, Kevin H. Mayo. (2008) Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Letters 265:2, 270-280
CrossRef406
Vitaly Margulis, Surena F. Matin, Nizar Tannir, Pheroze Tamboli, David A. Swanson, Eric Jonasch, Christopher G. Wood. (2008) Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma. The Journal of Urology 180:1, 94-98
CrossRef407
Cristiana Sessa, Aymeric Guibal, Gianluca Del Conte, Curzio Rüegg. (2008) Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. Nature Clinical Practice Oncology 5:7, 378-391
CrossRef408
Eric Jonasch, Walter M. Stadler, Ronald M. Bukowski, Teresa G. Hayes, Atul Varadhachary, Rajesh Malik, Robert A. Figlin, Sandy Srinivas. (2008) Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer 113:1, 72-77
CrossRef409
J.S. Penn, A. Madan, R.B. Caldwell, M. Bartoli, R.W. Caldwell, M.E. Hartnett. (2008) Vascular endothelial growth factor in eye disease. Progress in Retinal and Eye Research 27:4, 331-371
CrossRef410
Barrett W. Newsome, Marc S. Ernstoff. (2008) The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. British Journal of Clinical Pharmacology 66:1, 6-19
CrossRef411
H NIMEIRI, A OZA, R MORGAN, G FRIBERG, K KASZA, L FAORO, R SALGIA, W STADLER, E VOKES, G FLEMING. (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
. Gynecologic Oncology 110:1, 49-55
CrossRef412
Saby George, Thomas E. Hutson, Tarek Mekhail, Laura Wood, James Finke, Paul Elson, Robert Dreicer, Ronald M. Bukowski. (2008) Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology 62:2, 347-354
CrossRef413
S Shahrzad, S Shirasawa, T Sasazuki, J W Rak, B L Coomber. (2008) Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. Oncogene 27:26, 3729-3738
CrossRef414
M H Strijbos, J W Gratama, J Kraan, C H Lamers, MA den Bakker, S Sleijfer. (2008) Circulating endothelial cells in oncology: pitfalls and promises. British Journal of Cancer 98:11, 1731-1735
CrossRef415
Premal H. Patel, G. Varuni Kondagunta, Lawrence Schwartz, Nicole Ishill, Jennifer Bacik, John DeLuca, Paul Russo, Robert J. Motzer. (2008) Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Investigational New Drugs 26:3, 273-276
CrossRef416
Ping Chen, Ling-lin Yang, Han-shuo Yang, Yong-sheng Wang, Gang Li, Yang Wu, Fang Fang, Kang Liu, Jie Li, Xia Zhao, Huo-zhen Hu, Yu-quan Wei. (2008) Synergistic antitumor effect of CXCL10 with hyperthermia. Journal of Cancer Research and Clinical Oncology 134:6, 679-687
CrossRef417
Minoru Kobayashi, Hitoshi Ikeda, Akinori Nukui, Kazumi Suzuki, Yasuhiro Sugaya, Masayuki Yuzawa, Tatsuo Morita. (2008) Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: a single-institution experience. International Journal of Clinical Oncology 13:3, 257-262
CrossRef418
Stanislao Rizzo, Federica Genovesi-Ebert, Emanuele Bartolo, Andrea Vento, Sofia Miniaci, George Williams. (2008) Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefe's Archive for Clinical and Experimental Ophthalmology 246:6, 837-842
CrossRef419
Kevin T. Palka, Robbert J. Slebos, Christine H. Chung. (2008) Update on Molecular Diagnostic Tests in Head and Neck Cancer. Seminars in Oncology 35:3, 198-210
CrossRef420
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Michaelson, M. Dror, Iliopoulos, Othon, McDermott, David F., McGovern, Francis J., Harisinghani, Mukesh G., Oliva, Esther, . (2008) Case 17-2008. New England Journal of Medicine 358:22, 2389-2396
Full Text421
Felix Bokstein, Shulim Shpigel, Deborah T. Blumenthal. (2008) Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112:10, 2267-2273
CrossRef422
Gregory L Beatty, Bruce J Giantonio. (2008) Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer. Expert Review of Anticancer Therapy 8:5, 683-688
CrossRef423
Wai T Wong, Emily Y Chew. (2008) Ocular von Hippel???Lindau disease: clinical update and emerging treatments. Current Opinion in Ophthalmology 19:3, 213-217
CrossRef424
Rogerio Lilenbaum, Luis Raez, Jennifer Tseng, Leonard Seigel, Enrique Davila. (2008) Efficacy and Safety of Oxaliplatin and Gemcitabine with Bevacizumab in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:5, 511-515
CrossRef425
Raffaele Longo, Giampietro Gasparini. (2008) Anti-VEGF therapy: the search for clinical biomarkers. Expert Review of Molecular Diagnostics 8:3, 301-314
CrossRef426
Elizabeth Cartwright Pfaffenroth, W Marston Linehan. (2008) Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opinion on Biological Therapy 8:6, 779-790
CrossRef427
Jae Ho Kim, Stephen L. Brown, Kenneth A. Jenrow, Samuel Ryu. (2008) Mechanisms of radiation-induced brain toxicity and implications for future clinical trials. Journal of Neuro-Oncology 87:3, 279-286
CrossRef428
Taner Demirer, Lisbeth Barkholt, Didier Blaise, Paolo Pedrazzoli, Massimo Aglietta, Angelo Michele Carella, Jacques-Olivier Bay, Fikret Arpaci, Giovanni Rosti, Gunhan Gurman, Dietger Niederwieser, Marco Bregni. (2008) Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nature Clinical Practice Oncology 5:5, 256-267
CrossRef429
M. Sommerauer, C. Doehn. (2008) Bevacizumab plus Interferon alfa-2a in der Therapie des metastasierten Nierenzellkarzinoms. Der Onkologe 14:5, 535-538
CrossRef430
Kiran Gupta, Jeffrey D. Miller, Jim Z. Li, Mason W. Russell, Claudie Charbonneau. (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treatment Reviews 34:3, 193-205
CrossRef431
Keith T. Flaherty. (2008) The future of tyrosine kinase inhibitors: Single agent or combination?. Current Oncology Reports 10:3, 264-270
CrossRef432
Axel Grothey, Lee M. Ellis. (2008) Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies. The Cancer Journal 14:3, 170-177
CrossRef433
C.N.A.M. Oldenhuis, S.F. Oosting, J.A. Gietema, E.G.E. de Vries. (2008) Prognostic versus predictive value of biomarkers in oncology. European Journal of Cancer 44:7, 946-953
CrossRef434
Naomi B. Haas, Robert Uzzo. (2008) Adjuvant therapy for renal cell carcinoma. Current Oncology Reports 10:3, 245-252
CrossRef435
J.D. WRIGHT, A.A. SECORD, T.M. NUMNUM, R.P. ROCCONI, M.A. POWELL, A. BERCHUCK, R.D. ALVAREZ, R.K. GIBB, K. TRINKAUS, J.S. RADER, D.G. MUTCH. (2008) A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. International Journal of Gynecological Cancer 18:3, 400-406
CrossRef436
Chris Coppin, Lyly Le, Franz Porzsolt, Timothy Wilt, Chris Coppin. 2008. Targeted therapy for advanced renal cell carcinoma. .
CrossRef437
E Jonasch, C Wood, P Tamboli, L C Pagliaro, S M Tu, J Kim, P Srivastava, C Perez, L Isakov, N Tannir. (2008) Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. British Journal of Cancer 98:8, 1336-1341
CrossRef438
A H R Varey, E S Rennel, Y Qiu, H S Bevan, R M Perrin, S Raffy, A R Dixon, C Paraskeva, O Zaccheo, A B Hassan, S J Harper, D O Bates. (2008) VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. British Journal of Cancer 98:8, 1366-1379
CrossRef439
Edith M. Marom, Carlos H. Martinez, Mylene T. Truong, Xiudong Lei, Bradley S. Sabloff, Reginald F. Munden, Gregory W. Gladish, Roy S. Herbst, Rodolfo C. Morice, David J. Stewart, Carlos A. Jimenez, George R. Blumenschein, Amir Onn. (2008) Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. Journal of Thoracic Oncology 3:4, 351-357
CrossRef440
Enric Carcereny Costa, Núria Viñolas Segarra, Pere Gascón Vilaplana. (2008) Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology 10:4, 198-203
CrossRef441
William E. Osai, Chaan S. Ng, Lance C. Pagliaro. (2008) Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anti-Cancer Drugs 19:4, 427-429
CrossRef442
Marcella M.L. Baldewijns, Iris J.H. van Vlodrop, Leo J. Schouten, Patricia M.M.B. Soetekouw, Adriaan P. de Bruïne, Manon van Engeland. (2008) Genetics and epigenetics of renal cell cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1785:2, 133-155
CrossRef443
Patricia S Steeg, Dan Theodorescu. (2008) Metastasis: a therapeutic target for cancer. Nature Clinical Practice Oncology 5:4, 206-219
CrossRef444
Egbert Oosterwijk, Otto C. Boerman, Wim J. C. Oyen, Lloyd J. Old, Peter F. A. Mulders. (2008) Antibody therapy in renal cell carcinoma. World Journal of Urology 26:2, 141-146
CrossRef445
Jean-Jacques Patard, Damien Pouessel, Karim Bensalah, Stéphane Culine. (2008) Targeted therapy in renal cell carcinoma. World Journal of Urology 26:2, 135-140
CrossRef446
Damien Pouessel, Stéphane Culine, Gregory Verhoest, Jean-Jacques Patard. (2008) Antiangiogenèse et cancer du rein. La Presse Médicale 37:4, 628-633
CrossRef447
F. Lordick, J.R. Siewert. (2008) Bevacizumab- (Avastin®-)bedingte chirurgische Komplikationen. Der Chirurg 79:4, 356-360
CrossRef448
Divya-Devi Joshi, Tarit Banerjee. (2008) Vascular endothelial growth factor (VEGF) receptor antibody bevacizumab (avastin) induces regression of renal cell carcinoma in an adolescent resulting in residual tumorectomy. Pediatric Blood & Cancer 50:4, 903-904
CrossRef449
Jean-Jacques Patard, Toni K. Choueiri, Eric Lechevallier, Nicolas Mottet. (2008) Recent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007. European Urology Supplements 7:6, 494-507
CrossRef450
F. Trotta, G. Apolone, S. Garattini, G. Tafuri. (2008) Stopping a trial early in oncology: for patients or for industry?. Annals of Oncology 19:7, 1347-1353
CrossRef451
Claire Louise Cole, Gordon C Jayson. (2008) Oligosaccharides as anti-angiogenic agents. Expert Opinion on Biological Therapy 8:3, 351-362
CrossRef452
Pierre Fumoleau. (2008) Future options in the treatment of ErbB2 (HER2)-positive breast cancer. European Journal of Cancer Supplements 6:5, 25-31
CrossRef453
Christian Jackisch. (2008) Challenges in the treatment of ErbB2 (HER2)-positive breast cancer. European Journal of Cancer Supplements 6:5, 7-14
CrossRef454
Andres Jan Schrader, Rainer Hofmann. (2008) Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anti-Cancer Drugs 19:3, 235-245
CrossRef455
Neelima Denduluri, Sandra M Swain. (2008) Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opinion on Investigational Drugs 17:3, 423-435
CrossRef456
José Manuel Trigo, Joaquim Bellmunt. (2008) Estrategias actuales en el tratamiento del carcinoma de células renales: fármacos dirigidos a dianas moleculares. Medicina Clínica 130:10, 380-392
CrossRef457
Nadia Harbeck. (2008) Clinical data for anti-angiogenic agents in previously treated advanced breast cancer. European Journal of Cancer Supplements 6:6, 14-20
CrossRef458
Richard Bell, David Cameron. (2008) Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer. European Journal of Cancer Supplements 6:6, 1-6
CrossRef459
Masaki Watanabe, Julie L. Boyer, Neil R. Hackett, Jianping Qiu, Ronald G. Crystal. (2008) Gene Delivery of the Murine Equivalent of Bevacizumab (Avastin), an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody, to Suppress Growth of Human Tumors in Immunodeficient Mice. Human Gene Therapy 19:3, 300-310
CrossRef460
Erin Grothey, Oliver Sartor, Ronald Bukowski. (2008) Highlights from: The 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CA. Clinical Genitourinary Cancer 6:1, 9-14
CrossRef461
C Lance Cowey, W Kimryn Rathmell. (2008) Using molecular biology to develop drugs for renal cell carcinoma. Expert Opinion on Drug Discovery 3:3, 311-327
CrossRef462
Pisut Katavetin, Reiko Inagi, Toshio Miyata, Tetsuhiro Tanaka, Ryoji Sassa, Julie R. Ingelfinger, Toshiro Fujita, Masaomi Nangaku. (2008) Albumin suppresses vascular endothelial growth factor via alteration of hypoxia-inducible factor/hypoxia-responsive element pathway. Biochemical and Biophysical Research Communications 367:2, 305-310
CrossRef463
A. JAISHUEN, J.P. BERRIOS-RIVERA, N. SIRISABYA, H.G. ZHENG, Y. LI, J.J. KAVANAGH. (2008) Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary. International Journal of Gynecological Cancer 18:2, 379-383
CrossRef464
Jeffrey A Sosman. (2008) Improving outcomes in patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy 8:3, 481-490
CrossRef465
M ELIZABETH HARTNETT, R JEFFREY BOARD, ODETTE HOUGHTON. (2008) SUBRETINAL HEMORRHAGE AFTER LENS-SPARING VITRECTOMY IN INFANTS BORN AT OR UNDER 24 WEEKS GESTATION. Retina 28:Supplement, S69-S74
CrossRef466
Ronald M. Bukowski. (2008) Randomized trial of bevacizumab in advanced renal cell carcinoma. Current Oncology Reports 10:2, 99-100
CrossRef467
N. ARORA, D. TEWARI, C. COWAN, B. SAFFARI, B.J. MONK, R.A. BURGER. (2008) Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma. International Journal of Gynecological Cancer 18:2, 369-372
CrossRef468
Miltiadis Papathanassiou, Panagiotis G. Theodossiadis, Vasilios S. Liarakos, Alexandros Rouvas, Evaggelos J. Giamarellos-Bourboulis, Ioannis A. Vergados. (2008) Inhibition of Corneal Neovascularization by Subconjunctival Bevacizumab in an Animal Model. American Journal of Ophthalmology 145:3, 424-431.e1
CrossRef469
Shinichi Sakamoto, A. Jacqueline Ryan, Natasha Kyprianou. (2008) Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance. Journal of Cellular Biochemistry 103:3, 691-708
CrossRef470
A. S.R. Maharaj, T. E. Walshe, M. Saint-Geniez, S. Venkatesha, A. E. Maldonado, N. C. Himes, K. S. Matharu, S. A. Karumanchi, P. A. D'Amore. (2008) VEGF and TGF- are required for the maintenance of the choroid plexus and ependyma. Journal of Experimental Medicine 205:2, 491-501
CrossRef471
Farhad Haghighi Rad, Ayhan Ulusakarya, Sophie Gad, Mathilde Sibony, Fabrice Juin, Stéphane Richard, David Machover, Georges Uzan. (2008) Novel somatic mutations of theVHL gene in an erythropoietin-producing renal carcinoma associated with secondary polycythemia and elevated circulating endothelial progenitor cells. American Journal of Hematology 83:2, 155-158
CrossRef472
Daniela D. Rosa, Gustavo Ismael, Lissandra Dal Lago, Ahmad Awada. (2008) Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treatment Reviews 34:1, 61-80
CrossRef473
Bridget F. Koontz, Edward F. Miles, Mary Ann D. Rubio, John F. Madden, Samuel R. Fisher, Richard L. Scher, David M. Brizel. (2008) Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: Two case studies. Head & Neck 30:2, 262-266
CrossRef474
Ali-Reza Golshayan, Ashley J Brick, Toni K Choueiri. (2008) Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncology 4:1, 85-92
CrossRef475
H. Kirchner, H. Heinzer, J. Roigas, F. Overkamp. (2008) Differenzialtherapie beim metastasierenden Nierenzellkarzinom. Der Onkologe 14:2, 191-197
CrossRef476
Guru Sonpavde, Thomas E Hutson, Cora N Sternberg. (2008) Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opinion on Investigational Drugs 17:2, 253-261
CrossRef477
Joaquim Bellmunt. (2008) The Oncologist's View: Targeted Therapies in Advanced Renal Cell Carcinoma. European Urology Supplements 7:2, 55-62
CrossRef478
Jiazhong Li, Jin Qin, Huanxiang Liu, Xiaojun Yao, Mancang Liu, Zhide Hu. (2008) In Silico Prediction of Inhibition Activity of Pyrazine–Pyridine Biheteroaryls as VEGFR-2 Inhibitors Based on Least Squares Support Vector Machines. QSAR & Combinatorial Science 27:2, 157-164
CrossRef479
Damien Pouessel, Stéphane Culine. (2008) High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor. European Urology 53:2, 376-381
CrossRef480
Seung-Ah Yoo, Seung-Ki Kwok, Wan-Uk Kim. (2008) Proinflammatory Role of Vascular Endothelial Growth Factor in the Pathogenesis of Rheumatoid Arthritis: Prospects for Therapeutic Intervention. Mediators of Inflammation 2008, 1-6
CrossRef481
Walter P. Mutter, S. Ananth Karumanchi. (2008) Molecular mechanisms of preeclampsia. Microvascular Research 75:1, 1-8
CrossRef482
W Kimryn Rathmell, Shufen Chen. (2008) VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Review of Anticancer Therapy 8:1, 63-73
CrossRef483
Benjamin Leader, Quentin J. Baca, David E. Golan. (2008) Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug Discovery 7:1, 21-39
CrossRef484
Yuditiya Purwosunu, Akihiko Sekizawa, Antonio Farina, Noroyono Wibowo, Keiko Koide, Shiho Okazaki, Masamitsu Nakamura, Takashi Okai. (2008) Evaluation of physiological alterations of the placenta through analysis of cell-free messenger ribonucleic acid concentrations of angiogenic factors. American Journal of Obstetrics and Gynecology 198:1, 124.e1-124.e7
CrossRef485
Juan Gonzales Posada, Arthur E. Frankel. 2008. Monoclonal Antibody Therapy of Cancer. , 671-678.
CrossRef486
Konstantinos Anargyrou, Meletios-Athanassios Dimopoulos, Orhan Sezer, Evangelos Terpos. (2008) Novel anti-myeloma agents and angiogenesis. Leukemia & Lymphoma 49:4, 677-689
CrossRef487
E.L. Mayer. (2008) Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. Breast Diseases: A Year Book Quarterly 19:3, 272-273
CrossRef488
Katsuyuki Kiura, Nagio Takigawa, Isao Oze, Masayuki Yasugi, Nobuaki Ochi, Daijiro Harada, Mitsune Tanimoto. (2008) Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 119:3, 285-292
CrossRef489
Georg Bartsch, Katharina Eggert, Shay Soker, Carsten Bokemeyer, Richard Hautmann, Gunter Schuch. (2008) Combined Antiangiogenic Therapy is Superior to Single Inhibitors in a Model of Renal Cell Carcinoma. The Journal of Urology 179:1, 326-332
CrossRef490
PETER HEIDUSCHKA, SYLVIE JULIEN, SABINE HOFMEISTER, KARL ULRICH BARTZ-SCHMIDT, ULRICH SCHRAERMEYER. (2008) BEVACIZUMAB (AVASTIN) DOES NOT HARM RETINAL FUNCTION AFTER INTRAVITREAL INJECTION AS SHOWN BY ELECTRORETINOGRAPHY IN ADULT MICE. Retina 28:1, 46-55
CrossRef491
Rishi Sawhney, Fairooz Kabbinavar. (2008) Angiogenesis and angiogenic inhibitors in renal cell carcinoma. Current Urology Reports 9:1, 26-33
CrossRef492
Jonathan Friedberg, Eric Jacobsen, Donna Neuberg, Jeffrey Kutok, Olivier Munoz, Vassiliki Boussiotis, Hazel Reynolds, David Fisher, Agnieszka Szot, Annick Van Den Abbeele, Arnold Freedman. (2008) Targeting the follicular lymphoma microenvironment through blockade of TNFα with etanercept. Leukemia & Lymphoma 49:5, 902-909
CrossRef493
Janaka Karalliedde, Luigi Gnudi. (2008) Future strategies to prevent renal microvascular disease complications in diabetes. Future Cardiology 4:1, 77-83
CrossRef494
Moritsugu Kimura, Masao Toyoda, Mayuko Kato, Keiko Kobayashi, Makiko Abe, Takako Kobayashi, Masaaki Miyauchi, Naoyuki Yamamoto, Tomoya Umezono, Daisuke Suzuki. (2008) Expression of Alpha-actinin-4 in Human Diabetic Nephropathy. Internal Medicine 47:12, 1099-1106
CrossRef495
Richard L. Schilsky, David Geary, Linda Skoog, Apurva A. Desai, Joyce Valickas, Bee-Lian Chen, Eric Masson, Dirk Laurent, Cynthia Pendowski, Everett E. Vokes, Mark J. Ratain. (2008) Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer. Targeted Oncology 3:1, 3-11
CrossRef496
Brian Keith, M. Celeste Simon. 2008. Tumor Angiogenesis. , 241-251.
CrossRef497
Christian Doehn, Torsten Böhmer, Ingo Kausch, Martin Sommerauer, Dieter Jocham. (2008) Prostate Cancer Vaccines. BioDrugs 22:2, 71-84
CrossRef498
Yoko Hasumi, Agnieszka Kłosowska-Wardęga, Masao Furuhashi, Arne Östman, Carl-Henrik Heldin, Carina Hellberg. (2007) Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. International Journal of Cancer 121:12, 2606-2614
CrossRef499
Daniel Y. C. Heng, Ronald M. Bukowski. (2007) Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma. Oncology Reviews 1:3, 170-176
CrossRef500
Sonali Ghosh, Putul Maity. (2007) Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. International Immunopharmacology 7:13, 1598-1608
CrossRef501
Wai-Man Chan, Timothy Y.Y. Lai, David T.L. Liu, Dennis S.C. Lam. (2007) Intravitreal Bevacizumab (Avastin) for Myopic Choroidal Neovascularization. Ophthalmology 114:12, 2190-2196.e2
CrossRef502
A Khwaja, M El Kossi, J Floege, M El Nahas. (2007) The management of CKD: A look into the future. Kidney International 72:11, 1316-1323
CrossRef503
Robert J Motzer, Ethan Basch. (2007) Targeted drugs for metastatic renal cell carcinoma. The Lancet 370:9605, 2071-2073
CrossRef504
Lauren C Harshman, Sandy Srinivas. (2007) Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 7:12, 1749-1761
CrossRef505
Alejandro R Rodriguez, Mayer N Fishman. (2007) Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines. Expert Opinion on Pharmacotherapy 8:17, 2979-2990
CrossRef506
James P.B. O'Connor, Yvonne Watson, Alan Jackson. (2007) Dynamic contrast-enhanced MR imaging in cancer. Radiography 13, e45-e53
CrossRef507
Hernan D. Kopcow, S. Ananth Karumanchi. (2007) Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. Journal of Reproductive Immunology 76:1-2, 23-29
CrossRef508
Peter C. Black, Colin P. N. Dinney. (2007) Bladder cancer angiogenesis and metastasis—translation from murine model to clinical trial. Cancer and Metastasis Reviews 26:3-4, 623-634
CrossRef509
Enrichetta Corgna, Maura Betti, Gemma Gatta, Fausto Roila, Pieter H.M. De Mulder. (2007) Renal cancer. Critical Reviews in Oncology/Hematology 64:3, 247-262
CrossRef510
Christodoulos Stefanadis, Konstantinos Toutouzas, Elli Stefanadi, Andreas Lazaris, Efstratios Patsouris, Nicholas Kipshidze. (2007) Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: An experimental study. Atherosclerosis 195:2, 269-276
CrossRef511
Bernard Escudier, Anna Pluzanska, Piotr Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, Marek Filipek, Bohuslav Melichar, Emilio Bajetta, Vera Gorbunova, Jacques-Olivier Bay, Istvan Bodrogi, Agnieszka Jagiello-Gruszfeld, Nicola Moore. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet 370:9605, 2103-2111
CrossRef512
Deborah A. Bradley, Bruce G. Redman. (2007) The times they are a-changin' (Bob Dylan, 1964). Cancer 110:11, 2366-2369
CrossRef513
Vicki L. Keedy, Alan B. Sandler. (2007) Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Science 98:12, 1825-1830
CrossRef514
Rakhi P. Naik, David Jin, Ellen Chuang, Ellen G. Gold, Eleni A. Tousimis, Anne L. Moore, Paul J. Christos, Tatiana Dalmas, Diana Donovan, Shahin Rafii, Linda T. Vahdat. (2007) Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Research and Treatment 107:1, 133-138
CrossRef515
J. S. Rudge, J. Holash, D. Hylton, M. Russell, S. Jiang, R. Leidich, N. Papadopoulos, E. A. Pyles, A. Torri, S. J. Wiegand, G. Thurston, N. Stahl, G. D. Yancopoulos. (2007) Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proceedings of the National Academy of Sciences 104:47, 18363-18370
CrossRef516
Rosamonde E. Banks, Rachel A. Craven, Patricia Harnden, Sanjeev Madaan, Adrian Joyce, Peter J. Selby. (2007) Key clinical issues in renal cancer: a challenge for proteomics. World Journal of Urology 25:6, 537-556
CrossRef517
Gerald C. O'Sullivan, Mark Tangney, Garret Casey, Monica Ambrose, Aileen Houston, Orla P. Barry. (2007) Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma. International Journal of Cancer 121:9, 1930-1940
CrossRef518
Jean C.Y. Wang. (2007) Evaluating Therapeutic Efficacy against Cancer Stem Cells: New Challenges Posed by a New Paradigm. Cell Stem Cell 1:5, 497-501
CrossRef519
Xabier García-Albeniz, Alejandro Martinez-Fernandez, Pere Gascon. (2007) Combining targeted therapies. Targeted Oncology 2:4, 241-252
CrossRef520
Olivier Rixe, Ronald M Bukowski, M Dror Michaelson, George Wilding, Gary R Hudes, Oliver Bolte, Robert J Motzer, Paul Bycott, Katherine F Liau, James Freddo, Peter C Trask, Sinil Kim, Brian I Rini. (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet Oncology 8:11, 975-984
CrossRef521
Robert J. Motzer, M. Dror Michaelson, Jonathan Rosenberg, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, Kim A. Margolin, George Wilding. (2007) Sunitinib Efficacy Against Advanced Renal Cell Carcinoma. The Journal of Urology 178:5, 1883-1887
CrossRef522
Wolfram E Samlowski, Nicholas J Vogelzang. (2007) Emerging drugs for the treatment of metastatic renal cancer. Expert Opinion on Emerging Drugs 12:4, 605-618
CrossRef523
Bernard Escudier, Toni K. Choueiri, Stéphane Oudard, Cezary Szczylik, Sylvie Négrier, Alain Ravaud, Christine Chevreau, Peter Venner, Pierre Champagne, Daniel Croteau, Eric Dupont, Claude Hariton, Ronald M. Bukowski. (2007) Prognostic Factors of Metastatic Renal Cell Carcinoma After Failure of Immunotherapy: New Paradigm From a Large Phase III Trial With Shark Cartilage Extract AE 941. The Journal of Urology 178:5, 1901-1905
CrossRef524
Naomi B. Haas, Robert G. Uzzo. (2007) Tyrosine Kinase Inhibitors and Anti-Angiogenic Therapies in Kidney Cancer. Current Treatment Options in Oncology 8:3, 211-226
CrossRef525
M. R. Chintalapudi, M. Markiewicz, N. Kose, V. Dammai, K. J. Champion, R. S. Hoda, M. Trojanowska, T. Hsu. (2007) Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells. Carcinogenesis 29:4, 696-703
CrossRef526
Dana Rathkopf, Howard I. Scher. 2007. Multidisciplinary Management of Genitourinary Malignancies. .
CrossRef527
Brian I Rini. (2007) Sunitinib. Expert Opinion on Pharmacotherapy 8:14, 2359-2369
CrossRef528
Daphne R. Friedman, Amy P. Abernethy. (2007) <I>REVIEW</I>. Progress in Palliative Care 15:5, 225-232
CrossRef529
Sebastiano Buti, Matteo Brighenti, Cristiano Bongiovanni, Carlo Buzio, Matteo Dalla Chiesa, Federico Alberici, Rodolfo Passalacqua. (2007) Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC). Journal of Immunotherapy 30:7, 780-786
CrossRef530
Yoshihisa Kawai, Shigeru Sakano, Yoshihito Korenaga, Satoshi Eguchi, Katsusuke Naito. (2007) Associations of Single Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Gene with the Characteristics and Prognosis of Renal Cell Carcinomas. European Urology 52:4, 1147-1155
CrossRef531
Phillip M. Pierorazio, James M. McKiernan, Tara R. McCann, Supriya Mohile, Daniel Petrylak, Mitchell C. Benson. (2007) Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU International 100:4, 755-759
CrossRef532
SIEGFRIED G. PRIGLINGER, ARMIN H. WOLF, THOMAS C. KREUTZER, DANIEL KOOK, ANJA HOFER, RUPERT W. STRAUSS, CLAUDIA S. ALGE, CHRISTIAN KUNZE, CHRISTOS HARITOGLOU, ANSELM KAMPIK. (2007) INTRAVITREAL BEVACIZUMAB INJECTIONS FOR TREATMENT OF CENTRAL RETINAL VEIN OCCLUSION. Retina 27:8, 1004-1012
CrossRef533
Christine H. Chung, Stuart Wong, K. Kian Ang, Elizabeth H. Hammond, Adam P. Dicker, Paul M. Harari, Quynh-Thu Le. (2007) Strategic Plans to Promote Head and Neck Cancer Translational Research Within the Radiation Therapy Oncology Group: A Report From the Translational Research Program. International Journal of Radiation Oncology*Biology*Physics 69:2, S67-S78
CrossRef534
Jean-Jacques Patard, Damien Pouessel, Stéphane Culine. (2007) New therapies in renal cell carcinoma. Current Opinion in Supportive and Palliative Care 1:3, 174-179
CrossRef535
Ernest S Han, Bradley J Monk. (2007) Bevacizumab in the treatment of ovarian cancer. Expert Review of Anticancer Therapy 7:10, 1339-1345
CrossRef536
Wenfang Shi, Cunye Qu, Qijun Qian. (2007) Trends in therapeutic monoclonal antibodies of cancer. Expert Opinion on Therapeutic Patents 17:9, 1047-1059
CrossRef537
Thomas E Hutson. (2007) Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. Expert Review of Anticancer Therapy 7:9, 1193-1202
CrossRef538
Susana Banerjee, Mitch Dowsett, Alan Ashworth, Lesley-Ann Martin. (2007) Mechanisms of Disease: angiogenesis and the management of breast cancer. Nature Clinical Practice Oncology 4:9, 536-550
CrossRef539
Michael B. Atkins, David Carbone, George Coukos, Madhav Dhodapkar, Marc S. Ernstoff, James Finke, Thomas F. Gajewski, Jared Gollob, Michael T. Lotze, Walter Storkus, Louis M. Weiner. (2007) Report on the ISBTC Mini-symposium on Biologic Effects of Targeted Therapeutics. Journal of Immunotherapy 30:6, 577-590
CrossRef540
Manish Jain, Raymond R. Townsend. (2007) Chemotherapy agents and hypertension: A focus on angiogenesis blockade. Current Hypertension Reports 9:4, 320-328
CrossRef541
Peter C. Black, Piyush K. Agarwal, Colin P.N. Dinney. (2007) Targeted therapies in bladder cancer—an update. Urologic Oncology: Seminars and Original Investigations 25:5, 433-438
CrossRef542
Alain Ravaud. (2007) Current options for the treatment of locally advanced and metastatic renal cell carcinoma: focus on sunitinib. European Journal of Cancer Supplements 5:7, 4-11
CrossRef543
Bernard J. Escudier. (2007) Temisorlimus in the treatment of advanced renal cell carcinoma. Oncology Reviews 1:2, 73-80
CrossRef544
Giuseppe Di Lorenzo. (2007) Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal Cell Cacinoma Guideline. Eur Urol 2007;51:1502–10. European Urology 52:3, 926-928
CrossRef545
Peter E Clark. (2007) Recent advances in targeted therapy for renal cell carcinoma. Current Opinion in Urology 17:5, 331-336
CrossRef546
Manisha Gupta, Erin Grothey, Ronald Bukowski, Oliver Sartor. (2007) Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL. Clinical Genitourinary Cancer 5:6, 362-370
CrossRef547
Thomas E. Hutson, Robert A. Figlin. (2007) Renal Cell Cancer. The Cancer Journal 13:5, 282-286
CrossRef548
Naomi B. Haas, Robert G. Uzzo. (2007) Targeted therapies for kidney cancer in urologic practice. Urologic Oncology: Seminars and Original Investigations 25:5, 420-432
CrossRef549
Rakesh K Jain, Aloke V Finn, Frank D Kolodgie, Herman K Gold, Renu Virmani. (2007) Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nature Clinical Practice Cardiovascular Medicine 4:9, 491-502
CrossRef550
Yoichi Makari, Takushi Yasuda, Yuichiro Doki, Hiroshi Miyata, Yoshiyuki Fujiwara, Shuji Takiguchi, Jin Matsuyama, Makoto Yamasaki, Takafumi Hirao, Mitsuhiro Koyama Koyama, Hironobu Nakamuara, Morito Monden. (2007) Correlation between tumor blood flow assessed by perfusion CT and effect of neoadjuvant therapy in advanced esophageal cancers. Journal of Surgical Oncology 96:3, 220-229
CrossRef551
(2007) Pegaptanib 1-Year Systemic Safety Results from a Safety–Pharmacokinetic Trial in Patients with Neovascular Age-Related Macular Degeneration. Ophthalmology 114:9, 1702-1712.e2
CrossRef552
Rakesh Chibber, Surina Chibber, Eva M Kohner. (2007) 21st Century treatment of diabetic retinopathy. Expert Review of Endocrinology & Metabolism 2:5, 623-631
CrossRef553
Alain Ravaud. (2007) Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse-event management and key considerations. European Journal of Cancer Supplements 5:7, 1-3
CrossRef554
Rogério A. Costa, Rodrigo Jorge, Daniela Calucci, Luiz A. S. Melo, José A. Cardillo, Ingrid U. Scott. (2007) Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefe's Archive for Clinical and Experimental Ophthalmology 245:9, 1273-1280
CrossRef555
Agniezka Michael, Ekaterini Politi, Erik Havranek, Catherine Corbishley, Lena Karapanagiotou, Chris Anderson, Kate Relph, Konstantinos N. Syrigos, Hardev Pandha. (2007) Prognostic significance of erythropoietin expression in human renal cell carcinoma. BJU International 100:2, 291-294
CrossRef556
Hassane Izzedine, Olivier Rixe, Bertrand Billemont, Alain Baumelou, Gilbert Deray. (2007) Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension. American Journal of Kidney Diseases 50:2, 203-218
CrossRef557
Walter M Stadler, Russell Z Szmulewitz. (2007) Sunitinib—a new standard of care for metastatic renal cell carcinoma. Nature Clinical Practice Oncology 4:8, 458-459
CrossRef558
Kazutaka Nakayama, Nizar M. Tannir, Ping Liu, Jay K. Wathen, Yee Chung Cheng, Richard E. Champlin, Naoto T. Ueno. (2007) Natural History of Metastatic Renal Cell Carcinoma in Patients Who Underwent Consultation for Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 13:8, 975-985
CrossRef559
Toni K. Choueiri, Jorge A. Garcia, Paul Elson, Mohamad Khasawneh, Saif Usman, Ali Reza Golshayan, Rachid C. Baz, Laura Wood, Brian I. Rini, Ronald M. Bukowski. (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:3, 543-550
CrossRef560
D.M. Patterson, G.J.S. Rustin. (2007) Vascular Damaging Agents. Clinical Oncology 19:6, 443-456
CrossRef561
James MG Larkin, Simon Chowdhury, Martin E Gore. (2007) Drug Insight: advances in renal cell carcinoma and the role of targeted therapies. Nature Clinical Practice Oncology 4:8, 470-479
CrossRef562
Brian Rini, Santwana Kar, Peter Kirkpatrick. (2007) Temsirolimus. Nature Reviews Drug Discovery 6:8, 599-600
CrossRef563
D Ribatti. (2007) The history of angiogenesis inhibitors. Leukemia 21:8, 1606-1609
CrossRef564
Kimberly A. Varker, Jennifer E. Biber, Cheryl Kefauver, Rhonda Jensen, Amy Lehman, Donn Young, Haifeng Wu, Gregory B. Lesinski, Kari Kendra, Helen X. Chen, Michael J. Walker, William E. Carson III. (2007) A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma. Annals of Surgical Oncology 14:8, 2367-2376
CrossRef565
Gérard Tobelem. (2007) VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. Targeted Oncology 2:3, 153-164
CrossRef566
J.P. MICHA, B.H. GOLDSTEIN, M.A. RETTENMAIER, M. GENESEN, C. GRAHAM, K. BADER, K.L. LOPEZ, M. NICKLE, J.V. BROWN. (2007) A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. International Journal of Gynecological Cancer 17:4, 771-776
CrossRef567
Lodovico Balducci. (2007) Molecular insight in cancer treatment and prevention. The International Journal of Biochemistry & Cell Biology 39:7-8, 1329-1336
CrossRef568
Hassane Izzedine, Irina Buhaescu, Olivier Rixe, Gilbert Deray. (2007) Sunitinib malate. Cancer Chemotherapy and Pharmacology 60:3, 357-364
CrossRef569
J.-Y. Blay. (2007) Thérapeutiques antiangiogéniques des tumeurs solides. La Revue de Médecine Interne 28, S7-S8
CrossRef570
Allan J. Pantuck, David B. Seligson, Tobias Klatte, Hong Yu, John T. Leppert, Laurence Moore, Timothy O'Toole, Jay Gibbons, Arie S. Belldegrun, Robert A. Figlin. (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 109:11, 2257-2267
CrossRef571
Wai-Man Chan, Timothy Y.Y. Lai, David T.L. Liu, Dennis S.C. Lam. (2007) Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy, Secondary to Punctate Inner Choroidopathy, or of Idiopathic Origin. American Journal of Ophthalmology 143:6, 977-983.e1
CrossRef572
Jin-Young Park, Pei-yin Lin, Robert H Weiss. (2007) Targeting the PI3K–Akt pathway in kidney cancer. Expert Review of Anticancer Therapy 7:6, 863-870
CrossRef573
Dan G. Duda, Tracy T. Batchelor, Christopher G. Willett, Rakesh K. Jain. (2007) VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends in Molecular Medicine 13:6, 223-230
CrossRef574
Nikolaos Kavantzas, Helen Paraskevakou, Sofia Tseleni-Balafouta, Kyriaki Aroni, Pauline Athanassiades, George Agrogiannis, Efstratios Patsouris. (2007) Association between microvessel density and histologic grade in renal cell carcinomas. Pathology & Oncology Research 13:2, 145-148
CrossRef575
Pierre I. Karakiewicz, Quoc-Dien Trinh, Naeem Bhojani, Karim Bensalah, Laurent Salomon, Alexandre de la Taille, Jacques Tostain, Luca Cindolo, Vincenzo Altieri, Vincenzo Ficarra, Luigi Schips, Richard Zigeuner, Peter F.A. Mulders, Antoine Valeri, Jean-Luc Descotes, Arnaud Mejean, Jean-Jacques Patard. (2007) Renal Cell Carcinoma with Nodal Metastases in the Absence of Distant Metastatic Disease: Prognostic Indicators of Disease-Specific Survival. European Urology 51:6, 1616-1624
CrossRef576
Andreas Skolarikos, Gerasimos Alivizatos, Pilar Laguna, Jean de la Rosette. (2007) A Review on Follow-Up Strategies for Renal Cell Carcinoma after Nephrectomy. European Urology 51:6, 1490-1501
CrossRef577
Aleix Prat, Josep Baselga. (2007) Bioterapia: aplicaciones actuales y futuras en oncología. Medicina Clínica 129:5, 184-193
CrossRef578
Takashi Koyama, Kaori Togashi. (2007) Functional MR imaging of the female pelvis. Journal of Magnetic Resonance Imaging 25:6, 1101-1112
CrossRef579
Jeffrey M. Farma, Markus Puhlmann, Perry A. Soriano, Derrick Cox, Giulio F. Paciotti, Lawrence Tamarkin, H. Richard Alexander. (2007) Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. International Journal of Cancer 120:11, 2474-2480
CrossRef580
Henk. M. W. Verheul, Herbert M. Pinedo. (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer 7:6, 475-485
CrossRef581
M. Dror Michaelson. (2007) ASCO 2006 highlights: Targeted therapy for renal cell carcinoma. Cancer Treatment Reviews 33:4, 381-390
CrossRef582
N.V. Rajeshkumar, George Matwyshyn, Anil Gulati. (2007) IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats. The Prostate 67:7, 701-713
CrossRef583
R. Longo, G. Gasparini. (2007) Challenges for patient selection with VEGF inhibitors. Cancer Chemotherapy and Pharmacology 60:2, 151-170
CrossRef584
Brendan Doyle, Noel Caplice. (2007) Plaque Neovascularization and Antiangiogenic Therapy for Atherosclerosis. Journal of the American College of Cardiology 49:21, 2073-2080
CrossRef585
Karen L. Reckamp, Robert A. Figlin, Nancy Moldawer, Allan J. Pantuck, Arie S. Belldegrun, Marie D. Burdick, Robert M. Strieter. (2007) Expression of CXCR3 on Mononuclear Cells and CXCR3 Ligands in Patients With Metastatic Renal Cell Carcinoma in Response to Systemic IL-2 Therapy. Journal of Immunotherapy 30:4, 417-424
CrossRef586
Jennifer F. De Los Santos, Gillian M. Thomas. (2007) Anemia correction in malignancy management: Threat or opportunity?. Gynecologic Oncology 105:2, 517-529
CrossRef587
Janet E. Dancey. 2007. Early Clinical Trial Design Issues: Patient Populations, End Points, and Barriers. , 25-44.
CrossRef588
Andrew C. Novick. (2007) Kidney cancer: Past, present, and future. Urologic Oncology: Seminars and Original Investigations 25:3, 188-195
CrossRef589
Maurie Markman. (2007) Use of progression-free survival as a valid endpoint in phase II cancer clinical trials. Current Oncology Reports 9:3, 159-160
CrossRef590
Daniel Roncone, Anjali Satoskar, Tibor Nadasdy, J Paul Monk, Brad H Rovin. (2007) Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nature Clinical Practice Nephrology 3:5, 287-293
CrossRef591
John T. Leppert, Allan J. Pantuck, Robert A. Figlin, Arie S. Belldegrun. (2007) The role of molecular markers in the staging of renal cell carcinoma. BJU International 99:5b, 1208-1211
CrossRef592
Eric C. Nelson, Christopher P. Evans, Primo N. Lara. (2007) Renal cell carcinoma: Current status and emerging therapies. Cancer Treatment Reviews 33:3, 299-313
CrossRef593
Keith T Flaherty. (2007) Sorafenib: delivering a targeted drug to the right targets. Expert Review of Anticancer Therapy 7:5, 617-626
CrossRef594
Egbert Oosterwijk, Chaitanya Divgi, Neil H. Bander. (2007) Active and passive immunotherapy: vaccines and antibodies. BJU International 99:5b, 1301-1304
CrossRef595
S A Karumanchi, F H Epstein. (2007) Placental ischemia and soluble fms-like tyrosine kinase 1: Cause or consequence of preeclampsia?. Kidney International 71:10, 959-961
CrossRef596
Sophie Sun, Joan H. Schiller. (2007) Angiogenesis inhibitors in the treatment of lung cancer. Critical Reviews in Oncology/Hematology 62:2, 93-104
CrossRef597
Ramaprasad Srinivasan, Andrew J. Armstrong, William Dahut, Daniel J. George. (2007) Anti-angiogenic therapy in renal cell cancer. BJU International 99:5b, 1296-1300
CrossRef598
Pieter H.M. De Mulder, Jean-Jaques Patard, Cezary Szczylik, Thomas Otto, Tim Eisen. (2007) Current Status of Targeted Therapy in Metastatic Renal Cell Carcinoma. European Urology Supplements 6:10, 665-671
CrossRef599
F. FRANCHI, P. GRASSI, D. FERRO, G. PIGLIUCCI, M. DE CHICCHIS, G. CASTIGLIANI, C. PASTORE, P. SEMINARA. (2007) Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer. European Journal of Cancer Care 16:3, 258-262
CrossRef600
Frank D. Kolodgie, Jagat Narula, Chun Yuan, Allen P. Burke, Aloke V. Finn, Renu Virmani. (2007) Elimination of Neoangiogenesis for Plaque Stabilization. Journal of the American College of Cardiology 49:21, 2093-2101
CrossRef601
P Hinnen, F A L M Eskens. (2007) Vascular disrupting agents in clinical development. British Journal of Cancer 96:8, 1159-1165
CrossRef602
Monika K. Krzyzanowska, Ian F. Tannock, Gina Lockwood, Jennifer Knox, Malcolm Moore, Georg A. Bjarnason. (2007) A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology 60:1, 135-141
CrossRef603
Alain Ravaud, Henri Clermont, Gilles Pasticier, Denis Smith, Véronique Vendrely, Jean Philippe Maire. (2007) Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma. Targeted Oncology 2:2, 99-105
CrossRef604
Chiara Dell’Agnola, Arya Biragyn. (2007) Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Review of Vaccines 6:2, 267-283
CrossRef605
Roy L Pañares, Agustin A Garcia. (2007) Bevacizumab in the management of solid tumors. Expert Review of Anticancer Therapy 7:4, 433-445
CrossRef606
Graham J. Caine, Paul S. Stonelake, Gregory Y.H. Lip, Andrew D. Blann. (2007) Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer. Cancer Letters 248:1, 131-136
CrossRef607
Christophe Le Tourneau, Eric Raymond, Sandrine Faivre. (2007) Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Therapeutics and Clinical Risk Management 3:2, 341-348
CrossRef608
Ravi A Madan, Philip M Arlen, James L Gulley. (2007) PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opinion on Biological Therapy 7:4, 543-554
CrossRef609
Adam S. Kibel. (2007) Editorial Comment. The Journal of Urology 177:4, 1272
CrossRef610
Tiffany A. Traina, Hope S. Rugo, Maura Dickler. (2007) Bevacizumab for Advanced Breast Cancer. Hematology/Oncology Clinics of North America 21:2, 303-319
CrossRef611
Christoph W. M. Reuter, Michael A. Morgan, Viktor Grünwald, Thomas R. W. Herrmann, Martin Burchardt, Arnold Ganser. (2007) Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. World Journal of Urology 25:1, 59-72
CrossRef612
M Abdulrahman, E N Maina, M R Morris, M Zatyka, R R Raval, R E Banks, M S Wiesener, F M Richards, C M Johnson, F Latif, E R Maher. (2007) Identification of novel VHL targets that are associated with the development of renal cell carcinoma. Oncogene 26:11, 1661-1672
CrossRef613
Joaquim Bellmunt. (2007) Current Treatment in Advanced Renal Cell Carcinoma (RCC): Impact of Targeted Therapies in the Management of RCC. European Urology Supplements 6:7, 484-491
CrossRef614
Bernard Escudier. (2007) New Perspectives: An Oral Multikinase Inhibitor in Patients with Advanced RCC. European Urology Supplements 6:7, 499-504
CrossRef615
Bryan P Schneider, George W Sledge. (2007) Drug Insight: VEGF as a therapeutic target for breast cancer. Nature Clinical Practice Oncology 4:3, 181-189
CrossRef616
Luciano J. Costa, Robert M. Gemmill, Harry A. Drabkin. (2007) Upstream Signaling Inhibition Enhances Rapamycin Effect on Growth of Kidney Cancer Cells. Urology 69:3, 596-602
CrossRef617
John M. Hollingsworth, David C. Miller, Stephanie Daignault, Rajal B. Shah, Brent K. Hollenbeck. (2007) Variable Penetrance of a Consensus Classification Scheme for Renal Cell Carcinoma. Urology 69:3, 452-456
CrossRef618
Philippe A Cassier, Armelle Dufresne, Jérôme Fayette, Laurent Alberti, Dominique Ranchere, Isabelle Ray-Coquard, Jean-Yves Blay. (2007) Emerging drugs for the treatment of soft tissue sarcomas. Expert Opinion on Emerging Drugs 12:1, 139-153
CrossRef619
Ramaprasad Srinivasan, W Marston Linehan. (2007) Antiangiogenic therapy in renal cell carcinoma: from concept to reality. Nature Clinical Practice Urology 4:2, 74-75
CrossRef620
Andrew Stone, Catherine Wheeler, Alan Barge. (2007) Improving the design of phase II trials of cytostatic anticancer agents. Contemporary Clinical Trials 28:2, 138-145
CrossRef621
Andrew Stone, Catherine Wheeler, Kevin Carroll, Alan Barge. (2007) Optimizing randomized phase II trials assessing tumor progression. Contemporary Clinical Trials 28:2, 146-152
CrossRef622
Joaquim Bellmunt, Clara Montagut, Santiago Albiol, Joan Carles, Pablo Maroto, Anna Orsola. (2007) Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU International 99:2, 274-280
CrossRef623
Ruth E. Board, Fiona C. Thistlethwaite, Robert E. Hawkins. (2007) Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treatment Reviews 33:1, 1-8
CrossRef624
Satoshi Inoue, Amanda Hartman, Cynthia D Branch, Corazan D Bucana, Benjamin N Bekele, L Clifton Stephens, Sunil Chada, Rajagopal Ramesh. (2007) mda-7 in Combination with Bevacizumab Treatment Produces a Synergistic and Complete Inhibitory Effect on Lung Tumor Xenograft. Molecular Therapy 15:2, 287-294
CrossRef625
Alexander Kamb, Susan Wee, Christoph Lengauer. (2007) Why is cancer drug discovery so difficult?. Nature Reviews Drug Discovery 6:2, 115-120
CrossRef626
Betsy A. George, Xin J. Zhou, Robert Toto. (2007) Nephrotic Syndrome After Bevacizumab: Case Report and Literature Review. American Journal of Kidney Diseases 49:2, e23-e29
CrossRef627
ROG??RIO A. COSTA, RODRIGO JORGE, DANIELA CALUCCI, LUIZ A. MELO, JOS?? A. CARDILLO, INGRID U. SCOTT. (2007) INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR CENTRAL AND HEMICENTRAL RETINAL VEIN OCCLUSIONS. Retina 27:2, 141-149
CrossRef628
Carlos Frangié, Carmen Lefaucheur, Jacques Medioni, Christian Jacquot, Garry S Hill, Dominique Nochy. (2007) Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. The Lancet Oncology 8:2, 177-178
CrossRef629
Napoleone Ferrara, Robert D. Mass, Claudio Campa, Robert Kim. (2007) Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration. Annual Review of Medicine 58:1, 491-504
CrossRef630
M. Iavarone, P. Lampertico, F. Iannuzzi, E. Manenti, M. F. Donato, E. Arosio, F. Bertolini, M. Primignani, A. Sangiovanni, M. Colombo. (2007) Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. Journal of Viral Hepatitis 14:2, 133-139
CrossRef631
Xiaolei Zhu, Shenhong Wu, William L. Dahut, Chirag R. Parikh. (2007) Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis. American Journal of Kidney Diseases 49:2, 186-193
CrossRef632
Susan Moore, Melody A. Cobleigh. (2007) Targeting Metastatic and Advanced Breast Cancer. Seminars in Oncology Nursing 23:1, 37-45
CrossRef633
Guru Sonpavde, Thomas E Hutson. (2007) Recent advances in the therapy of renal cancer. Expert Opinion on Biological Therapy 7:2, 233-242
CrossRef634
Yuji Takei, Hiroaki Mizukami, Yasushi Saga, Ichiro Yoshimura, Yoko Hasumi, Takeshi Takayama, Takahiro Kohno, Takashi Matsushita, Takashi Okada, Akihiro Kume, Mitsuaki Suzuki, Keiya Ozawa. (2007) Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. International Journal of Cancer 120:2, 278-284
CrossRef635
M Mathur, H H Samuels. (2007) Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Oncogene 26:2, 277-283
CrossRef636
Motzer, Robert J., Hutson, Thomas E., Tomczak, Piotr, Michaelson, M. Dror, Bukowski, Ronald M., Rixe, Olivier, Oudard, Stéphane, Negrier, Sylvie, Szczylik, Cezary, Kim, Sindy T., Chen, Isan, Bycott, Paul W., Baum, Charles M., Figlin, Robert A., . (2007) Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine 356:2, 115-124
Full Text637
Brugarolas, James, . (2007) Renal-Cell Carcinoma — Molecular Pathways and Therapies. New England Journal of Medicine 356:2, 185-187
Full Text638
Escudier, Bernard, Eisen, Tim, Stadler, Walter M., Szczylik, Cezary, Oudard, Stéphane, Siebels, Michael, Negrier, Sylvie, Chevreau, Christine, Solska, Ewa, Desai, Apurva A., Rolland, Frédéric, Demkow, Tomasz, Hutson, Thomas E., Gore, Martin, Freeman, Scott, Schwartz, Brian, Shan, Minghua, Simantov, Ronit, Bukowski, Ronald M., . (2007) Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. New England Journal of Medicine 356:2, 125-134
Full Text639
A. Dalgleish, J. Copier. (2007) New multitargeted treatments with antiangiogenic and antitumor activity: focus on sunitinib. Targeted Oncology 2:1, 17-29
CrossRef640
Mary Lee H. Villanueva, Ralph Hauke. (2007) Targeted therapies for renal cell carcinoma. Targeted Oncology 2:1, 7-16
CrossRef641
O. Mir, L. Mouthon, J. Alexandre, J.-M. Mallion, G. Deray, L. Guillevin, F. Goldwasser. (2007) Bevacizumab-Induced Cardiovascular Events: A Consequence of Cholesterol Emboli Syndrome?. JNCI Journal of the National Cancer Institute 99:1, 85-86
CrossRef642
Ivar Bleumer, Dorien M. Tiemessen, Jeannette C. Oosterwijk-Wakka, Maureen C. W. V??ller, Kim De Weijer, Peter F. A. Mulders, Egbert Oosterwijk. (2007) Preliminary Analysis of Patients With Progressive Renal Cell Carcinoma Vaccinated With CA9-peptide???Pulsed Mature Dendritic Cells. Journal of Immunotherapy 30:1, 116-122
CrossRef643
Stephen G. Schwartz, Harry W. Flynn. (2007) Pharmacotherapies for Diabetic Retinopathy: Present and Future. Experimental Diabetes Research 2007, 1-8
CrossRef644
Balázs Döme, Mary J.C. Hendrix, Sándor Paku, József Tóvári, József Tímár. (2007) Alternative Vascularization Mechanisms in Cancer. The American Journal of Pathology 170:1, 1-15
CrossRef645
Bernard Escudier. (2007) Advanced Renal Cell Carcinoma. Drugs 67:9, 1257-1264
CrossRef646
Martin E Gore, Michelle L Harrison, Ana Montes. (2007) New drug therapies for advanced renal cell carcinoma. Expert Review of Anticancer Therapy 7:1, 57-71
CrossRef647
Michael F Press, Heinz-Josef Lenz. (2007) EGFR, HER2 and VEGF Pathways. Drugs 67:14, 2045-2075
CrossRef648
M. Kurosch, S. Buse, J. Bedke, N. Wagener, A. Haferkamp, M. Hohenfellner. (2007) Palliative und supportive Therapie des Nierenzellkarzinoms. Der Urologe 46:1, 40-44
CrossRef649
T. Kessler, R. M. Mesters, W. E. Berdel. (2007) Angiogenesehemmung in der Onkologie. Der Onkologe 13:1, 20-31
CrossRef650
Alex Kiselyov, Konstantin V Balakin, Sergey E Tkachenko. (2007) VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opinion on Investigational Drugs 16:1, 83-107
CrossRef651
Michael Froehner, Oliver W. Hakenberg, Manfred P. Wirth. (2007) Molecular Therapy in Urologic Oncology. Urologia Internationalis 79:1, 1-7
CrossRef652
John T. Salter, Kathy D. Miller. 2007. Antiangiogenic Agents in Breast Cancer. , 269-284.
CrossRef653
Amelia B Zelnak, Ruth M O??Regan. (2007) Targeting Angiogenesis in Advanced Breast Cancer. BioDrugs 21:4, 209-214
CrossRef654
Maurizio Chiriva-Internati, Everardo Cobos, W. Martin Kast. (2007) Advances in Immunotherapy of Multiple Myeloma: From the Discovery of Tumor-Associated Antigens to Clinical Trials. International Reviews of Immunology 26:3-4, 197-222
CrossRef655
TOM J. WACHTEL. 2007. R. , 176-185.
CrossRef656
Florian Schuetz, Christof Sohn, Andreas Schneeweiss. (2007) Bevacizumab in the Treatment of Metastatic Breast Cancer. Breast Care 2:2, 82-88
CrossRef657
Suzanne Baumwell, S. Ananth Karumanchi. (2007) Pre-Eclampsia: Clinical Manifestations and Molecular Mechanisms. Nephron Clinical Practice 106:2, c72-c81
CrossRef658
2007. Cancer pathology and angiogenesis. , 11-26.
CrossRef659
Angelika M. Burger. (2007) Highlights in experimental therapeutics. Cancer Letters 245:1-2, 11-21
CrossRef660
Brian R. Lane, Brian I. Rini, Andrew C. Novick, Steven C. Campbell. (2007) Targeted Molecular Therapy for Renal Cell Carcinoma. Urology 69:1, 3-10
CrossRef661
Sean Collins, James McKiernan, Jaime Landman. (2006) Update on the Epidemiology and Biology of Renal Cortical Neoplasms. Journal of Endourology 20:12, 975-985
CrossRef662
Brian I Rini. (2006) Molecularly targeted therapy in renal cell carcinoma: where do we go from here?. Expert Review of Anticancer Therapy 6:12, 1753-1760
CrossRef663
Sofia Baka, Andrew R Clamp, Gordon C Jayson. (2006) A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opinion on Therapeutic Targets 10:6, 867-876
CrossRef664
Doru T Alexandrescu, Constantin A Dasanu. (2006) Kidney cancer therapy: new perspectives and avenues. Expert Opinion on Pharmacotherapy 7:18, 2481-2493
CrossRef665
Matthew M Cooney, Willem van Heeckeren, Shyam Bhakta, Jose Ortiz, Scot C Remick. (2006) Drug Insight: vascular disrupting agents and angiogenesis—novel approaches for drug delivery. Nature Clinical Practice Oncology 3:12, 682-692
CrossRef666
Kenneth T Eng, Peter J Kertes. (2006) Ranibizumab in neovascular age-related macular degeneration. Clinical Interventions in Aging 1:4, 451-466
CrossRef667
Daniel J. George, Cassandra Moore. (2006) Angiogenesis inhibitors in clinical oncology. Update on Cancer Therapeutics 1:4, 429-434
CrossRef668
Simon J Harrison, Gordon Cook, Robert JB Nibbs, H Miles Prince. (2006) Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Expert Review of Anticancer Therapy 6:12, 1769-1785
CrossRef669
Shandra S. Wilson. (2006) Genitourinary malignancies. Update on Cancer Therapeutics 1:4, 443-466
CrossRef670
Damien Pouessel, Stéphane Culine. (2006) Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. Expert Review of Anticancer Therapy 6:12, 1761-1767
CrossRef671
Toni K. Choueiri, Robert Dreicer, Brian I. Rini, Paul Elson, Jorge A. Garcia, Snehal G. Thakkar, Rachid C. Baz, Tarek M. Mekhail, Holly A. Jinks, Ronald M. Bukowski. (2006) Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107:11, 2609-2616
CrossRef672
James M.G. Larkin, Tim Eisen. (2006) Kinase inhibitors in the treatment of renal cell carcinoma. Critical Reviews in Oncology/Hematology 60:3, 216-226
CrossRef673
Ronald J. Halbert, Robert A. Figlin, Michael B. Atkins, Myriam Bernal, Thomas E. Hutson, Robert G. Uzzo, Ronald M. Bukowski, Khuda Dad Khan, Christopher G. Wood, Robert W. Dubois. (2006) Treatment of patients with metastatic renal cell cancer. Cancer 107:10, 2375-2383
CrossRef674
Cécile Gouttefangeas, Arnulf Stenzl, Stefan Stevanović, Hans-Georg Rammensee. (2006) Immunotherapy of renal cell carcinoma. Cancer Immunology, Immunotherapy 56:1, 117-128
CrossRef675
Nizar M. Tannir, Lorenzo Cohen, Xuemei Wang, Peter Thall, Paul F. Mathew, Eric Jonasch, Arlene Siefker-Radtke, Lance C. Pagliaro, Chaan S. Ng, Christopher Logothetis. (2006) Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b. Cancer 107:9, 2254-2261
CrossRef676
V. Grünwald, C. Reuter, A. Ganser, S. Ehrlich, P. Ivanyi. (2006) Therapie des Nierenzellkarzinoms. Der Onkologe 12:11, 1153-1168
CrossRef677
H Yazawa, T Murakami, H-M Li, T Back, K Kurosaka, Y Suzuki, L Shorts, Y Akiyama, K Maruyama, E Parsoneault, R H Wiltrout, M Watanabe. (2006) Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors. Cancer Gene Therapy 13:11, 993-1001
CrossRef678
Jérome Segers, Vincent Di Fazio, Réginald Ansiaux, Philippe Martinive, Olivier Feron, Pierre Wallemacq, Bernard Gallez. (2006) Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: Importance of optimal scheduling to exploit the ‘normalization’ window of the tumor vasculature. Cancer Letters 244:1, 129-135
CrossRef679
Michael Davies, Bryan Hennessy, Gordon B Mills. (2006) Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy 7:16, 2243-2261
CrossRef680
CHRISTOS HARITOGLOU, DANIEL KOOK, ALJOSCHA NEUBAUER, ARMIN WOLF, SIEGFRIED PRIGLINGER, RUPERT STRAUSS, ARND GANDORFER, MICHAEL ULBIG, ANSELM KAMPIK. (2006) INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA. Retina 26:9, 999-1005
CrossRef681
Lance C. Pagliaro, Cherie A. Perez, Shi-Ming Tu, Danai D. Daliani. (2006) Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 24:6, 487-491
CrossRef682
Jason D. Wright, Dana Viviano, Matthew A. Powell, Randall K. Gibb, David G. Mutch, Perry W. Grigsby, Janet S. Rader. (2006) Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecologic Oncology 103:2, 489-493
CrossRef683
RODRIGO JORGE, ROG??RIO A. COSTA, DANIELA CALUCCI, L??SSIA P. CINTRA, INGRID U. SCOTT. (2006) INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY). Retina 26:9, 1006-1013
CrossRef684
Roy S Herbst. (2006) Therapeutic options to target angiogenesis in human malignancies. Expert Opinion on Emerging Drugs 11:4, 635-650
CrossRef685
Ted Shih, Celeste Lindley. (2006) Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clinical Therapeutics 28:11, 1779-1802
CrossRef686
Ulka N. Vaishampayan, Lance K. Heilbrun, Anthony F. Shields, Jawana Lawhorn-Crews, Karen Baranowski, Daryn Smith, Lawrence E. Flaherty. (2006) Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma. Investigational New Drugs 25:1, 69-75
CrossRef687
Richard L. Schilsky. (2006) Phase I and II clinical trial design for targeted agents. Targeted Oncology 1:4, 220-227
CrossRef688
Yan Wu, Andrea T. Hooper, Zhaojing Zhong, Larry Witte, Peter Bohlen, Shahin Rafii, Daniel J. Hicklin. (2006) The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. International Journal of Cancer 119:7, 1519-1529
CrossRef689
Edward A. Sausville. 2006. Targeted Therapies for Cancer: Definitions and Attributes. , 27-38.
CrossRef690
Karen S Moulton. (2006) Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Current Opinion in Lipidology 17:5, 548-555
CrossRef691
Jan Roigas, Manfred Johannsen, Martin Ringsdorf, Gero Massenkeil. (2006) Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 6:10, 1449-1458
CrossRef692
Begoña Mellado, Pere Gascón. (2006) Molecular biology of renal cell carcinoma. Clinical and Translational Oncology 8:10, 706-710
CrossRef693
John T Leppert, Allan J Pantuck. (2006) Determining the prognosis of patients with renal cell carcinoma: is it time for a re-evaluation?. Nature Clinical Practice Urology 3:10, 510-511
CrossRef694
Rodolfo Passalacqua, Sebastiano Buti, Gianluca Tomasello, Raffaella Longarini, Matteo Brighenti, Matteo Dalla Chiesa. (2006) Immunotherapy options in metastatic renal cell cancer: where we are and where we are going. Expert Review of Anticancer Therapy 6:10, 1459-1472
CrossRef695
Alfredo Carrato, Javier Gallego-Plazas, Carmen Guillen-Ponce. (2006) Anti-VEGF therapy: a new approach to colorectal cancer therapy. Expert Review of Anticancer Therapy 6:10, 1385-1396
CrossRef696
Brian I. Rini, Erich Jaeger, Vivian Weinberg, Nancy Sein, Karen Chew, Kristen Fong, Jeffery Simko, Eric J. Small, Frederic M. Waldman. (2006) Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU International 98:4, 756-762
CrossRef697
Levine, Richard J., Lam, Chun, Qian, Cong, Yu, Kai F., Maynard, Sharon E., Sachs, Benjamin P., Sibai, Baha M., Epstein, Franklin H., Romero, Roberto, Thadhani, Ravi, Karumanchi, S. Ananth, . (2006) Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. New England Journal of Medicine 355:10, 992-1005
Full Text698
Takashi Koyama, Ken Tamai, Kaori Togashi. (2006) Current status of body MR imaging: fast MR imaging and diffusion-weighted imaging. International Journal of Clinical Oncology 11:4, 278-285
CrossRef699
S. Chowdhury, H. Pandha. (2006) Targeting Renal Cell Carcinoma. Clinical Oncology 18:7, 511-512
CrossRef700
Li Yan, Zhenping Zhu. (2006) Development of antibody-based therapeutics for oncology indications. Drug Development Research 67:9, 699-728
CrossRef701
Giuseppe Garcea, Helena Doucas, Will P. Steward, Ashley R. Dennison, David P. Berry. (2006) HYPOXIA AND ANGIOGENESIS IN PANCREATIC CANCER. ANZ Journal of Surgery 76:9, 830-842
CrossRef702
Andrea Mancuso, Cora N Sternberg. (2006) New treatment approaches in metastatic renal cell carcinoma. Current Opinion in Urology 16:5, 337-341
CrossRef703
A. Haferkamp, D. Rohde, S. C. Müller, H. Rübben, M. Hohenfellner. (2006) Das Nierenzellkarzinom. Der Urologe 45:S04, 74-84
CrossRef704
Shuji Mikami, Mototsugu Oya, Ryuichi Mizuno, Masaru Murai, Makio Mukai, Yasunori Okada. (2006) Expression of Ets-1 in human clear cell renal cell carcinomas: Implications for angiogenesis. Cancer Science 97:9, 875-882
CrossRef705
Robin L Jones, Michael S Ewer. (2006) Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Review of Anticancer Therapy 6:9, 1249-1269
CrossRef706
D. Goldstein, S. P. Ackland, D. R. Bell, I. N. Olver, I. D. Davis, M. A. Rosenthal, G. C. Toner, M. C. Pinel, M. Byrne. (2006) Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Investigational New Drugs 24:5, 429-434
CrossRef707
T. Michael Numnum, Rodney P. Rocconi, Jenny Whitworth, Mack N. Barnes. (2006) The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecologic Oncology 102:3, 425-428
CrossRef708
E. A. Sausville. (2006) Respecting Cancer Drug Transportability: A Basis for Successful Lead Selection. JNCI Journal of the National Cancer Institute 98:16, 1098-1099
CrossRef709
N. Young, C. N. Hahn, A. Poh, C. Dong, D. Wilhelm, J. Olsson, G. E. O. Muscat, P. Parsons, J. R. Gamble, P. Koopman. (2006) Effect of Disrupted SOX18 Transcription Factor Function on Tumor Growth, Vascularization, and Endothelial Development. JNCI Journal of the National Cancer Institute 98:15, 1060-1067
CrossRef710
Rekha T. Tripathi, Lance K. Heilbrun, Vikash Jain, Ulka N. Vaishampayan. (2006) Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma. Urology 68:2, 296-301
CrossRef711
Bradley J. Monk, Ernest Han, Carol A. Josephs-Cowan, Gordon Pugmire, Robert A. Burger. (2006) Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecologic Oncology 102:2, 140-144
CrossRef712
I Bernard Weinstein, Andrew K Joe. (2006) Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nature Clinical Practice Oncology 3:8, 448-457
CrossRef713
Naoyo Nishida, Hirohisa Yano, Takashi Nishida, Toshiharu Kamura, Masamichi Kojiro. (2006) Angiogenesis in cancer. Vascular Health and Risk Management 2:3, 213-219
CrossRef714
David E. Cohn, Sue Valmadre, Kimberly E. Resnick, Lynne A. Eaton, Larry J. Copeland, Jeffrey M. Fowler. (2006) Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecologic Oncology 102:2, 134-139
CrossRef715
Georgia B. McGaughey, J. Chris Culberson, Bradley P. Feuston, Constantine Kreatsoulas, Vladimir Maiorov, Joseph Shpungin. (2006) Scoring of KDR Kinase Inhibitors: Using Interaction Energy as a Guide for Ranking. Molecular Diversity 10:3, 341-347
CrossRef716
Nizar Tannir, Eric Jonasch, Lance C. Pagliaro, Paul Mathew, Arlene Siefker-Radtke, Laurence Rhines, Patrick Lin, Rita Tibbs, Kim-Anh Do, Sue-Hwa Lin, Shi-Ming Tu. (2006) Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma. Cancer 107:3, 497-505
CrossRef717
D K Wilkins, A Mayer. (2006) Development of antibodies for cancer therapy. Expert Opinion on Biological Therapy 6:8, 787-796
CrossRef718
Antonio Jimeno, Manuel Hidalgo. (2006) Multitargeted therapy: Can promiscuity be praised in an era of political correctness?. Critical Reviews in Oncology/Hematology 59:2, 150-158
CrossRef719
Carol Aghajanian. (2006) The role of bevacizumab in ovarian cancer—An evolving story. Gynecologic Oncology 102:2, 131-133
CrossRef720
Patricia S Steeg. (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nature Medicine 12:8, 895-904
CrossRef721
Masatoshi Eto, Seiji Naito. (2006) Molecular targeting therapy for renal cell carcinoma. International Journal of Clinical Oncology 11:3, 209-213
CrossRef722
Ana R. Quesada, Ramón Muñoz-Chápuli, Miguel A. Medina. (2006) Anti-angiogenic drugs: from bench to clinical trials. Medicinal Research Reviews 26:4, 483-530
CrossRef723
W. Scott Webster, Christine M. Lohse, R. Houston Thompson, Haidong Dong, Xavier Frigola, Demetrius L. Dicks, Shomik Sengupta, Igor Frank, Bradley C. Leibovich, Michael L. Blute, John C. Cheville, Eugene D. Kwon. (2006) Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 107:1, 46-53
CrossRef724
Joel Handler. (2006) Hypertension Complicating Cancer Chemotherapy. The Journal of Clinical Hypertension 8:7, 526-529
CrossRef725
Gilberto de Castro Junior, Fabio Puglisi, Evandro de Azambuja, Nagi S. El Saghir, Ahmad Awada. (2006) Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the “do ut des” paradigm). Critical Reviews in Oncology/Hematology 59:1, 40-50
CrossRef726
Jason D. Wright, Andrea Hagemann, Janet S. Rader, Dana Viviano, Randall K. Gibb, Lori Norris, David G. Mutch, Matthew A. Powell. (2006) Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma. Cancer 107:1, 83-89
CrossRef727
Mark L. Sundermeyer, Stuart R. Lessin, Neal J. Meropol. (2006) Targeted therapies in colorectal cancer: Complications and management. Current Colorectal Cancer Reports 2:3, 125-133
CrossRef728
Yusuke Oshima, Hirokazu Sakaguchi, Fumi Gomi, Yasuo Tano. (2006) Regression of Iris Neovascularization After Intravitreal Injection of Bevacizumab in Patients With Proliferative Diabetic Retinopathy. American Journal of Ophthalmology 142:1, 155-157.e1
CrossRef729
Daniel Von Hoff. 2006. Horizons for Cancer Chemotherapy (and Nonchemotherapy). , 445-457.
CrossRef730
Francesco M. Boccardo, Pamela Guglielmini, Laura Tacchini. (2006) Medical Treatment of Advanced Renal Cell Carcinoma: Present Options and Future Directions. European Urology Supplements 5:8, 619-626
CrossRef731
A Hara, T Wada, K Furuichi, N Sakai, H Kawachi, F Shimizu, M Shibuya, K Matsushima, H Yokoyama, K Egashira, S Kaneko. (2006) Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney International 69:11, 1986-1995
CrossRef732
C. Jochims, U. Mazitschek, D. Jäger, H. Goldschmidt. (2006) Zielgerichtete Therapie bei soliden Tumoren und in der Hämatoonkologie. Der Internist 47:6, 633-641
CrossRef733
P Nathan, D Chao, C Brock, P Savage, M Harries, M Gore, T Eisen. (2006) The place of VEGF inhibition in the current management of renal cell carcinoma. British Journal of Cancer 94:9, 1217-1220
CrossRef734
M. Autenrieth, A. Heidenreich, J. E. Gschwend. (2006) Systemische Therapie des metastasierten Nierenzellkarzinoms. Der Urologe 45:5, 594-599
CrossRef735
Alfredo Martínez. (2006) A new family of angiogenic factors. Cancer Letters 236:2, 157-163
CrossRef736
Robert J Motzer, Sakina Hoosen, Carlo L Bello, James G Christensen. (2006) Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opinion on Investigational Drugs 15:5, 553-561
CrossRef737
Laura C. Michaelis, Mark J. Ratain. (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nature Reviews Cancer 6:5, 409-414
CrossRef738
Brian I Rini, Steven C Campbell, W Kimryn Rathmell. (2006) Renal cell carcinoma. Current Opinion in Oncology 18:3, 289-296
CrossRef739
Shigeru Kanda, Yasuyoshi Miyata, Hiroshi Kanetake. (2006) Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. International Journal of Clinical Oncology 11:2, 90-107
CrossRef740
Olivier Rouvière, Raymonde Bouvier, Sylvie Négrier, Lionel Badet, Denis Lyonnet. (2006) Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?. Nature Clinical Practice Oncology 3:4, 200-213
CrossRef741
Simon Chowdhury, James F. Spicer, Peter G. Harper. (2006) Hypertension and targeted therapy. Targeted Oncology 1:2, 104-108
CrossRef742
Pier Paolo Piccaluga, Giovanni Martinelli, Michele Baccarani. (2006) Advances in the treatment for haematological malignancies. Expert Opinion on Pharmacotherapy 7:6, 721-732
CrossRef743
Lucas T. van Eijk, Arjan Nooteboom, Thijs Hendriks, Tom Sprong, Mihai G. Netea, Paul Smits, Johannes G. van der Hoeven, Peter Pickkers. (2006) PLASMA OBTAINED DURING HUMAN ENDOTOXEMIA INCREASES ENDOTHELIAL ALBUMIN PERMEABILITY IN VITRO. Shock 25:4, 358-362
CrossRef744
Michael Atkins, Carole A. Jones, Peter Kirkpatrick. (2006) Sunitinib maleate. Nature Reviews Drug Discovery 5:4, 279-280
CrossRef745
Derek Atkins, Detlef Rohde, Stephan Störkel. (2006) Differential expression of EGFR and TGFα in VHL-mutated renal cell carcinomas of the clear cell type: implications for targeted therapeutic approaches. Targeted Oncology 1:2, 71-78
CrossRef746
Monika Jermann, Rolf A Stahel, Marc Salzberg, Thomas Cerny, Markus Joerger, Silke Gillessen, Rudolf Morant, Fritz Egli, Kaspar Rhyner, Jean A Bauer, Miklos Pless. (2006) A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemotherapy and Pharmacology 57:4, 533-539
CrossRef747
Richard J. Levine, Cong Qian, Sharon E. Maynard, Kai F. Yu, Franklin H. Epstein, S. Ananth Karumanchi. (2006) Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. American Journal of Obstetrics and Gynecology 194:4, 1034-1041
CrossRef748
Brian I. Rini. (2006) VEGF-targeted therapy in renal cell carcinoma: Active drugs and active choices. Current Oncology Reports 8:2, 85-89
CrossRef749
Brian I Rini. (2006) Sorafenib. Expert Opinion on Pharmacotherapy 7:4, 453-461
CrossRef750
Lijun Zhu ., Yun Yen ., Jimin Shao ., Christina H. Qi ., Christina Yen ., Jianhong Luo ., Bingsen Zhou .. (2006) Fibroblast Growth Factor Receptor 3 Up-regulates Vascular Endothelial Growth Factor Expression in L6 Cells. International Journal of Pharmacology 2:3, 324-330
CrossRef751
John T. Sisko, Thomas J. Tucker, Mark T. Bilodeau, Carolyn A. Buser, Patrice A. Ciecko, Kathleen E. Coll, Christine Fernandes, Jackson B. Gibbs, Timothy J. Koester, Nancy Kohl, Joseph J. Lynch, Xianzhi Mao, Debra McLoughlin, Cynthia M. Miller-Stein, Leonard D. Rodman, Keith W. Rickert, Laura Sepp-Lorenzino, Jennifer M. Shipman, Kenneth A. Thomas, Bradley K. Wong, George D. Hartman. (2006) Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase. Bioorganic & Medicinal Chemistry Letters 16:5, 1146-1150
CrossRef752
R. Kuefer, M. Autenrieth, K. Herkommer, P. Blum, A. Merseburger, M. Hofer, L. Rinnab, J. Gschwend, M. Ringhoffer. (2006) Translation molekularer Zusammenhänge in die klinische Anwendung. Der Urologe 45:3, 328-335
CrossRef753
Domenico Vitolo, Luciano Ciocci, Gloria Deriu, Silvia Spinelli, Stefania Cortese, Laura Masuelli, Stefania Morrone, Mary Jo Filice, Giorgio Furio Coloni, Pier Giorgio Natali, Carlo Davide Baroni. (2006) Laminin α2 Chain-Positive Vessels and Epidermal Growth Factor in Lung Neuroendocrine Carcinoma. The American Journal of Pathology 168:3, 991-1003
CrossRef754
A. J. Schrader, Z. Varga, A. Hegele, S. Pfoertner, P. Olbert, R. Hofmann. (2006) Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. Journal of Cancer Research and Clinical Oncology 132:3, 137-149
CrossRef755
ROBERTA P. A. MANZANO, GHOLAM A. PEYMAN, PALWASHA KHAN, MUHAMET KIVILCIM. (2006) TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN). Retina 26:3, 257-261
CrossRef756
ANDRES J. SCHRADER, ZOLTAN VARGA, SUSANNE PFOERTNER, ULRIKE GOELDEN, JAN BUER, RAINER HOFMANN. (2006) Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer. BJU International 97:3, 461-465
CrossRef757
Rachel E Sanborn, Alan B Sandler. (2006) The safety of bevacizumab. Expert Opinion on Drug Safety 5:2, 289-301
CrossRef758
P H Patel, R S K Chaganti, R J Motzer. (2006) Targeted therapy for metastatic renal cell carcinoma. British Journal of Cancer
CrossRef759
D. T. Rein, P. Dall, M. Breidenbach. (2006) Antiangiogene Therapiestrategien in der gynäkologischen Onkologie. Der Gynäkologe 39:2, 153-157
CrossRef760
Apurva A. Desai, Walter M. Stadler. (2006) Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents. Current Urology Reports 7:1, 16-22
CrossRef761
John T Leppert, Allan J Pantuck. (2006) Significance of gene expression analysis of renal cell carcinoma. Expert Review of Anticancer Therapy 6:2, 293-299
CrossRef762
Johannes Czernin, Wolfgang A. Weber, Harvey R. Herschman. (2006) Molecular Imaging in the Development of Cancer Therapeutics. Annual Review of Medicine 57:1, 99-118
CrossRef763
George V Thomas. (2006) mTOR and cancer: reason for dancing at the crossroads?. Current Opinion in Genetics & Development 16:1, 78-84
CrossRef764
Brian I. Rini, Vivian Weinberg, Sarah Dunlap, Alexandra Elchinoff, Nancy Yu, Robert Bok, Jeffery Simko, Eric J. Small. (2006) Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 106:3, 566-575
CrossRef765
R H Weiss, P-Y Lin. (2006) Kidney cancer: Identification of novel targets for therapy. Kidney International 69:2, 224-232
CrossRef766
(2006) Abstracts. Cancer Investigation 24:s1, 5-64
CrossRef767
Ulas Sunar, Harry Quon, Turgut Durduran, Jun Zhang, Juan Du, Chao Zhou, Guoqiang Yu, Regine Choe, Alex Kilger, Robert Lustig, Laurie Loevner, Shoko Nioka, Britton Chance, Arjun G. Yodh. (2006) Noninvasive diffuse optical measurement of blood flow and blood oxygenation for monitoring radiation therapy in patients with head and neck tumors: a pilot study. Journal of Biomedical Optics 11:6, 064021
CrossRef768
I. Bleumer, E. Oosterwijk, J.C. Oosterwijk-Wakka, M.C.W. Völler, S. Melchior, S.O. Warnaar, C. Mala, J. Beck, P.F.A. Mulders. (2006) A Clinical Trial With Chimeric Monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell Carcinoma. The Journal of Urology 175:1, 57-62
CrossRef769
Simon C Ling. (2006) Novel Therapeutic Targets for Prevention of Portal-Systemic Collaterals in Portal Hypertension. Journal of Pediatric Gastroenterology and Nutrition 42:1, 121-122
CrossRef770
Giampietro Gasparini, Raffaele Longo, Francesco Torino, Domenico Gattuso, Alessandro Morabito, Giuseppe Toffoli. (2006) Is tailored therapy feasible in oncology?. Critical Reviews in Oncology/Hematology 57:1, 79-101
CrossRef771
Andreas A. Skolarikos, Athanasios G. Papatsoris, Gerasimos Alivizatos, Charalambos Deliveliotis. (2006) Molecular Pathogenetics of Renal Cancer. American Journal of Nephrology 26:3, 218-231
CrossRef772
Erin A. Donovan, Shivaani Kummar. (2006) Targeting VEGF in Cancer Therapy. Current Problems in Cancer 30:1, 7-32
CrossRef773
Klaus Podar, Teru Hideshima, Yu-Tzu Tai, Paul G Richardson, Dharminder Chauhan, Kenneth C Anderson. (2006) Emerging Therapies for Multiple Myeloma. American Journal of Cancer 5:3, 141-153
CrossRef774
Dick Johan van Spronsen, Pieter H.M. De Mulder. (2006) Targeted Approaches for Treating Advanced Clear Cell Renal Carcinoma. Onkologie 29:8-9, 394-402
CrossRef775
Robert J Amato, Jaroslaw Jac. (2006) Targeted Anti-Cancer Therapies for Renal Cancer. Drugs 66:17, 2161-2171
CrossRef776
Napoleone Ferrara, Robert S. Kerbel. (2005) Angiogenesis as a therapeutic target. Nature 438:7070, 967-974
CrossRef777
Cohen, Herbert T., McGovern, Francis J., . (2005) Renal-Cell Carcinoma. New England Journal of Medicine 353:23, 2477-2490
Full Text778
Laura Sanz, Luis Álvarez-Vallina. (2005) Antibody-based antiangiogenic cancer therapy. Expert Opinion on Therapeutic Targets 9:6, 1235-1245
CrossRef779
Peter Pickkers, Tom Sprong, Lucas van Eijk, Hans van der Hoeven, Paul Smits, Marcel van Deuren. (2005) VASCULAR ENDOTHELIAL GROWTH FACTOR IS INCREASED DURING THE FIRST 48 HOURS OF HUMAN SEPTIC SHOCK AND CORRELATES WITH VASCULAR PERMEABILITY. Shock 24:6, 508-512
CrossRef780
D. Rohde. (2005) Studienlandschaft Nierenzellkarzinom. Der Urologe 44:12, 1423-1430
CrossRef781
W. K. RATHMELL, M. C. SIMON. (2005) VHL: oxygen sensing and vasculogenesis. Journal of Thrombosis and Haemostasis 3:12, 2627-2632
CrossRef782
Alan B. Sandler. (2005) Targeting Angiogenesis in Lung Cancer. Seminars in Oncology 32, 16-22
CrossRef783
W Kimryn Rathmell, Tricia M Wright, Brian I Rini. (2005) Molecularly targeted therapy in renal cell carcinoma. Expert Review of Anticancer Therapy 5:6, 1031-1040
CrossRef784
Marina Noris, Norberto Perico, Giuseppe Remuzzi. (2005) Mechanisms of Disease: pre-eclampsia. Nature Clinical Practice Nephrology 1:2, 98-114
CrossRef785
Kelly E. Fathers, Courtney M. Stone, Kanwal Minhas, Jason J.A. Marriott, Janice D. Greenwood, Daniel J. Dumont, Brenda L. Coomber. (2005) Heterogeneity of Tie2 Expression in Tumor Microcirculation. The American Journal of Pathology 167:6, 1753-1762
CrossRef786
Walter M. Stadler. (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104:11, 2323-2333
CrossRef787
Aparna A. Kamat, Anil K. Sood. (2005) The merits of vascular targeting for gynecologic malignancies. Current Oncology Reports 7:6, 444-450
CrossRef788
Robert O Dillman. (2005) Lymphocyte therapy of renal cell carcinoma. Expert Review of Anticancer Therapy 5:6, 1041-1051
CrossRef789
Janice P. Dutcher, Larry Leon, Judith Manola, David M. Friedland, Bruce Roth, George Wilding. (2005) Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy. Cancer 104:11, 2392-2399
CrossRef790
Atsuo Shida, Shuichi Fujioka, Yoshio Ishibashi, Katsutoshi Kobayashi, Hiroshi Nimura, Norio Mitsumori, Yutaka Suzuki, Makio Kawakami, Mitsuyoshi Urashima, Katsuhiko Yanaga. (2005) Prognostic Significance of Vascular Endothelial Growth Factor D in Gastric Carcinoma. World Journal of Surgery 29:12, 1600-1607
CrossRef791
Philip E. Shaheen, Walter Stadler, Paul Elson, Jennifer Knox, Eric Winquist, Ronald M. Bukowski. (2005) Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Investigational New Drugs 23:6, 577-581
CrossRef792
Beverly J. Drucker. (2005) Renal cell carcinoma: Current status and future prospects. Cancer Treatment Reviews 31:7, 536-545
CrossRef793
Anaadriana Zakarija, Gerald Soff. (2005) Update on angiogenesis inhibitors. Current Opinion in Oncology 17:6, 578-583
CrossRef794
Alfredo Martínez, Virginia G. Marín, Santiago Ramón y Cajal Junquera, Ricardo Martínez-Murillo, Miguel Freire. (2005) The contributions of Santiago Ramón y Cajal to cancer research — 100 years on. Nature Reviews Cancer 5:11, 904-909
CrossRef795
Mani Mohindru, Amit Verma. (2005) Engineered antibodies act as targeted therapies in cancer treatment. The Indian Journal of Pediatrics 72:11, 943-947
CrossRef796
Philip E Shaheen, Ronald M Bukowski. (2005) Emerging drugs for renal cell carcinoma. Expert Opinion on Emerging Drugs 10:4, 773-795
CrossRef797
Giampietro Gasparini, Raffaele Longo, Masakazu Toi, Napoleone Ferrara. (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nature Clinical Practice Oncology 2:11, 562-577
CrossRef798
Renhai Cao, Yihai Cao, Ebba Brakenhielm. 2005. Resveratrol as an Angiogenesis Inhibitor. , 149-165.
CrossRef799
John S. Lam, John T. Leppert, Robert A. Figlin, Arie S. Belldegrun. (2005) Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66:5, 1-9
CrossRef800
Justin P Favaro, Daniel J George. (2005) Targeted therapy in renal cell carcinoma. Expert Opinion on Investigational Drugs 14:10, 1251-1258
CrossRef801
Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers, Douglas Hanahan. (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:4, 299-309
CrossRef802
Matthew M. Cooney, Scot C. Remick, Nicholas J. Vogelzang. (2005) Promising systemic therapy for renal cell carcinoma. Current Treatment Options in Oncology 6:5, 357-365
CrossRef803
Stamatis-Nick C. Liossis, George C. Tsokos. (2005) Monoclonal antibodies and fusion proteins in medicine. Journal of Allergy and Clinical Immunology 116:4, 721-729
CrossRef804
Brian R Lane, Michael W Kattan. (2005) Predicting outcomes in renal cell carcinoma. Current Opinion in Urology 15:5, 289-297
CrossRef805
Robert M Strieter. (2005) Masters of angiogenesis. Nature Medicine 11:9, 925-927
CrossRef806
Chan-Wook Park, Joong Shin Park, Soon-Sup Shim, Jong Kwan Jun, Bo Hyun Yoon, Roberto Romero. (2005) An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. American Journal of Obstetrics and Gynecology 193:3, 984-989
CrossRef807
D.J. van Spronsen, P.F.A. Mulders, P.H.M. De Mulder. (2005) Novel treatments for metastatic renal cell carcinoma. Critical Reviews in Oncology/Hematology 55:3, 177-191
CrossRef808
Daniel Morgensztern, Howard L. McLeod. (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-Cancer Drugs 16:8, 797-803
CrossRef809
Clark, Matthew A., Fisher, Cyril, Judson, Ian, Thomas, J. Meirion, . (2005) Soft-Tissue Sarcomas in Adults. New England Journal of Medicine 353:7, 701-711
Full Text810
Brian I. Rini, Jeffrey A. Sosman, Robert J. Motzer. (2005) Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU International 96:3, 286-290
CrossRef811
Qin Yu. (2005) The dynamic roles of angiopoietins in tumor angiogenesis. Future Oncology 1:4, 475-484
CrossRef812
S. J. Harrison, G. Cook. (2005) Immunotherapy in multiple myeloma - possibility or probability?. British Journal of Haematology 130:3, 344-362
CrossRef813
D. J. van Spronsen, K. J. M. de Weijer, P. F. A. Mulders, P. H. M. De Mulder. (2005) Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anti-Cancer Drugs 16:7, 709-717
CrossRef814
Jay Rhee, Paulo M Hoff. (2005) Angiogenesis inhibitors in the treatment of cancer. Expert Opinion on Pharmacotherapy 6:10, 1701-1711
CrossRef815
John T. Leppert, John S. Lam, Allan J. Pantuck, Robert A. Figlin, Arie S. Belldegrun. (2005) Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU International 96:3, 281-285
CrossRef816
Taro Matsumoto, Svante Bohman, Johan Dixelius, Tone Berge, Anna Dimberg, Peetra Magnusson, Ling Wang, Charlotte Wikner, Jian Hua Qi, Christer Wernstedt, Jiong Wu, Skjalg Bruheim, Hideo Mugishima, Debrabata Mukhopadhyay, Anne Spurkland, Lena Claesson-Welsh. (2005) VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. The EMBO Journal 24:13, 2342-2353
CrossRef817
S. TANGJITGAMOL, P.T. RAMIREZ, C.C. SUN, H.T. SEE, A. JHINGRAN, J.J. KAVANAGH, M.T. DEAVERS. (2005) Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. International Journal of Gynecological Cancer 15:4, 646-656
CrossRef818
Napoleone Ferrara, Kenneth J. Hillan, William Novotny. (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications 333:2, 328-335
CrossRef819
John S. Lam, John T. Leppert, Arie S. Belldegrun, Robert A. Figlin. (2005) Novel approaches in the therapy of metastatic renal cell carcinoma. World Journal of Urology 23:3, 202-212
CrossRef820
Mitchell H. Sokoloff, Siamak Daneshmand, Christopher W. Ryan. (2005) Current clinical trials in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 23:4, 289-292
CrossRef821
Patricia Parsons-Wingerter, Ian M. Kasman, Scott Norberg, Anette Magnussen, Sara Zanivan, Alberto Rissone, Peter Baluk, Cecile J. Favre, Ursula Jeffry, Richard Murray, Donald M. McDonald. (2005) Uniform Overexpression and Rapid Accessibility of α5β1 Integrin on Blood Vessels in Tumors. The American Journal of Pathology 167:1, 193-211
CrossRef822
Michael C. Cox, Matthew Permenter, William D. Figg. (2005) Angiogenesis and prostate cancer: Important laboratory and clinical findings. Current Oncology Reports 7:3, 215-219
CrossRef823
Richard J Levine, S Ananth Karumanchi. (2005) Circulating Angiogenic Factors in Preeclampsia. Clinical Obstetrics and Gynecology 48:2, 372-386
CrossRef824
A. R. Padhani, M. O. Leach. (2005) Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdominal Imaging 30:3, 325-342
CrossRef825
S. Ananth Karumanchi, Sharon E. Maynard, Isaac E. Stillman, Franklin H. Epstein, Vikas P. Sukhatme. (2005) Preeclampsia: A renal perspective. Kidney International 67:6, 2101-2113
CrossRef826
Takeshi Isobe, Roy S. Herbst, Amir Onn. (2005) Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy. Seminars in Oncology 32:3, 315-328
CrossRef827
Fabian Benencia, Maria C. Courreges, José R. Conejo-García, Ronald J. Buckanovich, Lin Zhang, Richard H. Carroll, Mark A. Morgan, George Coukos. (2005) Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma. Human Gene Therapy 16:6, 765-778
CrossRef828
Ruud P.M. Dings, Brent W. Williams, Chang W. Song, Arjan W. Griffioen, Kevin H. Mayo, Robert J. Griffin. (2005) Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. International Journal of Cancer 115:2, 312-319
CrossRef829
J LAM, O SHVARTS, J LEPPERT, R FIGLIN, A BELLDEGRUN. (2005) RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPY. The Journal of Urology 173:6, 1853-1862
CrossRef830
Andrea Mancuso, Cora N. Sternberg. (2005) What's new in the treatment of metastatic kidney cancer?. BJU International 95:9, 1171-1180
CrossRef831
R S Herbst. (2005) Role of novel targeted therapies in the clinic. British Journal of Cancer 92, S21-S27
CrossRef832
Alain Ravaud, Marie-Sarah Dilhuydy. (2005) Interferon alpha for the treatment of advanced renal cancer. Expert Opinion on Biological Therapy 5:6, 749-762
CrossRef833
M O Leach, K M Brindle, J L Evelhoch, J R Griffiths, M R Horsman, A Jackson, G C Jayson, I R Judson, M V Knopp, R J Maxwell, D McIntyre, A R Padhani, P Price, R Rathbone, G J Rustin, P S Tofts, G M Tozer, W Vennart, J C Waterton, S R Williams, P Workman. (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. British Journal of Cancer 92:9, 1599-1610
CrossRef834
SHARON E. MAYNARD, SHIVALINGAPPA VENKATESHA, RAVI THADHANI, S ANANTH KARUMANCHI. (2005) Soluble Fms-like Tyrosine Kinase 1 and Endothelial Dysfunction in the Pathogenesis of Preeclampsia. Pediatric Research 57:5 Part 2, 1R-7R
CrossRef835
W Kimryn Rathmell, Paul A Godley, Brian I Rini. (2005) Renal cell carcinoma. Current Opinion in Oncology 17:3, 261-267
CrossRef836
C. Doehn, I. Kausch, D. Jocham. (2005) Immuntherapie urologischer Tumoren. Der Onkologe 11:5, 536-553
CrossRef837
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin. (2005) Treatment for Pancreatic Cancer: Current Therapy and Continued Progress. Gastroenterology 128:6, 1642-1654
CrossRef838
Cassandra N Moore, Daniel J George. (2005) Update in the management of patients with hormone-refractory prostate cancer. Current Opinion in Urology 15:3, 157-162
CrossRef839
Daniel J Schoeffner, Shannon L Matheny, Takemi Akahane, Valentina Factor, Adam Berry, Glenn Merlino, Unnur P Thorgeirsson. (2005) VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Laboratory Investigation 85:5, 608-623
CrossRef840
Henk MW Verheul, Herbert M Pinedo. (2005) Inhibition of angiogenesis in cancer patients. Expert Opinion on Emerging Drugs 10:2, 403-412
CrossRef841
Francesco Caponigro, Roberta Formato, Michele Caraglia, Nicola Normanno, Rosario Vincenzo Iaffaioli. (2005) Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Current Opinion in Oncology 17:3, 212-217
CrossRef842
Masakazu Ogura, Toru Shibata, Junlin Yi, Junye Liu, Runjiang Qu, Hiroshi Harada, Masahiro Hiraoka. (2005) A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas. Cancer Science 96:5, 288-294
CrossRef843
Michael B. Atkins. (2005) Management of advanced renal cancer. Kidney International 67:5, 2069-2082
CrossRef844
M. Stern, R. Herrmann. (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Critical Reviews in Oncology/Hematology 54:1, 11-29
CrossRef845
VICKI LEVIDIOTIS, DAVID A POWER. (2005) New insights into the molecular biology of the glomerular filtration barrier and associated disease. Review Article. Nephrology 10:2, 157-166
CrossRef846
Klaus Podar, Teru Hideshima, Dharminder Chauhan, Kenneth C Anderson. (2005) Targeting signalling pathways for the treatment of multiple myeloma. Expert Opinion on Therapeutic Targets 9:2, 359-381
CrossRef847
Apurva A. Desai, Walter M. Stadler. (2005) Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents. Current Oncology Reports 7:2, 116-122
CrossRef848
Christopher Bangard, Axel Gossmann, Armine Papyan, Samir Tawadros, Martin Hellmich, Christiane J. Bruns. (2005) Magnetic resonance imaging in an orthotopic rat model: Blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth. International Journal of Cancer 114:1, 131-138
CrossRef849
Antonio Jimeno, Manuel Hidalgo. (2005) Blockade of epidermal growth factor receptor (EGFR) activity. Critical Reviews in Oncology/Hematology 53:3, 179-192
CrossRef850
(2005) Inhibitors targeting vascular endothelial growth factor receptor kinases and cyclin-dependent kinases. Expert Opinion on Therapeutic Patents 15:3, 337-341
CrossRef851
M. van der Flier, F.E. Coenjaerts, P.N. Mwinzi, E. Rijkers, M. Ruyken, J. Scharringa, J.L.L. Kimpen, A.I.M. Hoepelman, S.P.M. Geelen. (2005) Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis. Journal of Neuroimmunology 160:1-2, 170-177
CrossRef852
Jennifer M. Roth, Abebe Akalu, Anat Zelmanovich, Desiree Policarpio, Bruce Ng, Shannon MacDonald, Silvia Formenti, Leonard Liebes, Peter C. Brooks. (2005) Recombinant α2(IV)NC1 Domain Inhibits Tumor Cell-Extracellular Matrix Interactions, Induces Cellular Senescence, and Inhibits Tumor Growth in Vivo. The American Journal of Pathology 166:3, 901-911
CrossRef853
Bradley J. Monk, David C. Choi, Gordon Pugmire, Robert A. Burger. (2005) Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecologic Oncology 96:3, 902-905
CrossRef854
Robert M. Borzilleri, Zhen-wei Cai, Christopher Ellis, Joseph Fargnoli, Aberra Fura, Tracy Gerhardt, Bindu Goyal, John T. Hunt, Steven Mortillo, Ligang Qian, John Tokarski, Viral Vyas, Barri Wautlet, Xioping Zheng, Rajeev S. Bhide. (2005) Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 15:5, 1429-1433
CrossRef855
K PAPP. (2005) Potential future therapies for psoriasis. Seminars in Cutaneous Medicine and Surgery 24:1, 58-63
CrossRef856
Domenico Ribatti. (2005) The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. British Journal of Haematology 128:3, 303-309
CrossRef857
Raoul Tibes, Jonathan Trent, Razelle Kurzrock. (2005) TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS*. Annual Review of Pharmacology and Toxicology 45:1, 357-384
CrossRef858
Francesco Caponigro, Maria Basile, Vincenzo de Rosa, Nicola Normanno. (2005) New Drugs in Cancer Therapy, National Tumor Institute, Naples, 17???18 June 2004. Anti-Cancer Drugs 16:2, 211-221
CrossRef859
Dahlia T Lainer, Ernest Brahn. (2005) New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opinion on Investigational Drugs 14:1, 1-17
CrossRef860
Aristotle Bamias, Meletios A Dimopoulos. (2005) Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opinion on Investigational Drugs 14:1, 45-55
CrossRef861
J.-Y. Blay. (2005) Médicaments actuels et optimisation. Annales Pharmaceutiques Françaises 63:1, 17-24
CrossRef862
Eduardo Huarte, Iñigo Tirapu, Ainhoa Arina, María Vera, Carlos Alfaro, Oihana Murillo, Belén Palencia, Victoria Busto, Verónica Marín, Guillermo Mazzolini, Ignacio Melero. (2005) Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opinion on Biological Therapy 5:1, 7-22
CrossRef863
J.-P. Armand. (2005) Les anti-angiogéniques en cancérologie : mythe ou réalité ?. Annales Pharmaceutiques Françaises 63:1, 25-27
CrossRef864
Maartje Los, Emile E. Voest, Inne H.M. Borel Rinkes. (2005) VEGF as a Target of Therapy in Gastrointestinal Oncology. Digestive Surgery 22:4, 282-293
CrossRef865
Brian I. Rini. (2005) New approaches in advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 23:1, 65-66
CrossRef866
George Youssef, Matthew Links. (2005) The Prevention and Management of Cardiovascular Complications of Chemotherapy in Patients with Cancer. American Journal of Cardiovascular Drugs 5:4, 233-243
CrossRef867
G. Marx, J. Taylor, D. Goldstein. (2005) Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience. Internal Medicine Journal 35:1, 34-38
CrossRef868
Yoo-Joung Ko, Michael B. Atkins. (2005) Chemotherapies and immunotherapies for metastatic kidney cancer. Current Urology Reports 6:1, 35-42
CrossRef869
J.S. RUDGE, G. THURSTON, S. DAVIS, N. PAPADOPOULOS, N. GALE, S.J. WIEGAND, G.D. YANCOPOULOS. (2005) VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and VelociGeneR- based Discovery of the Next Generation of Angiogenesis Targets. Cold Spring Harbor Symposia on Quantitative Biology 70:1, 411-418
CrossRef870
Mark A Pearson, Doriano Fabbro. (2004) Targeting protein kinases in cancer therapy: a success?. Expert Review of Anticancer Therapy 4:6, 1113-1124
CrossRef871
Riyaz NH Shah, Tanya Ahmad, Tim G Eisen. (2004) Treatment of recurrent or metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 4:6, 1069-1080
CrossRef872
Manuela Schmidinger, Michael Hejna, Christoph C Zielinski. (2004) Aldesleukin in advanced renal cell carcinoma. Expert Review of Anticancer Therapy 4:6, 957-980
CrossRef873
John S Lam, Arie S Belldegrun, Robert A Figlin. (2004) Advances in immune-based therapies of renal cell carcinoma. Expert Review of Anticancer Therapy 4:6, 1081-1096
CrossRef874
Charles Sawyers. (2004) Targeted cancer therapy. Nature 432:7015, 294-297
CrossRef875
David J Kerr. (2004) Targeting angiogenesis in cancer: clinical development of bevacizumab. Nature Clinical Practice Oncology 1:1, 39-43
CrossRef876
Yuval Bdolah, Vikas P. Sukhatme, S. Ananth Karumanchi. (2004) Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. Seminars in Nephrology 24:6, 548-556
CrossRef877
Margareta M. Mueller, Norbert E. Fusenig. (2004) Friends or foes — bipolar effects of the tumour stroma in cancer. Nature Reviews Cancer 4:11, 839-849
CrossRef878
G Deplanque, S Madhusudan, P H Jones, S Wellmann, K Christodoulos, D C Talbot, T S Ganesan, A Blann, A L Harris. (2004) Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. British Journal of Cancer
CrossRef879
Ralph L. Nachman, Eric A. Jaffe. (2004) Endothelial cell culture: beginnings of modern vascular biology. Journal of Clinical Investigation 114:8, 1037-1040
CrossRef880
I K Dev, R E Dornsife, T M Hopper, J A Onori, C G Miller, L E Harrington, K M Dold, R J Mullin, J H Johnson, R M Crosby, A T Truesdale, A H Epperly, K W Hinkle, M Cheung, J A Stafford, D K Luttrell, R Kumar. (2004) Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. British Journal of Cancer 91:7, 1391-1398
CrossRef881
Eric W. Fitz, Steven A. Newman. (2004) Neuro-ophthalmology of von Hippel-Lindau. Current Neurology and Neuroscience Reports 4:5, 384-390
CrossRef882
Jill Allen, Emily K. Bergsland. (2004) Angiogenesis in colorectal cancer: therapeutic implications and future directions. Hematology/Oncology Clinics of North America 18:5, 1087-1119
CrossRef883
Benjamin Purow, Howard A. Fine. (2004) Antiangiogenic therapy for primary and metastatic brain tumors. Hematology/Oncology Clinics of North America 18:5, 1161-1181
CrossRef884
Phyllis Wachsberger, Randy Burd, Adam P. Dicker. (2004) Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematology/Oncology Clinics of North America 18:5, 1039-1057
CrossRef885
Scot W. Ebbinghaus, Michael S. Gordon. (2004) Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. Hematology/Oncology Clinics of North America 18:5, 1143-1159
CrossRef886
Harold Frucht, Peter D. Stevens, David R. Fogelman, Elizabeth C. Verna, Johnson Chen, John A. Chabot, Robert L. Fine. (2004) Advances in the genetic screening, work-up, and treatment of pancreatic cancer. Current Treatment Options in Gastroenterology 7:5, 343-354
CrossRef887
Mary J MacKenzie. (2004) Molecular therapy in pancreatic adenocarcinoma. The Lancet Oncology 5:9, 541-549
CrossRef888
W.Marston Linehan, Berton Zbar. (2004) Focus on kidney cancer. Cancer Cell 6:3, 223-228
CrossRef889
Tamás Lórincz, József Tímár, Miklós Szendrói. (2004) Alterations of microvascular density in bone metastases of adenocarcinomas. Pathology & Oncology Research 10:3, 149-153
CrossRef890
S. Richard. (2004) The growing family of hereditary renal cell carcinoma. Nephrology Dialysis Transplantation 19:12, 2954-2958
CrossRef891
Mani Mohindru, Amit Verma. (2004) Kinase inhibitors translate lab discoveries into exciting new cures for cancers. The Indian Journal of Pediatrics 71:8, 713-718
CrossRef892
Chris Coppin, Franz Porzsolt, Michael Autenrieth, Julia Kumpf, Andrew Coldman, Timothy Wilt, Chris Coppin. 2004. Immunotherapy for advanced renal cell cancer. .
CrossRef893
W. R. Parulekar, E. A. Eisenhauer. (2004) Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice. JNCI Journal of the National Cancer Institute 96:13, 990-997
CrossRef894
Aernout Luttun, Peter Carmeliet. (2004) Angiogenesis and lymphangiogenesis: highlights of the past year. Current Opinion in Hematology 11:4, 262-271
CrossRef895
Brian I. Rini, Vivian Weinberg, Vanessa Shaw, Janet Scott, Robert Bok, John W. Park, Eric J. Small. (2004) Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer 101:1, 90-95
CrossRef896
Srinivasan Madhusudan, Trivadi S. Ganesan. (2004) Tyrosine kinase inhibitors in cancer therapy. Clinical Biochemistry 37:7, 618-635
CrossRef897
Arthur E Frankel, Parkash S Gill. (2004) VEGF and myeloid leukemias. Leukemia Research 28:7, 675-677
CrossRef898
Tetsuichiro Inai, Michael Mancuso, Hiroya Hashizume, Fabienne Baffert, Amy Haskell, Peter Baluk, Dana D. Hu-Lowe, David R. Shalinsky, Gavin Thurston, George D. Yancopoulos, Donald M. McDonald. (2004) Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts. The American Journal of Pathology 165:1, 35-52
CrossRef899
Edith Huland, Hans Heinzer. (2004) Renal cell carcinoma - innovative medical treatments. Current Opinion in Urology 14:4, 239-244
CrossRef900
BRADLEY K. McCOLL, STEVEN A. STACKER, MARC G. ACHEN. (2004) Molecular regulation of the VEGF family â inducers of angiogenesis and lymphangiogenesis. APMIS 112:7-8, 463-480
CrossRef901
ANDREW J. STEPHENSON, MICHAEL P. CHETNER, KEITH ROURKE, MARTIN E. GLEAVE, M. SIGNAEVSKY, BRUCE PALMER, JAMES KUAN, GERALD B. BROCK, SIMON TANGUAY. (2004) GUIDELINES FOR THE SURVEILLANCE OF LOCALIZED RENAL CELL CARCINOMA BASED ON THE PATTERNS OF RELAPSE AFTER NEPHRECTOMY. The Journal of Urology 172:1, 58-62
CrossRef902
Robert Wild, Ruud P.M. Dings, Indira Subramanian, S. Ramakrishnan. (2004) Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. International Journal of Cancer 110:3, 343-351
CrossRef903
Hurwitz, Herbert, Fehrenbacher, Louis, Novotny, William, Cartwright, Thomas, Hainsworth, John, Heim, William, Berlin, Jordan, Baron, Ari, Griffing, Susan, Holmgren, Eric, Ferrara, Napoleone, Fyfe, Gwen, Rogers, Beth, Ross, Robert, Kabbinavar, Fairooz, . (2004) Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. New England Journal of Medicine 350:23, 2335-2342
Full Text904
Mark T. Bilodeau, Leonard D. Rodman, Georgia B. McGaughey, Kathleen E. Coll, Timothy J. Koester, William F. Hoffman, Randall W. Hungate, Richard L. Kendall, Rosemary C. McFall, Keith W. Rickert, Ruth Z. Rutledge, Kenneth A. Thomas. (2004) The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase. Bioorganic & Medicinal Chemistry Letters 14:11, 2941-2945
CrossRef905
Shingo Takano, Hiroshi Kamiyama, Koji Tsuboi, Akira Matsumura. (2004) Angiogenesis and antiangiogenic therapy for malignant gliomas. Brain Tumor Pathology 21:2, 69-73
CrossRef906
Carlos L. Arteaga, Jose Baselga. (2004) Tyrosine kinase inhibitors. Cancer Cell 5:6, 525-531
CrossRef907
Michel Vulfovich, Nabil Saba. (2004) Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs 13:6, 577-607
CrossRef908
BRIAN I. RINI, VIVIAN WEINBERG, ERIC J. SMALL. (2004) PRACTICE AND PROGRESS IN KIDNEY CANCER: METHODOLOGY FOR NOVEL DRUG DEVELOPMENT. The Journal of Urology 171:6, 2115-2121
CrossRef909
Sheila A Doggrell. (2004) Vascular biology support for the use of bevacizumab in colorectal cancer. Expert Opinion on Investigational Drugs 13:6, 703-705
CrossRef910
Marion Harris. (2004) Monoclonal antibodies as therapeutic agents for cancer. The Lancet Oncology 5:5, 292-302
CrossRef911
Ross R Jennens, Mark A Rosenthal, Geoffrey J Lindeman, Michael Michael. (2004) Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. Urologic Oncology: Seminars and Original Investigations 22:3, 193-196
CrossRef912
W Kimryn Rathmell, Paul A Godley. (2004) Renal cell carcinoma. Current Opinion in Oncology 16:3, 247-252
CrossRef913
Napoleone Ferrara, Kenneth J. Hillan, Hans-Peter Gerber, William Novotny. (2004) Case history: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery 3:5, 391-400
CrossRef914
Edward V Prochownik. (2004) c-Myc as a therapeutic target in cancer. Expert Review of Anticancer Therapy 4:2, 289-302
CrossRef915
Laurie Goodman. (2004) Persistence—luck—Avastin. Journal of Clinical Investigation 113:7, 934-934
CrossRef916
Jesus Prieto, Cheng Qian, Bruno Sangro, Ignacio Melero, Guillermo Mazzolini. (2004) Biologic therapy of liver tumors. Surgical Clinics of North America 84:2, 673-696
CrossRef917
Paul William Manley, Guido Bold, Josef Brüggen, Gabrielle Fendrich, Pascal Furet, Jürgen Mestan, Christian Schnell, Barbara Stolz, Thomas Meyer, Bernd Meyhack, Wilhelm Stark, Andre Strauss, Jeanette Wood. (2004) Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1697:1-2, 17-27
CrossRef918
Arjan A. van de Loosdrecht, Peter C. Huijgens, Gert J. Ossenkoppele. (2004) Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. Anti-Cancer Drugs 15:3, 189-201
CrossRef919
Levine, Richard J., Maynard, Sharon E., Qian, Cong, Lim, Kee-Hak, England, Lucinda J., Yu, Kai F., Schisterman, Enrique F., Thadhani, Ravi, Sachs, Benjamin P., Epstein, Franklin H., Sibai, Baha M., Sukhatme, Vikas P., Karumanchi, S. Ananth, . (2004) Circulating Angiogenic Factors and the Risk of Preeclampsia. New England Journal of Medicine 350:7, 672-683
Full Text920
Reade B Roberts, Carlos L Arteaga, David W Threadgill. (2004) Modeling the cancer patient with genetically engineered mice. Cancer Cell 5:2, 115-120
CrossRef921
Ahmad Awada, Max Mano, Alain Hendlisz, Martine Piccart. (2004) New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Expert Review of Anticancer Therapy 4:1, 53-60
CrossRef922
Zhicai Wu, Mark E. Fraley, Mark T. Bilodeau, Mildred L. Kaufman, Edward S. Tasber, Adrienne E. Balitza, George D. Hartman, Kathleen E. Coll, Keith Rickert, Jennifer Shipman, Bin Shi, Laura Sepp-Lorenzino, Kenneth A. Thomas. (2004) Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR. Bioorganic & Medicinal Chemistry Letters 14:4, 909-912
CrossRef923
Robert S Kerbel. (2004) Antiangiogenic drugs and current strategies for the treatment of lung cancer. Seminars in Oncology 31, 54-60
CrossRef924
C.O McDonnell, G Holden, M.E Sheridan, D Foley, M Moriarty, T.N Walsh, D.J Bouchier-Hayes. (2004) Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model. Journal of Surgical Research 116:1, 19-23
CrossRef925
Donald M. McDonald, Beverly A. Teicher, William Stetler-Stevenson, Sylvia S. W. Ng, William D. Figg, Judah Folkman, Douglas Hanahan, Robert Auerbach, Michael O’Reilly, Roy Herbst, David Cheresh, Michael Gordon, Alexander Eggermont, Steven K. Libutti. (2004) Report from the Society for Biological Therapy and Vascular Biology Faculty of the NCI Workshop on Angiogenesis Monitoring. Journal of Immunotherapy 27:2, 161-175
CrossRef926
David C. Sane, Lauren Anton, K. Bridget Brosnihan. (2004) Angiogenic growth factors and hypertension. Angiogenesis 7:3, 193-201
CrossRef927
Akash Nanda, Brad St. Croix. (2004) Tumor endothelial markers: new targets for cancer therapy. Current Opinion in Oncology 16:1, 44-49
CrossRef928
Dina M. Elaraj, Donald E. White, Seth M. Steinberg, Leah Haworth, Steven A. Rosenberg, James C. Yang. (2004) A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma. Journal of Immunotherapy 27:4, 259-264
CrossRef929
H. T. See, J. J. Kavanagh, W. Hu, R. C. Bast. (2003) Targeted therapy for epithelial ovarian cancer: Current status and future prospects. International Journal of Gynecological Cancer 13:6, 701-734
CrossRef930
Jennifer Klem, Edward Chu, Vinay K. Jain. (2003) Current Studies with PTK787, an Oral Inhibitor of Vascular Endothelial Growth Factor in Colorectal Cancer. Clinical Colorectal Cancer 3:3, 147-149
CrossRef931
Sonpavde, Guru, . (2003) Bevacizumab in Renal-Cell Cancer. New England Journal of Medicine 349:17, 1674-1674
Full Text932
George, Daniel J., Kaelin, William G. Jr., . (2003) The von Hippel–Lindau Protein, Vascular Endothelial Growth Factor, and Kidney Cancer. New England Journal of Medicine 349:5, 419-421
Full Text933
Keiichi Kondo, William Y. Kim, Mirna Lechpammer, William G. Kaelin. (2003) Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth. PLoS Biology 1:3, e3
CrossRef
- Letters
